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Abstract
Macaques are the most commonly used non-human primate in cognitive
neuroscience research due to similarities between the macaque and human
brain. Cephalic recording chambers (CRCs) are often surgically implanted
to obtain neuronal recordings. CRCs represent a persistent source of mi-
crobial contamination, which can occasionally progress to clinical sequelae
of meningitis and brain abscesses. In this thesis, we first examined aer-
obic and anaerobic bacterial species colonizing CRCs using both traditional
culture-dependent methods and 16S microbiota culture-independent meth-
ods. We evaluated the most prevalent species, and compared CRC bacterial
communities to skin, oral and fecal bacterial communities. Our results in-
dicated that CRC bacterial communities are predominantly composed of
anaerobic flora and are relatively unique between individual macaques.
Additionally CRC bacterial communities are more similar to skin and oral
bacterial communities than fecal bacterial communities, indicating that
fecal contamination of CRCs is a less likely source of contamination. Aer-
obic culture and sensitivity data from samples collected in 2011 identified
Staphylococcus aureus, Enterococcusfaecalis and Proteus spp. as the most
prevalent species isolated, and that E.faecalis isolates displayed marked re-
sistance to multiple antimicrobial classes. Routine CRC sanitization proce-
dures were revised in September 2014 to prohibit antimicrobial use within
CRCs, and we evaluated how E.faecalis lineages persisted and evolved be-
tween 2011 and 2017. We identified a shift in sequence type (ST) from ST4
and ST55, predominating in 2011, to ST48 predominating in macaques
implanted after 2013. ST48 lineages were less resistant to antimicrobials
and stronger biofilm producers as compared to ST4 and ST55 lineages.
We concluded that loss of selective pressure from antimicrobial use within
CRCs permitted ST48 to emerge as the predominant lineage due to its
strong biofilm-forming abilities. Finally, we evaluated alternative E.faecalis
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biofilm treatment strategies. We isolated lytic bacteriophages with activity
against ST55 E.faecalis and evaluated the use of phages and antimicrobial
peptides LL-37 and PR-39 against E. faecalis biofilm, alone, and in com-
bination with antimicrobials. Our results identified that bacteriophages
successfully decreased biofilm produced by ST55 and ST4 E. faecalis iso-
lates and should be evaluated further for treatment of animal and human
enterococcal-associated biofilm infections.
Thesis Supervisor: James G. Fox
Title: Director, Division of Comparative Medicine, Professor, Department of
Biological Engineering
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Chapter 1
Use of Macaques (Macaca spp.)
in Cognitive Neuroscience
Research and Complications
Associated with Cephalic
Implants
Portions of this chapter have been previously published [1].
1.1 Introduction
Nonhuman primates (NHP) are an important animal model for cognitive
neuroscience research, with the macaque (Macaca mulatta) being the most
commonly utilized species (Figure 1-1) [5]. The anatomical and functional
similarities between the human and macaque brain have been well char-
acterized, and features such as a highly developed cerebral cortex (Figure
1-2), binocular color vision and front-facing eyes allow comparisons to hu-
mans that are impossible in rodent models [5]. At MIT, the Brain and Cog-
nitive Science faculty are primarily studying visual pathways involved in
object recognition, learning and memory, motivation-based decision mak-
ing, and control of attention vs. distraction.
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Figure 1-1: The rhesus macaque (Macaca mulatta) is the most commonly
used non-human primate in research. Image reference: [2]
1.2 Description of typical cranial implants
used in macaques involved in cognitive
neuroscience research at MIT
Cognitive neuroscience researchers are often interested in elucidating spe-
cific pathways within the brain. These studies involve training macaques to
sit in a chair and perform tasks on a computerized system, such as visual
object recognition, or memory tasks [6]. Researchers are able to track eye
movements and record electrical impulses of the neuronal pathway under
study while macaques perform the tasks. The expertise of the investigator,
and the region of the brain under study determine the style of cranial im-
plant, its placement on the cranium, and the number and type of electrodes
placed.
In preparation for neuronal recordings, macaques must undergo sur-
gical procedures to facilitate access for placement of electrodes into the
brain. Surgical implants typically involve two types of implanted devices.
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Rat (Prosimian
(Rodent) p nmate)
(Simian primate) Human 5cm
Figure 1-2: A. Relative brain sizes as compared to a human brain, including
a macaque (monkey) and gorilla (ape). Image reference: [3]. B. Comparison
of prefrontal cortex size between rat, galago, macaque and human brains.
Originally published as Figure 3 in reference [4]; used with permission.
First, restraint pedestals are affixed to the cranium to permit head fixation
while the chaired macaque performs tasks. Restraint pedestals minimize
movement of the head during recordings and subsequent noise that might
interfere with interpretation of electrical impulses [7]. The style of restraint
pedestal used varies between investigators at MIT, but is most commonly
a single titanium or plastic restraint post mounted in the occipital region
Figure 1-3. Some investigators utilize a "pin-halo" style restraint involving
a metal halo to interface with 3-4 small pins placed around the skull and
attached using screws [8]. Traditionally, single restraint pedestal screws
were anchored using polymethylmethacrylate (PMMA) dental acrylic, al-
though updated designs are able to affix the restraint pedestal directly to
the skull with screws [9]. Following placement of the restraint pedestals, a
craniotomy is performed to perforate the bony skull and a cephalic record-
ing chamber (CRC) is placed (Figure 1-3). The number and sizes of the
craniotomies will depend on the area of the brain being studied and the
types of electrodes (single vs. microarray) used.
Historically, commercially available CRCs were made of stainless steel,
titanium, CILUX plastic, or thermoplastic polyetherimide Ultem plastic and
affixed to the skull using a combination of screws and PMMA dental acrylic
[10, 9, 11]. More recent innovations involve magnetic resonance imaging
(MRI) and/or computed tomography (CT) to map the skull followed by com-
puter aided design and 3D printing to customize the shape and size of the
CRC to the individual macaque. [10, 9, 11]. These new designs can thus
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Figure 1-3: Illustration of a traditional cephalic recording chamber and sin-
gle restraint pedestal with polymethylmethacrylate (PMMA) used to anchor
screws
be lower-profile, PMMA-free and also feature lightweight, next-generation
plastics such as carbon polyetheretherketone (PEEK) which are compatible
with MRI studies due to their nonferrous nature [10, 9, 11].
Microelectrodes placed into the brain can be used for recording neuronal
activity, stimulating neurons, or selective ablation of neuronal tissue in the
desired brain region [6]. Microelectrodes are commonly made of tungsten
or platinum and are a few microns in diameter [6]. In some cases, elec-
trodes are placed prior to every recording session but some experimental
paradigms involve chronic placement of microelectrode arrays . The latter
array approach allows the ability to target neurons repeatedly between ex-
periments. There are also described techniques for a hybrid of the two sys-
tems; Chronic Independently Movable Electrode systems permit repeated
sampling of the same sites as well as sampling of multiple sites [12].
1.3 Complications of cephalic implantation
Complications of chronic cephalic implantation have been documented in
macaques under study at MIT, as well as at other institutions. For the
purposes of this dissertation, we will be focusing on infection-related com-
plications with only brief discussions of other CRC implant complications.
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1.3.1 Acute complications
Acute complications of cephalic implantation include issues arising dur-
ing or in the early post-operative period, most commonly presenting within
the first month following surgery. Complications occurring during surgery
include hemorrhage, inadvertent damage to brain tissue or hematoma for-
mation during electrode placement, and breaks in sterile surgical technique
with introduction of bacteria into the brain, meninges or surrounding tis-
sues.
Clinical signs are non-specific for space-occupying cranial lesions (i.e.
brain abscess vs. hematoma) and deficits will depend on the location of
the lesion. At MIT, macaques affected by cephalic hematomas and abscess
have presented with hemi-inattention/visual deficits, hemiparesis, vomit-
ing, lethargy, and anorexia. Complete blood counts may reveal leukocyto-
sis, which can be a response etiher stress or infection. MRI imaging is the
preferred method for distinguishing hematomas from abscess (Figure 1-4.)
Treatment for small, subacute hematomas involves supportive care (anal-
gesics +/- corticosteroids, fluid and nutritional support) and monitoring;
euthanasia has been elected in cases of large hematomas resulting in more
extensive neurologic deficits.
If euthanasia is not elected, treatment for brain abscess involves as-
piration of abscess material for definitive aerobic and anaerobic culture,
with selection of antimicrobial therapy based on sensitivity testing results.
Periodic MRI imaging is essential during treatment to monitor abscess res-
olution and guide duration of antimicrobial therapy. Supportive care in-
cluding analgesics, fluid and nutritional support is also an essential part
of the treatment regimen. Brain abscess is most likely to arise from breaks
in aseptic technique, either during surgery, or post-operatively, with the
use of improperly sterilized electrodes or translocation of bacteria from the
dura during electrode penetration.
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Figure 1-4: T1 and T2-weighted coronal-plane MRI images of space-
occupying cranial lesions in research macaques. (A and B). Brain abscess
24 hours after clinical presentation; the asterisk designates the core while
the arrow identifies a thin, distinct capsule. Note loss of brain architecture
and edema (E) subadjacent to the abscess. (C and D). Hematoma 6 days
after clinical presentation; note hyperintense appearance on Ti-weighted
image (C) and hypointense appearance on T2-weighted image due to the
presence of paramagnetic intracellular methemoglobin. Interference from
implant metallic components results in the image artifact obscuring the
superior aspect of the brain in image C.
A case of acute post-surgical meningoencephalitis occurred in a macaque
at MIT as the result of improper screw placement. Clinical signs of vomit-
ing and stargazing presented 19 days following surgery; the macaque was
euthanized after a rapid decline to unresponsiveness necessitating venti-
latory support. During necropsy, hemorrhage and thick purulent mate-
rial were visualized covering the frontal and occipital lobes and meninges.
The tips of screws were observed to have penetrated through the skull.
Histopathology confirmed expansion of the dura mater and leptomeninges
24
by hemorrhage, granulocytes and mononuclear cells, with infiltration into
the brain and spinal cord parenchyma. Aerobic and anaerobic cultures
identified Staphylococcus aureus, Enterococcus faecalis, Lactobacillus sp.
and Micromonas micros. A break in sterile technique and inadvertent bac-
terial contamination of the screws was considered the most likely etiology.
1.3.2 Chronic complications
Chronic complications can occur months to years after surgical implanta-
tion and are often related to failure at the implant-tissue interface. Older-
style implants utilizing PMMA to anchor implant hardware are more likely to
be affected than PMMA-free implants. The curing of PMMA during surgery
results in an exothermic reaction, with temperatures reaching up to 1 10 C
and necessitating cooling techniques during application [13, 9]. As well as
causing thermal damage to bone and soft tissue, PMMA is cytotoxic and
does not bind well to bone [14, 11]. Over time, the natural healing physi-
ologic response is formation of a robust granulation tissue bed. Growth of
granulation tissue between the PMMA and bone can result in disruption of
implant, bone and tissue integrity, causing weakening or loss of the implant
hardware [10, 91. PMMA-free implants featuring a radial leg design can also
be affected by granulation tissue due to skin recession around the metal
legs. Skin recession can result in increased bone exposure, bone infection,
soft tissue infection and introduction of bacteria inside CRCs [10].
Within the CRC, formation of granulation tissue on the dura mater can
result from repeated electrode introduction, bacterial colonization of CRCs,
or a combination of these factors. Thickening of the dura will eventually
interfere with placement of electrodes, necessitating periodic scar tissue
removal, or alternate strategies to limit connective tissue growth [15, 161.
Meningitis results from bacterial infection of the meninges and has been
more commonly observed in macaques with chronic, traditional-style im-
plants utilizing PMMA. Over time, CRCs become colonized by bacteria when
opened to introduce electrodes, breaks in aseptic technique during CRC
sanitization, or from beneath PMMA associated with defects in the tissue-
implant interface. Most animals tolerate bacterial colonization of CRCs
without overt clinical signs; however, there is potential for bacteria to invade
through the meninges and cause pathology. Clinical signs of meningitis are
25
non-specific, and can include lethargy, anorexia, vomiting, "star-gazing",
head-pressing, and/or reluctance to move the head and neck [17, 181.
Definitive diagnosis of meningitis is made by sterile culture of cerebrospinal
fluid, which is most commonly collected via cisternal puncture. Com-
plete blood counts may reveal marked leukocytosis and can be sequen-
tially monitored to evaluate treatment efficacy. Sterile collection and aero-
bic/anaerobic cultures of blood are recommended to evaluate for concur-
rent sepsis. Cultures of CRCs are often performed, but does not necessarily
indicate the most likely causative bacterial species. Treatment of menin-
gitis includes broad-spectrum antimicrobial therapy, analgesic, fluid and
nutritional support and sometimes corticosteroids, depending on rapidity
of diagnosis. Historically, treatment had been initiated for suspected cases
without definitive diagnosis, and successful response to antimicrobial ther-
apy was interpreted as a correct diagnosis.
1.4 Frequency of Meningitis and Evaluation of
Implant Sanitization Practices
In 2011, the MIT Division of Comparative Medicine (DCM) surveyed in-
vestigators working with implanted macaques to characterize current CRC
sanitization practices and frequency of meningitis episodes. Practices var-
ied between investigators (and between macaques) regarding frequency of
CRC sanitization, solutions used for sanitization, use of topical antimi-
crobials within CRCs, placement of packing materials within CRCs, and
care of skin-implant wound margins. Detailed responses were available for
25 implanted macaques and it was determined that 4/25 macaques had
been treated for suspected meningitis between 2009 and 2011, with one
macaque treated on at least 5 separate occasions. Survey results from 2011
are available in Appendix A. To better understand potential etiologic agents
of meningitis, the veterinary staff initiated a study to characterize aero-
bic bacterial species inhabiting CRCs and their antimicrobial resistance
patterns. The results of these cultures and updates to CRC sanitization
protocols will be described in Chapter 2.
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1.5 Summary and Conclusions
In this chapter we have introduced the use of macaques as an essential
model for cognitive neuroscience research and discussed complications as-
sociated with cephalic implants required for studying neural pathways.
Bacterial meningitis and brain abscesses can be fatal, necessitating de-
tailed understanding of best practices to prevent and treat these cases
when they arise. Subsequent chapters will explore bacterial species com-
monly colonizing CRCs, examine how a particular bacterial species can per-
sist over time, and finally, evaluate novel treatments for bacterial biofilms.
Maintaining the highest standard of animal health and welfare is essen-
tial for both the veterinary and investigative staff privileged to work with
macaques and other non-human primates. MIT Brain and Cognitive Sci-
ence researchers are commended for their ongoing commitments to im-
provements to implant design and care, promotion of animal health, and
eager cooperation in facilitating sample collection during this project.
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Chapter 2
Characterization of Bacterial
Communities within Cephalic
Recording Chambers
Portions of this chapter have been previously published [1].
2.1 Introduction
As introduced in Chapter 1, macaques with chronic cephalic recording
chamber implants can develop a robust granulation tissue response, as well
as clinical sequelae of meningitis and brain abscesses secondary to bacte-
rial colonization of CRCs. Prior to 2014, diagnosis of macaques with "sus-
pect meningitis" was predominantly made based on clinical signs, a culture
of the cephalic recording chamber, and prophylactic treatment with vary-
ing antimicrobial regimens (trimethoprim-sulfamethoxazole, enrofloxacin,
ceftriaxone) and sometimes corticosteroids (dexamethasone sodium phos-
phate). This chapter focuses on techniques for identification of bacterial
species commonly inhabiting CRCs to better understand which species are
most common, and evaluate their pathogenic potential. First, we will in-
troduce results obtained from aerobic bacterial culture and antimicrobial
sensitivity testing performed in 2011. We will then discuss using culture-
independent methods to identify both aerobic and anaerobic species, and
compare communities between CRCs, the implant-skin margin, the oral
cavity, and feces from samples collected in 2017. Finally, we will com-
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pare results of culture-independent methods with aerobic and anaerobic
cultures from 2018 to validate the use of culture-independent methods to
characterize CRC bacterial communities.
2.2 Aerobic bacterial CRC cultures collected
from macaques in 2011
2.2.1 Animals
Twenty-five macaques (19 male, 6 female) with chronic cephalic recording
chambers were sampled in August, 2011. The population consisted of 25
rhesus macaques (Macaca mulatta) and 1 cynomolgus macaque (Macaca
fascicularis), with a mean and standard deviation age of 10.7 2.2 years
(range 6-15 years). The macaques sampled in this study were under inves-
tigation by four different cognitive neuroscience research laboratories (A-D;
Table 2.1). All macaques were housed in an AAALAC-International accred-
ited facility under standards outlined by the 8th edition of the Guide [19].
Briefly, husbandry parameters included a 12:12 light-dark cycle, a diet of
commercial primate biscuits (Purina 5038) supplemented with fruits, veg-
etables, nuts and cereal. Macaques were pair-housed, with exceptions for
animals showing incompatibility with conspecifics. For this study, 44 CRCs
with craniotomies, and 1 without a craniotomy, were sampled. The major-
ity of macaques (11/25) had one CRC; 8/25 had two, and the remaining 6
macaques had three CRCs. Most (26) of the CRCs had been in place be-
tween one and three years, 12 had been implanted between three and five
years, and 7 had been in place less than one year (Table 2.1). Antimicrobial
agents were routinely used within CRCs for 14/25 macaques and included
gentamicin sulfate 0.3%, oxytetracycline 5mg/g-polymyxin B 10,000U/g,
bacitracin zinc 300U/g-neomycin sulfate 5mg/g-polymyxin B 10,000U/g
and a 1:20 dilution of injectable enrofloxacin (2.27%). Packing materials
were used in 12/25 macaques and included sterile petroleum jelly (N=6),
non-woven sponge balls (n=5), and silicone elastomer (N=1). CRC saniti-
zation solutions varied by investigator and included chlorhexidine (n=20),
povidone-iodine (n=8), and hydrogen peroxide (N=3) (Appendix A). To mini-
mize discomfort and stress, sampling of cephalic chambers was performed
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under ketamine anesthesia (10mg/kg, intramuscular injection) during rou-
tine semi-annual physical examination. All animals remained on IACUC-
approved protocols for cognitive neuroscience research at the conclusion of
sampling and no animals were euthanized for reasons related to this study.
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Animal sex Age Lab Study # of Duration of CRC Antimicrobials Packing materials used in CRC
ID (years) ID ID CRCs implantation (years) used In CRC
I F 15 A Al 1 1-3 G None
2 F 14 A A2 1 1-3 None None
3 F 12 A A3 1 1-3 E None
4 M 11 B B1 2 1-3 None Sterile non-woven sponge balls
5 M 10 B B2 3 3-5 (2), 1-3 (1) T-PB None
6 M 13 B B3 2 3-5 T-PB Sterile non-woven sponge balls
7 M 12 B B4 3 3-5 None None
8 M 13 B 65 3 1-3 T-PB Sterile non-woven sponge balls
9 M 13 B B6 3 <1 T-PB Sterile non-woven sponge balls
10 M 10 B B7 1 <1 None Sterile non-woven sponge balls, onlypost-operatively
11 M 10 B B8 2 1-3 None Silicone elastomer
12 M 12 C C1 2 1-3 G None
13 M 12 C C2 3 1-3 BNP None
14 M 11 C C3 2 3-5 BNP or G None
15 M 8 C C4 1 1-3 BNP Sterile petroleum jelly, occasionally
with granulation tissue
16 F 10 C C5 2 1-3 BNP or G None
17 F 11 C C6 3 1-3 BNP None
18 M 10 C C7 2 1-3 G None
19 M 10 C C8 2 <1 G None
20 F 11 D D1 1 3-5 None Sterile petroleum jelly
21 M 8 D D2 1 3-5 None Sterile petroleum jelly
22 M 7 D D3 1 1-3 None None
23 M 7 D D4 1 <1 None Sterile petroleum jelly (when not onstudy)
24 M 11 D D5 1 3-5 None Sterile petroleum jelly
25 M 6 D D6 1 1-3 None Sterile petroleum jelly
Table 2.1: Population characteristics of 25 sampled research macaques in
August, 2011. At the time of sampling, macaque #10 had a CRC without a
craniotomy. Macaque #18 was a cynomolgus macaque; all other macaques
were rhesus macaques. Antimicrobial use within CRCs and CRC packing
material are listed for each animal as designated. Antimicrobial key: G,
gentamicin sulfate 0.3%; E, enrofloxacin 2.27% diluted 1:20, T-PB, oxyte-
tracycline 5mg/g-polymyxin B 10,OOOU/g; BNP, bacitracin zinc 400U/g-
neomycin sulfate 5mg/g-polymyxin B 10,OOOU/g
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2.2.2 Bacterial culture and Kirby-Bauer antimicrobial
susceptibility testing
Sterile culture swabs (CultureSwab MaxV(+), BD, Franklin Lakes, NJ) were
used to sample the interior of cephalic recording chambers, including any
discharge present. The swabs were plated onto chocolate agar, trypticase
soy agar with 5% sheep blood and MacConkey agar plates and incubated
at 37'C in 5% CO2 for 24h. The swabs, themselves, were then incubated
in thioglycollate broth at 37'C for 24h and re-plated onto the media listed
above. Microbial growth was streaked onto blood agar to obtain isolated
colonies, which were then identified using the Analytical Profile Index iden-
tification system (API 20 E and API 20 Strep, bioM6rieux, Durham, NC).
Antibiotic susceptibility profiles were determined by disk diffusion using
the Clinical and Laboratory Standards Institute break points (M2-A10) [20].
Antimicrobial agents tested included ampicillin, amoxicillin/clavulanic acid,
bacitracin, cephalothin, erythromycin, gentamicin, oxacillin, trimethoprim-
sulfamethoxazole, enrofloxacin, tetracycline, oxy-tetracycline, ceftriaxone,
doxycycline, neomycin, cefazolin, polymyxin B and vancomycin. Gentam-
icin, chloramphenicol, streptomycin, and vancomycin disks were purchased
from BD (BBL Sensi-Disc, Franklin Lakes, New Jersey); the remainder
of the antimicrobial disks were obtained from Oxoid (Basingstoke, United
Kingdom).
2.2.3 Aerobic bacterial culture results
From aerobic cultures of the 45 cephalic recording chambers sampled,
72 bacterial isolates were examined, with the most common species be-
ing Staphylococcus aureus (N=20), Enterococcus faecalis (N= 15), Proteus
mirabilis (N=6) and Streptococcus dysgalactiae (N=5) (Table 2.2). The vast
majority of cephalic recording chambers grew polymicrobial cultures with
a mean and standard deviation of 2.8 1.5 different species (Table 2.3).
Kirby-Bauer testing revealed that S. aureus and S. dysgalactiae isolates
were susceptible to the majority of antimicrobials tested, while E. faecalis
and Proteus spp. isolates displayed resistance to multiple classes of antimi-
crobial agents. Parenteral antimicrobial agents commonly used therapeuti-
cally and in the perioperative period included trimethoprim-sulfamethoxazole
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(TMS), enrofloxacin and ceftriaxone. Antimicrobial sensitivity results re-
vealed that 56% (40/72) of isolates tested were resistant to trimethoprim-
sulfamethoxazole, 69% (49/71) were resistant to enrofloxacin and 35%
(25/72) were resistant to ceftriaxone (Table 2.4). For topical antimicro-
bial agents used within CRCs, 40% (23/58) were resistant to bacitracin,
53% (38/72) were resistant to neomycin, 56% (35/62) were resistant to
polymyxin B and 32% (23/72) were resistant to gentamicin (Table 2.4). A
full list of bacterial isolates and their antimicrobial sensitivities is included
in Tables 2.5, 2.6, and 2.7. Due to the marked antimicrobial resistance to
multiple antimicrobial classes present in E. faecalis strains, further char-
acterization of 15 isolates was performed. These results will be presented
in Chapter 3.
Bacterial Isolate Number (%) of Isolates
Staphylococcus aureus 20 (27.8)
Enterococcus faecais 15 (20.8)
Proteus mirabilis 6(8.3)
Group C -Streptococcus dysgalactiae 5 (6.9)
Proteus vulgaris 4(5.6)
Staphylococcus intermedius 4 (5.6)
Enterococcus avium 3 (4.2)
Escherichia coli 2(2.8)
Group A 0-Streptococcus pyogenes 2 (2.8)
Leuconostoc spp. 2(2.8)
Streptococcus uberis 2 (2.8)
Aerococcus viridans 2 1 (1.4)
Enterococcus durans 1 (1.4)
Group F -Streptococcus constellatus 1 (1.4)
Proteus penneri 1 (1.4)
Proteus sp. 1 (1.4)
Staphylococcus epidermidis 1 (1.4)
Staphylococcus xylosus 1 (1.4)
72 (100)
45 CRCs of research
with multiple CRCs.
Total
Table 2.2: Aerobic bacterial culture results from
macaques (N=25). Cultures were pooled for animals
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Table 2.3: The majority of macaque CRCs display polymicrobial coloniza-
tion
35
Number of Isolates # (Percentage) of Macagues
0 1(4%)
1 4(16%)
2 7 (28%)
3 5 (20%)
4 4(16%)
5 3(12%)
6 1(4%)
Antimicrobial Phenotype -All AMP AMC B CR E GM OX SXT ENO TE T CRO D N CZ PB VAAerobic Isolates 111 1 __
ftiJstant 26 6 23 24 20 23 24 40 49 38 40 25 3 38 28 35 11
# Snsltive 44 62 28 40 22 46 34 31 11 31 31 45 24 29 39 8 4
# Intermediate 1 4 7 8 16 3 0 1 11 2 1 2 3 5 5 19 6
# Isolates Tested 71 72 58 72 58 72 58 72 71 71 72 72 30 72 72 62 21
% Resistant 36.62 8.333 39.66 33.33 34.48 31.94 41.38 55.56 69.01 53.52 55.56 34.72 10 52.78 38.89 56.45 52.38
61.97 86.11 46.26 55.56 37.93 63.89 58.62 43.06 15.49 43.66 43.06 62.5 80 40.28 54.17 12.9 19.05
Table 2.4: Percent of resistant and sensitive aerobic bacterial isolates as tested by Kirby-Bauer disk diffusion test-
ing. Antimicrobial key: AMP- Ampicillin, AMC- Amoxicillin/Clavulanic Acid, B- Bacitracin, CR- Cephalothin, E-
Erythromycin, GM- Gentamicin, OX- Oxacillin, SXT- Trimethoprim-Sulfamethoxazole, ENO- Enrofloxacin, TE-
Tetracycline, T- Oxytetracycline, CRO- Ceftriaxone, D- Doxycycline, N- Neomycin, CZ- Cefazolin, PB- Polymixin
B, VA- Vancomycin
Animal ID Study ID Antimcrobial Culture Results AMP AMC B CR E GM OX SXT ENO TE T CRO D N CZ PB VA
20 D1 Aerococcus virdans 2 S S 15 S S S S S S 31 30 S S S S
7 B4 Enterococcus avium 18 25 16 15 0 13 0 0 24 0 0 20 28 23 13 18
7 B4 Enterococcus avium 24 27 8 19 0 10 0 0 14 0 0 19 13 16 0 20
13 C2 N,P13 Entercoccus avium S S 21 32 15 28 0 21 0 0 0 0 17 0 13 10 17
5 82 T-P1 Enterococcus durans 25 25 9 2019 0 0 0 15 15 8 19 0 23 0 16
1 Al GM Enterococcus faecalis 17 25 13 11 0 0 0 0 0 0 0 0 12 9 0 15
4 12 Enterococcus faecalis 16 13 0 13 0 12 0 0 14 0 0 13 0 13 0 9
5 B32 T-PB Enterococcus faecalis 24 27 0 14 0 19 0 0 18 7 7 15 14 0 12 0
5 82 T-P1 Enterococcus faecalis 25 35 0 16 0 16 0 0 0 0 0 22 0 16 0 20
5 B2 T-PB Enterococcus faecalis 16 22 11 13 0 14 0 0 0 0 0 18 0 13 0 15
6 833 T-PB Entemococcusfabecafis 0 19 0 11 0 12 0 0 14 0 0 10 0 12 0 13
8 835 Enterococcus faecalis 18 19 0 12 0 10 0 19 13 0 0 0 0 12 0 13
9 86 T-PB Enterococcus faecalis 16 22 11 11 14 12 0 0 0 0 0 0 0 12 0 15
11 B8 Enterococcus faecais 19 19 11 9 0 12 0 0 0 0 0 0 10 11 0 13
11 838 Enterococcusfaecalis 21 24 11 11 10 13 0 0 0 0 0 0 10 12 0 13
15 C4 N, PB, B Enterococcus faecalis 23 25 0 13 0 18 0 0 18 0 0 11 16 0 11 0 12
16 CS N, 1, ~,GM Entero~ccus f-eca-is 20 21 0 13 0 18 0 0 17 0-0 10 14 0 11 0
16 Cs N, PB, ,GM Enterococcus feecafis 21 122 10 12 0 18 0 0 17 0 10 110 114 0 11 0 12
18 C7 GMV Enterococcus faecafis 19 24 11 11 10 0 0 0 0 0 0 10- 61 F 11 0 15
19 C8 GM Entemococcus faecais 25 27 15 10 0 0 0 0 0 0 0 10 1 1. 14 12 0 15
Table 2.5: Aerobic culture and Kirby-Bauer antimicrobial sensitivity results by isolate cultured, Part 1. Numbers
represent the zone of inhibition measured around each antimicrobial disk. Color coding indicates resistant
(red), sensitive (green) or intermediate (yellow) antimicrobial phenotype. Antimicrobial key: AMP- Ampicillin,
AMC- Amoxicillin/Clavulanic Acid, B- Bacitracin, CR- Cephalothin, E- Erythromycin, GM- Gentamicin, OX-
Oxacillin, SXT- Trimethoprim-Sulfamethoxazole, ENO- Enrofloxacin, TE- Tetracycline, T- Oxytetracycline, CRO-
Ceftriaxone, D- Doxycycline, N- Neomycin, CZ- Cefazolin, PB- Polymixin B, VA- Vancomycin
Animal ID Study ID Antimicrobial Culture Results AMP AMC B CR E GM OX SXT ENO TE T CRO D N CZ PB VA[Study Used___
7 B4 Escherichia coli 16 23 12 20 28 9 21 20 31 20 0
21 D2 Escherichia coli 17 20 14 19 24 9 18 19 26 11 0
13 C2 N, PB, B Group Afl-Streptococcus pyogenes 35 36 24 35 28 23 24 0 20 25 24 35 24 18 38 9
15 C4 N, PB, B Group A P-Streptococcus pyogenes 32 35 25 33 26 21 22 0 20 25 23 30 25 18 35 10
12 C1 GM Group C fl-Streptococcus dysgalactiae 38 40 26 37 30 21 25 0 15 25 26 36 24 0 26 11
13 C2 N, PB, B Group Cf-Streptococcus dysgalactiae 37 41 27 40 31 24 28 0 21 25 24 35 27 18 39 10
16 C5 N, PB, B, GM Group Cfl-Streptococcus dysgalactfae 37 39 27 38 28 22 27 0 20 27 26 35 28 18 35 10
19 C8 GM GroupC fl-Streptococcusdysgalactae 36 36 25 35 26 21 20 0 15 21 23 36 26 0 36 12
20 D1 Group C fl-Streptococcus dysgalactiae 43 43 29 41 32 25 29 0 30 31 30 42 31 18 42 8
5 B2 T-PB Group F f-Streptococcus constellatus 37 39 25 37 29 24 25 0 24 0 8 36 12 19 42 10
11 B8 Leuconostoc spp. 20 23 23 32 29 0 0 14 7 21 28 15 15 0
25 D6 Leuconostoc spp. 20 27 20 17 27 17 0 16 15 16 17 16 16 24 9 0
9 B6 T-PB Proteus mirabiis 0 19 15 18 0 12 8 0 33 17 9 0
14 C3 N, PB, B, GM Proteus mirabilis 0 20 18 0 0 0 0 29 0 15
15 C4 N, PB, B Proteus mirabilis 0 20 18 0 0 0 0 0 29 0 0
16 Cs N, PB, B, GM Proteus mirabilis 0 18 17 0 0 0 0 0 29 0 0
17 C6 N, PB, B Proteus mirabilis 0 20 17 0 0 12 0 0 23 0 0
24 D5 Proteus mirabilis 0 18 16 20 0 10 0 0 22 18 11
12 C1 GM Proteus penner 0 16 0 9 0 9 8 0 25 14 0 12
20 D1 Proteus sp. (unknown) 19 23 16 10 17 28 0 0 21 19 17 0
6 B3 T-PB Proteus vulgaris 0 15 0 9 0 31 0 0 0 17 21
6 B3 T-PB Proteus vulgaris 0 14 0 0 0 0 0 0 0 0 0
7 14 Proteus vulgaris 0 20 0 0 0 9 9 0 0 20 0
12 C1 GM Proteus vulgaris 0 16 0 11 0 10 8 0 24 15 0
Table 2.6: Aerobic culture and Kirby-Bauer antimicrobial sensitivity results by isolate cultured, Part 2. Numbers
represent the zone of inhibition measured around each antimicrobial disk. Color coding indicates resistant
(red), sensitive (green) or intermediate (yellow) antimicrobial phenotype. Antimicrobial key: AMP- Ampicillin,
AMC- Amoxicillin/Clavulanic Acid, B- Bacitracin, CR- Cephalothin, E- Erythromycin, GM- Gentamicin, OX-
Oxacillin, SXT- Trimethoprim-Sulfamethoxazole, ENO- Enrofloxacin, TE- Tetracycline, T- Oxytetracycline, CRO-
Ceftriaxone, D- Doxycycline, N- Neomycin, CZ- Cefazolin, PB- Polymixin B, VA- Vancomycin
CCO
Animal ID Study ID Antimicrobial Culture Results AMP AMC B CR E GM OX SXT ENO TE T CRO D N CZ PB VAUsed
1 Al GM Staphylococcus aureus 32 37 18 38 25 24 22 27 14 29 28 25 28 20 36 10
3 A3 ENO Staphylococcus aureus 37 38 15 37 0 29 23 22 10 29 27 26 30 25 35 11
4 B1 Staphylococcus aureus 31 35 18 38 28 23 20 29 14 29 28 27 29 18 34 0
5 B2 T-PB Staphylococcus aureus 38 37 19 39 28 22 21 28 14 27 27 26 29 21 33 14
6 B3 T-PB Staphylococcus aureus 39 37 18 37 25 18 21 26 12 23 23 24 19 35 8,
7 B4 Staphylococcus aureus 38 37 17 38 25 21 20 27 20 25 23 24 19 33 8
12 C1 GM Staphylococcus aureus 36 37 0 37 14 19 21 29 9 30 24 27 27 0 32 10
13 C2 N, PB, B Staphylococcus aureus 30 37 0 37 15 21 21 33 8 27 23 27 30 0 35 9
14 C3 N, PB, B, GM Staphylococcus aureus 36 34 0 34 19 21 21 28 8 26 25 25 28 0 33 9
15 C4 N, PB, B Staphylococcus aureus 30 33 0 35 14 21 20 28 0 25 24 24 27 0 34 10
16 C5 N, PB, B, GM Staphylococcus aureus 35 34 0 35 14 22 20 30 7 28 26 25 27 0 33 0
17 C6 N, PB, B Staphylococcus aureus 38 36 0 39 15 20 21 33 20 30 29 29 31 0 37 0
18 C7 GM Staphylococcus aureus 36 35 18 36 26 21 23 26 24 24 26 24 29 20 33 10
19 C8 GM Staphylococcus aureus 36 35 0 36 15 21 21 30 8 29 28 25 30 0 35 0
20 D1 Staphylococcus aureus 37 35 19 36 26 21 19 28 19 28 24 25 28 19 32 0
21 D2 Staphylococcus aureus 14 25 25 26 26 20 20 27 27 25 25 25 20 31 10
22 D3 Staphylococcus aureus 15 20 14 21 23 19 17 25 12 11 0 13 19 19 0
23 D4 Staphylococcus aureus 38 39 0 40 13 20 21 31 0 24 24 26 0 35 0
23 D4 Staphylococcus aureus 15 15 14 20 19 18 18 25 11 9 0 12 18 19 0
24 D5 Staphylococcus aureus 26 30 16 29 24 28 20 27 24 24 23 19 25 31 12
24 D5 Staphylococcus epidermnidis 45 45 14 46 27 28 27 29 29 26 26 35 23 40 12
5 B2 T-PB Staphylococcus intermedius 14 25 0 35 29 24 21 28 13 8 0 26 12 10 32 10
12 C1 GM Staphylococcus intermedius 32 39 0 40 16 21 22 31 0 28 28 29 29 0 34 10
14 C3 N, PB, B, GM Staphylococcus intermedius 30 34 0 35 14 22 20 29 8 24 23 24 24 0 33 10
24 D4 Staphylococcus intermedius 34 36 0 39 14 18 23 31 10 22 19 24 0 34 0
6 B3 T-PB Staphylococcus xylosus 0 14 0 0 0 0 0 0 9 0 0 25 19 35 8
8 B5 T-PB Streptococcus ubeis 18 20 0 13 0 0 0 0 12 0 0 17 0 12 0 13
10 B7 Streptococcus ubers 17 23 12 11 17 8 0 0 0 - 0 0 0 0 12 0 14
Table 2.7: Aerobic culture and Kirby-Bauer antimicrobial sensitivity results by isolate cultured, Part 3. Numbers
represent the zone of inhibition measured around each antimicrobial disk. Color coding indicates resistant
(red), sensitive (green) or intermediate (yellow) antimicrobial phenotype. Antimicrobial key: AMP- Ampicillin,
AMC- Amoxicillin/Clavulanic Acid, B- Bacitracin, CR- Cephalothin, E- Erythromycin, GM- Gentamicin, OX-
Oxacillin, SXT- Trimethoprim-Sulfamethoxazole, ENO- Enrofloxacin, TE- Tetracycline, T- Oxytetracycline, CRO-
Ceftriaxone, D- Doxycycline, N- Neomycin, CZ- Cefazolin, PB- Polymixin B, VA- Vancomycin
2.2.4 Updates to CRC sanitization protocols
implemented in September, 2014
Based on confirmed antimicrobial resistant phenotypes of bacterial species
present in chambers, in September, 2014, the MIT veterinary staff final-
ized updated recommendations for routine CRC sanitization procedures to
decrease indiscriminate antimicrobial use. Specific changes outlined tech-
niques to maintain asepsis when opening CRCs, including use of sterile,
single use instrument packs. Recommended solutions for sanitization in-
side CRCs were limited to 1-2% diluted povidone-iodine and sterile saline
due to the concern for neurotoxicity with hydrogen peroxide and chlorhexi-
dine. Recommendations for CRC sanitization frequency were based on the
amount and type of discharge present and determined by the veterinary
staff. Use of packing material other than silicone elastomer was discour-
aged, and use of topical antimicrobial agents within CRCs was strictly pro-
hibited without explicit veterinary approval. Perioperative systemic trimeth-
oprim-sulfamethoxazole and enrofloxacin have been replaced by cefazolin,
and post-operative ceftriaxone use is restricted to surgical procedures in-
volving a craniotomy. Animals with suspected meningitis now undergo
thorough diagnostic work-up, including culture and sensitivity testing of
isolates in cerebrospinal fluid to guide choices in antimicrobial therapy and
minimize further spread of bacterial resistance genes within the macaque
colony. Finally, Updated implant design utilizing MRI and computer-aided
design was recommended to customize implants to individual macaque
skull morphology and minimize the amount of PMMA required to stabilize
hardware.
2.3 Evaluation of bacterial species inhabiting
CRCs using next-generation sequencing
methods for 2017 samples
While culture-dependent methods can provide valuable insight into bac-
terial species colonizing CRCs, there are several limitations of these tech-
niques. First, species identification from 2011 was performed only from
aerobic cultures. We were interested in assessing anaerobic species, since
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they have been previously isolated from macaques with brain abscesses
and meningitis. Standard culture techniques are challenging to perform on
polymicrobial samples, as overgrowth of more prevalent, less-fastidious, or
rapidly-growing species may complicate isolation of less-prevalent, more-
fastidious and/or slower-growing species, and are dependent on the use
of selective media. Selection of unique, individual colonies for isolation in
mixed-culture samples is dependent on the skill of the microbiologist, and
colonies of closely-related species can look very similar on agar plates. Fi-
nally, use of biochemical testing based on commercially available API strips
is not 100% accurate in discriminating between closely related species
[21, 22, 231.
To overcome these limitations, we wished to explore culture-independent
methods for characterizing bacterial species living within CRCs. Advances
in next-generation sequencing technology have allowed multiple scientific
disciplines to characterize bacterial communities, from those colonizing
the human body, to those living beneath the ocean floor [24, 25]. The
microbiome is defined as the collective genomes of microbial symbionts,
while the microbiota is defined as the collective microbes, themselves [24].
Culture-independent methods of bacterial identification rely on using the
16S ribosomal RNA (rRNA) gene as a phylogenetic marker and comparison
of sequences to a reference database [26]. The 16S rRNA gene features
nine hypervariable regions, which display wide diversity between bacterial
species (Figure 2-1). The hypervariable regions are adjacent to highly con-
served sequences, which can be utilized for design of polymerase chain
reaction (PCR) primers [27].
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utilizes Illumina sequencing-by-synthesis techniques following PCR am-
plification of varying hypervariable regions (V1-V3, V3-V4, V4-V5, etc.)
[29, 30]. Sequences are compared to reference databases and typically
matched at a threshold of 95-97% sequence identity for assignment to an
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operational taxonomic unit (OTU); the microbiota equivalent of a "species"
[261. Ecological techniques used for macro-communities have been adapted
and widely used for microbiota diversity analysis. Alpha diversity metrics,
such as the Shannon diversity index, are used to estimate both the rich-
ness (number) and evenness (relative abundance) of OTUs within a single
community. Rarefaction curves are commonly displayed to illustrate the
relationship between the number of sequences per sample (i.e. richness)
as a function of the number of samples (sequencing depth) [26].
Amplify and Group similar
sExtract equence 16S -- sequences into
4 qUG DNA 797 rRNA gene Z OTUs
-Otis
Assign OTUs using database
'I (RDP, Greengenes)
Figure 2-2: Overview of steps from DNA extraction to community analysis
for microbiota studies.
Beta diversity measurements are used to compare overlap between pop-
ulations and can be evaluated using a distance or dissimilarity matrix such
as UniFrac [31]. Unweighted UniFrac uses both the presence and absence
of OTUs, as well as the branch length in a phylogenetic tree for population
comparisons, while weighted UniFrac also accounts for relative abundance
of OTUs [32]. Distances between populations can be visualized using prin-
cipal coordinate analysis (PCoA), where samples located closer together are
more closely related than samples located farther apart [31, 32]. The work-
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flow of microbiome analysis is illustrated in Figure 2-2.
To evaluate whether purulent exudate from macaque CRCs could be an-
alyzed using microbiota techniques, we performed a pilot study on seven
implanted macaques using samples collected in March-April 2017. The
goals of this study were to assess the anaerobic bacterial population of
CRC bacterial communities and compare bacterial communities between
macaques. Additionally, we were interested in comparing OTUs to previ-
ously identified and culture results.
2.4 Pilot study methods
2.4.1 Animals
Seven rhesus macaques (4 males and 3 females) under investigation by
three different laboratories were selected for sampling. Three macaques
had two CRCs, and four macaques had a single CRC. Samples from one
macaque with two CRCs were pooled, and samples for the other two mac-
aques with 2 CRCs were analyzed separately. Most CRCs had been in place
between 1-3 years (5 CRCs), 2 CRCs were implanted <1 year, and 2 CRCs
in the same individual (macaque #9) had been implanted 6 years previ-
ously (Table 2.8). Sampling was performed in chair-restrained macaques
just prior to routine CRC sanitization procedures. All macaques had a min-
imum washout period of 3 weeks with cessation of systemic antimicrobial
administration. A sterile syringe was used to collect 0.1-1 ml of exudate
from the CRC. Samples were collected into an empty sterile plastic vial,
and extra samples for culture, when available, were saved in freeze media
consisting of brucella broth with 20% glycerol and stored at -80'C until
processing.
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Animal Sex Age Lab ID Study ID Implant date # of CRCs CRC materials Culture Sample
ID (years) (month/year) Sampled Available?
26 F 7 A A4 10/16 1 Ultem, ceramic screws, PMMA Yes
27 M 8 E El 10/16 1 PEEK, titanium screws, PMMA No
28 M 17 B B9 3/15 2 PEEK, titanium screws, PMMA-free No
29 F 7 A A5 11/15 1 Ultem, ceramic screws, PMMA with gentamicin Yes
30 M 8 A A6 12/14 2 - pooled Delrin ceramic screws, PMMA with gentamicin Yes
9 M 18 B B6 4/11 2 Ultem, titanium screws, PMMA Yes
31 F 16 A A7 2/15 1 Delrin, ceramic screws, PMMA with gentamicin Yes
Table 2.8: Population characteristics of 7 research macaques sampled in March-April 2017.
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2.4.2 DNA extraction, sequencing and analysis
Genomic DNA was extracted from samples on the same day as collec-
tion using the DNA Microbiome kit according to manufacturer instructions
(Qiagen, USA). This kit was chosen due to inclusion of a benzonase pre-
treatment step. Benzonase degrades host DNA and was considered a ben-
eficial step, since most samples were visually purulent, containing a high
percentage of leukocytes. A maximum of 0.5 ml CRC exudate was used
for DNA extraction. Samples were submitted to the MIT BioMicro Cen-
ter Core facility for PCR amplification of the 16S rRNA V4 region, library
preparation and sequencing. Individual samples were barcoded and pooled
to construct the sequencing library using previously published protocols
[33]. F515 and R806 sequencing primers used are listed in Appendix B.
Sequencing was performed using an Illumina MiSeq to generate pair-ended
250x250 reads. Overlapping pair-end reads were aligned using QIIME 1.9.1
within the MicrobiomeHelper v. 2.0.0 virtual box [34, 33]. Quality filtering
of paired samples was performed using a Phred quality threshold of 20.
After quality filtering, the mean read length was approximately 295 bp.
The mean number of reads/sample was 270,886 (range 160,785-373,366
reads). Open reference OTU picking was performed on a total of 2,437,974
reads at 97% sequence similarity using the uclust method. Taxonomic as-
signments were determined using the Ribosomal Database Project classifier
against the GreenGenes database. Alpha diversity was determined using
Observed OTUs and Shannon Index metrics and displayed using rarefac-
tion curves. Beta-diversity was determined using unweighted and weighted
UniFrac and results displayed as PCoA plots [31]. Alpha and beta diversity
analyses were rarefied to the lowest sequencing depth of 160,785 reads.
OTUs were summarized at different taxonomic levels and displayed as bar
graphs.
2.4.3 Aerobic and anaerobic cultures of CRC samples
from pilot study animals
Samples from macaques #9, #26, #29, #30 and #31 were plated on 3%
Brucella agar plates in an anaerobic chamber (10% CO 2 , 10% H2, 80%
N 2 and incubated at 370 C for 48 hours. Morphologically different individ-
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ual colonies were selected for isolation, and replated onto 1.5% Brucella
agar (Remel). After 36-48 hours of incubation, colonies were examined,
Gram-stained and tested for aerotolerance. Aerotolerance was determined
by colony transfer to TSA with 5% sheep blood (Remel) and incubated aero-
bically at 370 C, 5% CO 2. For species identification, pure cultures of anaer-
obic and aerobic species were collected into lml of PBS, and spun for 3
minutes at 10,000 x g. Pellets were resuspended in 200pl of PBS, 25pil
was added to 75pld PBS and incubated for 10 minutes at 95'C. After heat-
ing, samples were centrifuged for 3 minutes at 10,000 x g. After measure-
ment of DNA concentrations using a NanoDrop spectrophotometer (Thermo
Fisher Scientific, Waltham, MA), samples were stored at -20 C. For samples
with low DNA yield (< 1 Ong/pl), 50pl of the resuspended pellet was added to
200pl of a mixture containing 5% Chelex- 100 resin and 0.02% proteinase K
and incubated at 560 C for 60 minutes. Samples were then vortexed, incu-
bated for 10 minutes at 95'C and centrifuged for 3 minutes at 10,000 x g.
PCR amplification of the 16S rRNA gene using the F9 and R1541 primers
was performed according to previously published protocols [35] using a
commercially-available bead-based PCR kit (illustra PuReTaq Ready-To-Go
PCR Beads, GE Healthcare Bio-Sciences, Pittsburgh, PA). PCR bands were
separated by electrophoresis on a 1% gel at 100- 120V for 30-40 minutes
and visualized with UV light following ethidium bromide staining. PCR
products (51 l) were purified by adding 2/l of a mixture containing 0.4 U/pl
exonuclease I and 0.4 U/pl shrimp alkaline phosphatase and incubated
for 20 min at 370 C followed by 20 min at 80-850 C. PCR products were sub-
mitted for sequencing at a commercial laboratory (Quintara Biosciences,
Cambridge, MA) and sequences identified using the Basic Local Alignment
Search Tool (https://blast.ncbi.nlm.nih.gov/Blast.cgi). For seven sam-
ples, multiple bands were visualized in the 1.5 Kb range and overnight cul-
tures plated on TSA with 5% sheep blood were identified using API Coryne
strips according to manufacturer instructions (bioM6rieux, Durham, NC).
2.4.4 Pilot results
Alpha diversity
Rarefaction curves, Shannon index and observed OTUs are displayed in
Figure 2-3. Rarefaction curves leveled off around 20,000 sequences sug-
47
gesting that sampling depth was sufficient to characterize bacterial com-
munities. The average Shannon diversity index was 4.76 and the average
number of observed OTUs was 989 per sample. Macaque #28 had a higher
number of observed OTUs (1883, 1953) and thus a higher Shannon index
(7.33 and 6.81) in CRCs 1 and 2, respectively as compared to the other
sampled macaques. Due to the small sample size and restriction of sample
type to CRCs only, no statistics were performed.
Beta diversity
PCoA plots of unweighted (top) and weighted (bottom) UniFrac distances
are displayed in Figure 2-4. On unweighted UniFrac plots, three predomi-
nant clusters were present. The 2 CRC samples from macaque#9 clustered
together, the 2 CRC samples from macaque #28 clustered together and 4
CRC samples from macaques #26, #27, #30 and #31 clustered together.
The CRC sample from macaque #29 was distinct from macaques #9 and
#28, and closer, but still slightly separated from the 4-sample CRC clus-
ter. On weighted UniFrac plots, the only discernable cluster were the two
samples from macaque #28.
Taxonomy Bar charts
Phylum and genus level bar charts are displayed in Figures 2-5 and 2-
6. At both the phylum and genus level, all macaques displayed a unique
CRC community composition. In macaques #26, #28 and #29, the Fir-
micutes phylum was predominant, while in macaques #30, #9 and #31,
the Fusobacteria phylum was predominant. Macaque #27 had approxi-
mately equal ratios of Firmicutes, Fusobacteria and Bacteroidetes phyla.
At the genus level, Fusobacterium spp. were detected in all macaques ex-
cept macaque #28. Fusobacterium spp. contributed to more than a quar-
ter of sample reads in CRC samples from macaques #9 (81% and 48%),
#27 (27%), #29 (27%), #30 (58%) and #31 (58%). The Clostridiales order
accounted for >70% and >54% of reads in the two CRCs from macaque
#28. Other selected OTUs representing >1% of sample reads in multiple
CRCs included Parvimonas, Bacteroides, Streptococcus, Peptinophilus, Pep-
trostreptococcus, and Porphyromonas, and Corynebacterium. Full pilot tax-
onomy results are archived at https : //f igshare. com/s/32f edb5a7ld548d52df 2.
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Figure 2-3: Rarefaction curves and alpha diversity results as calculated using the Shannon diversity index and
observed OTUs metrics for each CRC sample. Samples were rarefied to 160,785 reads
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Figure 2-5: Phylum-level taxonomic assignments for 9 CRCs from 7
macaques. Samples were rarefied to 160,785 reads
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Figure 2-6: Genus-level taxonomic assignments for 9 CRCs from 7 macaques. Note that genera representing
<1% of sample reads are represented as Other Bacteria. Samples were rarefied to 160,785 reads
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Pilot aerobic and anaerobic culture results
Aerobic and anaerobic culture results are displayed in Table 2.9. Overall,
despite the limited number of species cultured per sample, the majority
of culture results corresponded with identified OTUs representing more
than 0.5% of sample reads (Figure 2.9). Fusobacterium species were cul-
tured from 5/6 CRC samples with three CRCs culturing F. necrophorum
and two CRCs culturing F. nucleatum. Bacteroides was cultured from 4
CRCs, and Parvimonas micra and Corynebacterium ulcerans were cultured
from 3 CRCs each.
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Animal ID Isolate 02 tolerance 16S Sequencing Result Identity Coverage OTU Called OTU Percentage # Duplicateof Reads isolates
9 CRC 1 1 Anaerobic Fusobacterium necrophorum 99% 70% Fusobacterium 80.57%2 Anaerobic Bacteroides fragilis 100% 98% Bacteroides 0.56% 2
1 Anaerobic Finegoldia magna 99% 69% Finegoldia 7.42% 2
2 Anaerobic Fusobacterium necrophorum 99% 98% Fusobacterium 48.30% 2
3 Anaerobic Parvimonas micra 98% 69% Parvimonas 2.03%
9 CRC 2 4 Aerobic Corynebacterium ulcerans API Coryne Strip Corynebacterium 3.87% 4
5 Aerobic Streptococcus dysgalactiae subsp equisimilis 99% 86% Streptococcus 14.58%
6 Aerobic Enterococcus durans 99% 84% Enterococcus 0.93%
7 Aerobic Actinomyces sp. Marseille-P3257 90% 92% Actinomyces 0.09%
1 Anaerobic Parvimonas micra 99% 97% Parvimonas 37.40%
26 2 Aerobic Atopobacterphocae 98% 69% Carnobacteriaceae (family) 2.01%
3 Anaerobic Bacteroides fragilis 100% 86% Bacteroides 3.98%
1 Aerobic Staphylococcus aureus 99% 87% Staphylococcus 2.00% 3
2 Aerobic Streptococcus dysgalactiae subsp equisimilis 99% 70% Streptococcus 38.17%
29 3 Aerobic Corynebacterium ulcerans API Coryne Strip Corynebacterium 1.62% 24 Anaerobic Bacteroides fragiis 99% 98% Bacteroides 5.34% 3
5 Aerobic Neisseria baciiformis 99% 70% Neisseriaceae (family) 0.06%
6 Anaerobic Fusobacterium nucleatum 99% 70% Fusobacterium 26.67%
30 1 Anaerobic Fusobacterium necrophorum 99% 98% Fusobacterium 58.46% 32 Aerobic Streptococcus gordonfi 99% 71% Streptococcus 13.24%
1 Anaerobic Bacteroides fragilis 99% 70% Bacteroides 5.99% 2
2 Aerobic Staphylococcus aureus 99% 70% Staphylococcus 1.02%
3 Anaerobic Fusobacterium nucleatum 99% 99% Fusobacterium 57.95% 2
31 4 Anaerobic Negativicoccus massiliensis 96% 74% Dialister 0.45%
5 Aerobic Corynebacterium ulcerans 97% 98% Coiynebacterium 3.10% 5
6 Anaerobic Parvimonas micra 98% 96% Parvimonas 4.86%
Table 2.9: Aerobic and anaerobic culture results from
was performed by PCR amplification and sequencing
6 CRC samples from 5 macaques.
of the 1.5Kb 16S rRNA gene with
Species identification
identity and coverage
referring to results from NCBI BLAST. Two Corynebacterium ulcerans isolates were identified using the API Coryne
strip. Culture results are compared to the OTU called and OTU percentage of reads from microbiota sequencing
results for each macaque.
Discussion
The amount of variation in CRC communities was surprising, as was the
extent of the anaerobic component. We hypothesized that macaques with
multiple CRCs would have similar communities within their CRCs. While
this was the case for macaque #28, the bacterial communities in macaque
#9's two CRCs differed in OTU abundance, as visualized on both weighted
UniFrac plots (Figure 2-4) and taxonomy bar charts (Figures 2-5, 2-6). The
genus-level taxonomy bar chart identified larger percentages of reads as-
signed to Fusobacterium spp. and Parvimonas spp. in macaque #9's CRC
1, versus larger number of reads assigned to Streptococcus spp., Finegoldia
spp. and Staphylococcus spp. in CRC 2. The four CRC samples that clus-
tered together on unweighted UniFrac (from macaques #26, #27, #30 and
#31) represented animals under study by two different laboratories, with-
out obvious commonalities in age of CRC, CRC style, or implant materials
used. It should be noted that macaque #28 had PMMA-free CRCs, and this
is one possible factor contributing to the marked differences in observed
bacterial communities. Unfortunately, the small numbers of CRCs sam-
pled in this study complicates the ability to draw robust conclusions on
how CRC materials affect bacterial community composition.
When comparing culture-dependent and culture-independent bacterial
identification, two genera differed in results from sequencing the whole
1.5Kb 16S rRNA gene as compared to the OTU taxonomic assignment.
Atopobacter phocae, a member of the Lactobacillus order and Carnobacte-
riaceae family was identified from macaque #26, and Negativicoccus mas-
siliensis, a member of the Veillonellales order and Vellionellaceae family
from macaque #31 [36, 37]. OTU taxonomic assignment most likely clas-
sified Negativicoccus massiliensis as the Dialister genus; these species are
closely related, phylogenetically [37]. While, there were some OTUs identi-
fied as representing >1% of sample reads that were not identified on cul-
ture, (i.e. Porphyromonas spp. and Peptostreptococcus spp.) our culture
results did validate the use of the microbiota pipeline as a tool to correctly
identify many prominent species from grossly purulent samples.
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2.5 Expanded microbiota study
With pilot study results confirming that culture-independent methods were
able to successfully characterize CRC bacterial communities, we expanded
our investigation to include more macaques, and sample CRCs in parallel
with other body sites to identify primary sources of CRC colonization. 18
macaques were selected for sampling to compare CRC communities with
skin, oral and fecal communities.
2.5.1 Animals
Samples from 18 implanted macaques were used for the expanded micro-
biota study. The population consisted of 3 females and 15 males ranging
in age from 4 years to 19 years, and under investigation by four differ-
ent laboratories (Tables 2.10, 2.11). Four macaques had two CRCs sam-
pled separately, two macaques had three CRCs sampled separately and
the remaining 13 macaques had a single CRC. Macaques #37 and #39 had
PMMA-free implants. Oral swabs and fresh fecal samples were collected
from all 18 macaques, and swabs of the skin-CRC implant margin were
collected for 17/18 macaques for a total of 79 samples (Tables 2.10, 2.11).
3/18 macaques sampled for the expanded study were also sampled during
the pilot study (macaques #9, #29 and #30).
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Animal Age History of Pair Lab Study Samples CRC Implant materialsper
ID (years) Housing ID ID Implant date Sample
CRC 4/2011 Ultem, titanium scws, PMMA25
CRC 2 421UtettnuscesPMA6954
9 M 19 No B B6 oral swab 24824
skin margin 8661
feces 6761
CRC 1 11/2015 Ultem, ceramic screws, PMMA 3115
29 F 8 Yes A AS oral swab 32872
skin margin 3324
feces 5160
CRC 1 3660
CRC 2 12/14 Delrin, ceramic screws, PMMA w/gentamicin 1729
30 M 9 Yes A A6 CRC 3 987
oral swab 13481
feces 15100
CRC 9/2015 Ultem, ceramic screws, PMMA w/gentamicin 5245
32 F 13 Yes A AB oral swab 23604
skin margin 2139
feces 12361
CRC 7/2017 PEEK, titanium brackets/screws, PMMA 24457
33 M 5 Yes E E2 oral swab 33487
skin margin 19359
feces 8169
CRC 8/2017 PEEK, titanium brackets/screws, PMMA 7308
34 M 8 Yes E E3 oral swab 22533
skin margin 14318
feces 10392
CRC 2 4/2017 PEEK, ceramic screws, PMMA 12
35 M 19 No B B10 oral swab 24795
skin margin 4835
feces 6734
CRC 4/2017 PEEK, titanium brackets/screws, PMMA 6392
36 M 5 Yes E E4 oral swab 25590
skin margin 497
feces 7534
unknown; R2 8/2012 PEEK, titanium screws, PMMA-free 315
37 M mature Yes B B11 oral swab 24997
adult skin margin 19514
I_ I II I feces 2756
Table 2.10: Demographs of 18 implanted macaques, part 1
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Animal Sex Age History of Pair Lab Study [ CRC Implant matesCounts per
ID (years) Housing ID ID Implant date Sample
CRC 6/2017 Ultem, ceramic + titanium screws, PMMA 1379
38 F 7 Yes A A9 oral swab 24108skin margin 6962
feces 11311
CRC 1 2192
CRC 2 9/2017 PEEK, ceramic screws, PMMA-free 35
39 M 9 Yes B B11 CRC 3 255oral swab 27066
skin margin 10244
feces 2507
CRC 1 10/2014 Ultem, titanium screws, PMMA 60
CRC 2 6/2013 6010___________ ____
40 M 10 No B B12 oral swab 22912
skin margin 4287
feces 10185
CRC 1 5/2017 Cilux, ceramic screws, PMMA 309
41 M 5 Yes D D7 oral swab 28807skin margin 598
feces 15617
CRC 1 7/2014 Stainless steel, titanium, PMMA 3946
42 M 9 Yes D D8 oral swab 22390skin margin 3799
feces 2033
CRC 1 9/2017 Cilux, ceramic screws, PMMA 214
43 M 4 Yes D D9 oral swab 22685skin margin 473
feces 8226
CRC 1 2/2017 Stainless steel, titanium, PMMA 9617
44 M 5 Yes D D10 oral swab 26205skin margin 2088
feces 11506
CRC 1 5/2016 PEEK, titanium + stainless steel screws, PMMA 5221
45 M 8 Yes E E5 oral swab 29422
skin margin 3839
feces 32103
CRC 1 3/2017 PEEK, titanium screws, PMMA 7516
46 M 5 Yes E E6 oral swab 22175skin margin 23310
feces 6192
Table 2.11: Demographs of 18 implanted macaques, part 2
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2.5.2 DNA extraction, sequencing and analysis
Genomic DNA was extracted from samples using the DNeasy PowerLyzer
PowerSoil kit according to manufacturer instructions (Qiagen, USA). This
kit was chosen due to its versatility in handling a wide range of sam-
ple types, after consultation with the manufacturer for recommendations.
Samples were stored at -80'C if same-day processing could not be per-
formed. A maximum of 0.2 ml CRC exudate and 0.2g of feces was used for
DNA extraction; oral and skin swabs were added directly to the glass bead
tubes with solution C 1. Bead beating was performed for 8 minutes (Bullet
Blender, Next Advance, Troy, NY). Genomic DNA from individual samples
were barcoded and pooled to construct the sequencing library using previ-
ously published protocols [33] and submitted to the MIT BioMicro Center
core facility for PCR amplification of the 16S rRNA V4-V5 region. Sequenc-
ing was performed using an Illumina MiSeq to generate pair-ended 300x300
reads. F515 and R926 sequencing primers used are listed in Appendix
B. Overlapping pair-end reads were aligned using PEAR and paired reads
shorter than 200 bp were filtered out [38]. Subsequent analysis and nor-
malization were performed using QIIME 1.9.1 within the MicrobiomeHelper
v. 2.0.0 virtual box [34, 331. Chimeric sequences were removed by com-
parison to the database BacteriaRDPtrainseti5_092015.fa. OTUs were
assigned using open reference picking, as previously described for the pilot
study, and OTUs present at less than 0.1% of reads were removed. The
average number of reads/sample for all sites was 11,252 sequences. The
average number of reads for CRC, skin, oral and fecal samples were 5,158,
7,543, 25,108 and 9,702, respectively. Taxonomic assignments were deter-
mined using the Ribosomal Database Project classifier against the Green-
Genes database. To control for differences in sequencing depth, OTU tables
were rarified at a single sequencing depth. Alpha diversity was determined
using Observed OTUs and Shannon Index metrics and displayed using rar-
efaction curves. Differences in alpha diversity between sampling sites were
calculated using a non-parametric two-sample t-test using 999 Monte Carlo
permutations in QIIME with P < 0.05 considered significant. Beta-diversity
was determined using unweighted and weighted UniFrac and results dis-
played as PCoA plots [31]. Statistical analysis of beta diversity between
communities within samples from each macaque was evaluated using an
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unweighted Unifrac Monte Carlo significance test with 100 permutations,
with Boferroni-corrected P<0.05 considered significant. OTUs were sum-
marized at the phylum and genus level, and displayed as bar graphs. Tax-
onomy data rarefied to 200 sequences and 1000 sequences are archived at
https : //f igshare. com/s/75b7leeeOdOe2O84aldc. For display purposes, gen-
era representing <1% of reads were classified as "Other Bacteria".
2.5.3 May-June 2018 Diagnostic lab aerobic and
anaerobic cultures and Kirby-Bauer sensitivities
Sterile culture swabs (CultureSwab MaxV(+), BD, Franklin Lakes, NJ) were
used to sample the interior of cephalic recording chambers, including any
discharge present. The swabs were plated onto chocolate agar, trypticase
soy agar with 5% sheep blood, MacConkey agar and CDC anaerobic agar
with 5% sheep blood, and incubated at 370 C in 5% CO 2 for 24 h (aerobic)
or within anaerobic containers. The swabs, themselves, were then incu-
bated in thioglycollate broth at 370 C for 24 h and re-plated onto the media
listed above. Microbial growth was streaked onto blood agar to obtain iso-
lated colonies, which were then identified using the Analytical Profile Index
identification system (API 20 E, API 20 Staph and API 20 Strep, bioMerieux,
Durham, NC). Antibiotic susceptibility profiles were determined by disk dif-
fusion using the Clinical and Laboratory Standards Institute break points
(M2-A10) [20]. Antimicrobial agents tested on non-Corynebacterium aer-
obic isolates included ampicillin, amoxicillin/clavulanic acid, bacitracin
(Gram positive bacteria only), ceftriaxone, cefazolin, cephalothin, chloram-
phenicol, enrofloxacin, erythromycin (Gram positive bacteria only), gen-
tamicin, linezolid, meropenem, neomycin, oxacillin (Gram positive bacte-
ria only), streptomycin, trimethoprim/sulfa-methoxazole, tetracycline, and
vancomycin. Gentamicin, chloramphenicol, streptomycin, and vancomycin
disks were purchased from BD (BBL Sensi-Disc, Franklin Lakes, New Jer-
sey); the remainder of the antimicrobial disks were obtained from Oxoid
(Basingstoke, United Kingdom).
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2.6 Results
2.6.1 Sequence counts
Ten samples had sequence counts <1000, including macaque #30 CRC 3,
macaque #35 CRC 2, macaque #36 skin margin, macaque #37 CRC 1,
macaque #39 CRC 2 and 3, macaque #41 CRC 1 and skin margin, and
macaque #43 CRC 1 and skin margin (Tables 2.10, 2.11). To account
for discrepancies in sequence counts, and minimize sample loss, diversity
analysis was performed with rarefaction to both 200 sequences and 1000
sequences. Unless otherwise stated, results from samples rarefied to 1000
sequences will be presented.
2.6.2 Alpha diversity
Rarefaction curves and alpha diversity were analyzed from samples rarefied
to 1000 sequences. Shannon diversity, observed OTUs and boxplots com-
paring sampling sites are displayed in Figure 2-7. Non-parametric Monte
Carlo permutations identified that fecal samples have a significantly higher
alpha diversity as measured by both the Shannon index and observed OTU
metrics compared to CRC samples, oral samples and skin margin samples
(** P=0.006, *P=0.012). Oral samples displayed a higher alpha diversity
than CRC samples for both the Shannon index and observed OTU metrics
(**P=0.006, *P=0.018). Skin samples displayed a higher alpha diversity
than CRC samples as measured by the Shannon diversity index (*P=0.0 18),
but not from the observed OTU metric. Differences between these methods
are because the Shannon diversity index accounts for both richness and
evenness, while the observed OTU metric only accounts for richness. Av-
erage alpha diversity measurements are displayed in Table 2.12. Overall,
the mean CRC alpha diversity was decreased for the expanded study as
compared to the pilot study (Shannon 3.4 vs. 4.8; observed OTUs 61 vs.
989). These differences may be related to low numbers of reads for some
CRC samples, and differences in extraction kits (smaller sample volumes
used in the PowerLyzer kit and decreased efficiency for extracting bacterial
from host DNA without the benzonase pre-treatment step).
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Site J Average Shannon Diversity Index Average Observed OTUs
CRC (N=19) 3.427863696 61
Feces(N=18) 6.1937195 230
Oral (N=18) 4.987944393 109
Skin (N=14) 4.715879701 126
Table 2.12: Average Shannon diversity index and observed OTUs for each
sampling site.
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Figure 2-7: Rarefaction curves and boxplots comparing alpha diversity results as calculated using the Shannon
diversity index and observed OTUs metrics between sampling sites. Differences between alpha diversity calcu-
lated using a non-parametric, two-sample t-test using 999 Monte Carlo permutations. ** P=0.OO6, *P<0.02.
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2.6.3 Beta Diversity
PCoA plots of unweighted and weighted UniFrac distances of samples by
site, rarefied to 1000 sequences, are displayed in Figure 2-8. On both un-
weighted and weighted UniFrac plots, fecal samples and oral samples clus-
tered together, while CRC and skin margin samples were more intermixed.
To better understand the source of bacteria colonizing CRCs, we compared
unweighted Unifrac beta-diversity within all samples from each macaque,
individually. Unweighted UniFrac was chosen for this comparison to focus
on OTUs only, rather than their abundance. Non-parametric Monte Carlo
simulations identified that CRC communities were significantly different
from fecal, skin, oral, and other CRC communities in 85% (22/26), 26%
(6/23), 27% (7/26), and 20% (2/10) of macaques, respectively (Table 2.13).
Within-Macaque N Bonferroni-Corrected P 5 0.01 Bonferroni-Corrected P = 1
Comparison (significant) (non-significant)
CRC vs. Feces 26 22 (85%) 4 (15%)
CRC vs. Skin 23 6 (26%) 17 (74%)
CRC vs. Oral 26 7 (27%) 19 (73%)
CRC vs. CRC 10 2(20%) 8 (80%)
Table 2.13: Number (%) of macaques with significant and non-significant
differences in beta diversity between CRCs and other body sites, as mea-
sured by unweighted UniFrac.
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2.6.4 Taxonomy Bar Charts
Comparison of sampling sites
At the phylum level, fecal samples were predominated by Bacteroidetes and
Firmicutes, whereas oral, CRC, and skin samples had contributions from
Fusobacteria. CRC and skin samples had larger contributions from Acti-
nobacteria, and oral samples had larger contributions from Proteobacteria
(Figure 2-9).
At the genus level, fecal samples had a larger contribution of samples
from the Bacteriodales order (18%) and Prevotella spp. (24%) compared
to oral, CRC, and skin samples (Figure 2-10). Oral, CRC, and skin sam-
ples had larger contributions of samples reads from Porphyromonas spp.,
which was present at <1% of reads in fecal samples. Streptococcus spp.
were present in higher percentages in oral and skin samples (14-15%) as
compared to CRC and fecal samples (2-3%). Parvimonas spp. were present
in both CRC and skin samples around 6% and present at <1% in fecal and
oral samples.
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Figure 2-9: Phylum-level taxonomy bar chart from samples rarefied to 1000 sequences. Feces (N=18), Oral
(N=18), CRC (N=19), Skin (N=14) samples.
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Figure 2-10: Genus-level taxonomy bar chart from samples rarefied to 1000 sequences. Feces (N=18), Oral
(N=18), CRC (N=19), Skin (N=14) samples.
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Individual sites
CRCs
As in the pilot study, all macaques displayed a unique CRC community
composition at both the phylum and genus level (Figures 2-11, 2-12). At
the phylum level, 15/19 CRCs were comprised of >40% Bacteroidetes phyla
with varying contributions from the Firmicutes and Fusobacteria phyla.
CRC 1 from Macaque #39 displayed a markedly different distribution of
phyla compared to the other macaques, with Firmicutes contributing as
69.7% of phyla. The CRC from macaque #38 was also different, with Fu-
sobacteria contributing 55% of phyla with Bacteroidetes and Firmicutes
only contributing 7-8% each. Macaque #44 was mostly split between Bac-
teroidetes (49%) and Fusobacteria (45%) phyla.
At the genus level, OTUs identified in high prevalence were similar to
those identified in the pilot study, including Fusobacterium spp., Bacteroides
spp., Corynebacterium spp., Porphyromonas spp., Prevotella spp., Parvi-
monas spp., Streptococcus spp., and Staphylococcus spp.. Staphlyococcus
spp. was identified to contribute 35% of reads for CRC 1 from Macaque
#39, explaining the source of the high percentage of Firmicutes identified
at the phylum level. Macaque #39 had a PMMA-free implant and the two
other CRCs of this animal had low sample reads (35 and 255; Table 2.11).
We did not appreciate any effects of the age of CRC implant duration on the
taxonomy distribution.
69
I I I I I I I I I I I
9CRC19CRC2 29 30 CRC 30 CRC 32 33 34 35 CRC 36 37
1 2 1
I I I I I I I I0.90.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
"Unassigned;Other
"*k__Bacteria; p__WPS-2
*k__Bactenia;perrucomicrobia
"k__Bacteriam-penericutes
" k_Bacteria;pSynergistetes
" k_Bacteria;p_Spirochaetes
" k_Bacteria;p_SR1
Sk__Bacteria;pProteobacteria
Sk__Bacteria;pPlanctomycetes
" k_Bacteria;pLentisphaerae
*k_Bactera;pFusobactera
Sk__Bactera;p_Firmicutes
Sk__Bactera;p__Fibrobacteres
Sk__Archaea;pEuryarchaeota
k__Bacteria;p_Elusimicrobia
" k_Bactera;pCyanobactera
" k_Bacteria;p__Bacteroidetes
Sk_Bacteria;p_Actinobacteria
Figure 2-11: Phylum-level taxonomy bar chart from CRC samples rarefied to 1000 sequences.
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* Proteobacteria;cEpsilonproteobacteria;o_CampylobacteralesIfCampybacteraceae;g__Campylobacter
Fusobacteria;Fusobacteria;cFusobacteriao__Fusobacteralef_Fusobacteraceae;gFusobcteium
* Fusobacteria;cFusobacterla;o_Fusobacteriales;f_Leptoichlaceae;Other
Fusobacteria;c_Fusobacterla-o_Fusobacteriales;fLeptotichlaceae;g__Leptotrichia
* Fusobacteria;cFusobacterla;o_FusobacteriaesIfLeptotrichIaceae;g_
*Firmicutes;c_Bacilli;oLactobacdlaesf_Streptococcaceae;g_Streptococcus
* Firmicutes;c_Bacill;o_Lactobacillalesf_Lactobacillaceae;g_Lactobacillus
* Firmcutes;c_Bacilli;o_LactobacllalesIf_Enterococcaceae;gEnterococcus
EFirmicutes;c_Badlli;o_BacialesfStaphylococceceae;gStaphylococcus
*Firmicutes;c_Erysipelotrichi;_ErysipelotichalesfErysipelotrichacee;g_[Eubacterium
* Firmicutes;c_Costridia;o_Clostridialeslf_Vellbonelaceae;gSelenomonas
* Firmicutes;c__Clostridia;o_Clostridiales;f_Ruminococcaceae;gRuminococcus
* Firmicutes;cClostridla;o_Clostridialeslf_Ruminococcaceae;g_
* Firmicutes;c_Clostridla;o_ClostridialeslPeptostreptococcacee;g_Pepto8treptococcus
" Firmicutes;cClostrida;o_Clostridiales;fPeptostreptococcaceae;g_Flifactor
* Firmicutes;cClostridla;oClostridiales;fPeptococcaceae;gPeptococcus
* Firmicutes;cClostridla;o_Clostridiales;f_Lachnospiraceae;gBlautla
* Firmicutes;cClostridia;o_Clostridiales.fLachnospraceae;g_
" Firmicutes;c__Clostridia;o_Clostridiales;f_[Tssierllacee];gPeptonlphilus
* FirmIcutes;_CostridIa;oClostddiales;f _[TsserIIaceae];gParvmonas
"Firmicutes;c_Clostridla;o_Clostridiales;f__Tsslerellaceae];gAnaerococcus
* Firmicutes;c__Clostrdia;o_Clostridiales;f___;g_
* BacteroIdetes;c__Flavobacterliao_Flavobacteuiales;f__Flavobacteriaceae;gCapnocytophaga
* Bacteroidetes;cBacteroidla;o_Baeroidales;fS24-7;g_
" Bacteroidetes;c_Bacteroidia;o_Bacteroidales;fPrevotellaceae;g___.Prevotella
* Bacteroldetes;c_Bactemidia;o_Bacteroidales;fPorphyromonadaceae;g_Tannerella
"Bacterokdetes;c_Bacteroidia;o_Bacteroidales;LGp-2534-18B5;g_
" Bacterokdetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidacee;g_Bacterodes
" Bacteroidetes;c_Bactemidia;o_Bacteroidales;f_[Paraprevotellaceae];gCF231
" Bacteroidetes;c__Bacteroidia;o_Bacteroidales;f_;g_
" Bacteroidetes;Bacteroidetes;cBacteroidia;o_Bacteroidales;I_Porphyromonadaceae;g_Porphyromonas
" Actinobacteria;c_Aclnobacteria;o_AcUtnomycetales*f_Corynebacteriaceae;g_Corynebacterium
* Actinobacteria;cActnobactea;oAcflnomycetalesf_Adinomycetaceae;g_Arcanobacterium
Figure 2-12: Genus-level taxonomy bar chart from CRC samples rarefied
to 1000 sequences.
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Macaques with multiple CRCs
To better compare communities in macaques with multiple CRCs we exam-
ined phylum-level and genus-level taxonomy bar charts for samples rarefied
to 200 sequences for macaques #9 (2 CRCs), #30 (3 CRCs), #35 (2 CRCs),
#37 (2 CRCs), #39 (2 CRCs) and #40 (2 CRCs) (Figure 2-13). Even with
rarefaction to a sequence count of 200, CRC 2 from macaque #39 did not
have enough reads for inclusion in the analysis. At the phylum level, sim-
ilar community compositions were noted for macaques #9, #30 (CRCs 1
and 3) and #40. Macaque #30 CRC 2 had higher levels of the Actinobac-
teria phyla compared to CRCs 1 and 3. Macaque #37 CRC 1 had more
Firmicutes in CRC 1 and more Bacteroidetes and Fusobacteria in CRC 2.
Macaque #39 had more Tenericutes and Actinobacteria and less Firmicutes
and Bacteroidetes in CRC 3 vs. CRC 1.
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Figure 2-13: Phylum-level taxonomy bar chart from macaques with multiple CRC samples, rarefied to 200
sequences.
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At the genus level (Figure 2-14), differences in community composi-
tion between CRCs from the same macaque were more readily apparent.
Macaque #9 (CRC 1 and 2) and macaque # 30 (CRC 1 and 3) had the most
visually similar bar charts of all paired CRC samples. The two macaques
with significant differences between CRCs, as identified by unweighted
UniFrac Monte Carlo simulations, were macaques #30 (CRC 1 vs. 2) and
macaque #37. Macaque #30 CRC 2 had a larger contribution from Coryne-
bacterium spp. as compared to CRCs 1 and 3. Macaque #37 also dis-
played marked differences in taxonomic contributions, as CRC 2 had 69%
of sample reads from Porphyromonas spp. and 17% of sample reads from
Fusobacterium spp. while CRC 1 had more diverse contributions from the
Ruminococceacaea family, BS1 1 family from the Bacteriodales order and
Staphylococcus genus. For macaque #35, CRC 1 had large contributions of
sample reads from Porphyromonas spp. (47%) and Bacteroides spp. (31%),
whereas CRC 2 had more OTUs contributing to diversity and only 4% of
reads from Porphyromonas spp..
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WPS-2;c_;o_;f 
_;g_
Tenericutes;c_Mollicutes;o_RF39;f_;g_
Tenericutes;c__Mollicutes;o__MycoplasmatalesfMycopIasmataceae;gMycoplasma
Synergistetes;cSynergisUa;o_Synergistaes;fDethiosulfovibronaceae;gTG5
Spirochates;cSpirochaetes;oSpiochatales;fSpirochaetaceae;g_Treponema
Proteobacteria;cGammaproteobacteria;oPseudomonadales;fPseudomonadaceae;gPseudomonas
Proteobacteria;cGammaproteobacteria;o_Pasteurelalesf_Pasteurellacese;gActinobacillus
SProteobacteria;c._Gammaproteobacteriao_Enterobacterlales;__Enterobacteracee;gProteus
a Proteobacterla;cGammaproteobacteria;o_Enterobacterales;f_Enterobacterlaceae;g_
- Proteobacteria;cDeltaproteobacteria;oDesulfovtbrionales;fDesulfovibrionaceae;g_Desulfovibrio
Proteobacteria;cDeltaproteobacterla;o_Desuftvbrionales;Desulfovibrionacee;gBilophila
Proteobacteria;cBetaproteobacteria;oNeisserlales;fNeisserlaceae;g_
*Fusobacteria;c_Fusobacterlia;o_Fusobacteriales;fLeptotdchlaceae;gLeptotichia
Fusobacteria;c_Fusobacteria;o__Fusobacteriales;f_Fusobacteriaceae;gFusobacterium
'Firmlicutes;cEryspelotrchl;oErysipelotrlchles;fErysipeloichaceae;gJEubacterium]
* Firnicutes;c_Erysipelotrchi;oErysipelotrichalesILErysiplotrichaceae;g_Catenibacterium
*Firmicutes;cClostridia;o_Clostridialesl__Tsslerellaceae;gParvimonas
"Firmicutes;c__Clostridia;oClostidiales;_Ruminococcaceae;gOscillospira
*Firmicutes;cClostridia;oClosrdialesfRuminococcacee;g_
Firmicutes;cClostridia;o_Ckostridales;fRuminococcaceae;Other
*Firmicutes; _Closridia;oClostridiales_Peptostreptococcaceae;gPeptostreptococcus
*Firmicutes;cClostddia;oClostridialesl__Lachnospiraceae;g_Blautla
*Firmicutes;cClostridia;oClostidiales;i_Lachnospiraceae;g_
'Firmicutes;cClostddia;o_Costridiales;fChristensenellaceae;g_
*Firmicutes;cClostridia;o__Cslrdiales;f_;g_
*Firmicutes; _Bacilli;o_Lactobacillaies-f_Streptococcceae;gStreptococcus
" Firmicutes;cBacilli;o_Lactobaciflaies;f__Lactobacdllaceae;g_.Lactobailus
" Firmicutes;cBacilli;o_Lactobacillales;f__Enterococcaceae;gEnterococcus
"Firmicutes;cBacilli;o__Bacillales;fStaphylococcaceae;g__.Staphylococcus
* Fibrobacteres;c_Fibmbacteria;o_Fibrobacterales_Fibrobacteraceae;g_Fbrobacter
" Bacteroidetes;c_Flavobacterioa;__Flavobacterlales;fFlavobacteraceae;g_Capnocytophaga
a Bacteroidetes;c_Bacteroidia;o__Bacteroldalesf_p-2534-18B5;g_
" Bacteroidetes;c_Bacteroldla;o_Bacteroldalesf_[Paraprevotellaceae;g_YRC22
" Bacteroidetes;c_Bacteroldioa;_Bacteroldales.f_[Paraprevotellaceae);gCF231
" Bacteroidetes;c_Bacteroldia;o_Bacterodales;fjOdodbacteraceae];gOdoribacter
* Bacteroidetes;c__Bacteroidia;o_Bacteroidales;fS24-7;g_
" Bacteroidetes;c_Bacteroidia;o_Bacteroidalesif_Prevotellaceae;gPrevotella
" Bacteroidetes;c__Bacteroidla;o_Bacteroidales;_Porphyromonadaeae;gTannerella
" Bacteroidetes;c._Bacteroidia;o_Bacterodales;fPorphyromonadaceae;gPorphyromonas
" Bacteroidetes;c_Bacteroidla;o_Bacteroidales;fPorphyromonadaceae;gParabacterodes
" Bacteroidetes;c_Bacteroidia;o_Bacteridaleslf_Bacteroidaceae;gBacteroides
" Bacteroidetes;c__Bacteroidia;o_Bacteroidales;fBS 11;g_
" Bacteroidetes;c_ia;Q_Bio_Bateroidales;f_;g_
" Actinobacterla;c_Actinobacteria;oAcnomycetales;fProponibacteraceae;gPropionibcterium
" Actnobacteria;c_Acfinobacteria;oActlnomycetales;f_Corynebacteraceae;g_Corynebacterium
" Actinobacterla;cAcinobacteria;oActlnomycetales;fActnomycetaceae;gArcanobactedum
Figure 2-14: Genus-level taxonomy bar chart from macaques with multiple
CRC samples, rarefied to 200 sequences. Note that genera representing
<1% of sample reads are represented as Other Bacteria.
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Skin swabs
At the phylum level, bacterial community composition of skin-implant mar-
gin swabs were very similar with minor differences (Figure 2-15). The Bac-
teriodetes phylum contributed approximately 33% of sample reads on av-
erage, with smaller contributions for macaques #29, #33 and #38 (9-10%)
and larger contributions for macaques #32, #35 and #40 (60-70%). The Fir-
micutes phylum contributed 40% of sample reads on average, with smaller
contributions in the three macaques with more Bacteriodetes. Fusobac-
terium contributed approximately 18% of samples reads on average, with
macaques #9 and #29 having larger contributions (38-46%).
At the genus level, genera contributing to a higher prevalence of reads
for skin sample communities included Staphylococcus, Streptococcus, Fu-
sobacterium, Porphyromonas, Parvimonas, Corynebacterium and Prevotella
(Figure 2-16).
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Figure 2-15: Phylum-level taxonomy bar chart for skin-implant swab samples rarefied to 1000 sequences.
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Tenerdcutes;cMollicutes;oRF39;f_;g_
S istetes;c Synergisa;o Synergistales;fDethiosulfovibrionaceae; TG5
Spioaetes;c pih aeteso Spirochaetalesf Spirochaetaceae; Treponema
Proteobacteriac GammapmteoacterIa;o Pseudoonadales;f Psmonadaceae;gPseudomonas
Proteobacteria;c...Gammaprotobacteda;o Pseudomonadales;frMoraxellaceae;g MoraxellaProteobacteria;c Gammaprotobacteria;o~~Pasteureales;f Pateurellaceae;gKgregaIbacter
sProteobacteria;c Gammaproobacteria;o~Entebacterialf Enterobacteriaceae;gProteus
SProteobacteria;c Betaproteobacterta;o Burkholderl es;fCoamonadaceae;gComamonas
Fusobacteria;c Tusobacteriia;o_Fusobacteriales;f Leptotrchiacae;gLeptodchia
Fusobacteria;c__Fusobacterila;oFusobacteriales; Leptotrichlaeae;g
* Fusobacterla;c FusobactedIa;cLFusobacteriales Leptobchaceae;Other
Fusobactera;c Fusobactedia;o Fusobacteriales;_Fusobacteriaceae;g_FusobacteriumjwFIrmicutes;c iysipelotrchi;o_ pelotichales;f EryaIpelotrichaceae;g [Eubacternum]
w Firmicutes;c Clostridla;o Cltridialesf iere acea ;g_PeptonIphHus
* Firmicutes;c Clostridia;o~.Clostridales;f ' re acea ;gParvimonas
" Firmicutes;a Clostridaal CstedIales, re Iaceae;gAnaerococcus
" Firmicutes;c ClostrIdla;o iCosi sslerelaceae g_
" Firmicutes;c Clot*dia;o ClostrdIales, obactraceae];g
Firmicutes;cClostridia;oCostdiaes umInococcaceae;gRuminococcus
Firmicutes;cClostridla o ClostddasFRuminococcaeae;gOsclospira
FIrmicutes;c.C ostridla:oClostdidialesf Rococcaceae; g
Firmicuts;c~Clostridia;oClostrdlales fpRumInococcaceae;Silaer
* Firmicute;c Clostrida;o Clostridiales; Peptosrptoocaceae;g_Peptostreptococcus
Firmiutes;cClostridla;o Clostbdlales;f Pa ep aep caceae;g_Fifactor
aFirmicutes;c Clostridia;o :Clostrdlwe;f Peptococcaceae;g_Peptococcus
FirmIcutes;c Closridla;o CostridialesfLachnospiraceae;_Orbacterium
*Firmicuteex. Cbostridlamo ClostrdlalesfLachnospiraceae;gBlautia
Firmicutes; Closridia;o Ctridiales-f Lachnospiraceae;g_
* Firmicutes;c Closridia;o CosrdialesfClostrdiaceae;g_
SFirmicutes;c Cstrdla;o ClosdlakeCfChdstenenenaceae;g_
SFirmicutes;c Closila;o Clostridlalesf;g
Firmicutes;c~Bacii;oLctobaclaIesf Streptococcaceae;gStreptococcus
*FIrmiutes;cBadijj;oLactobacIalesfStreptococcaceae;gLactooccus
SFirmicutes;c.Bacilli;oLactobadlIales;f Lactobaclaceae;g_actbacius
EFirmicutes;c Bacili;ooLactbacialesf Aerococcaceae;g Aerococcus
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aFirmicutes;c BaIlll;oBadifales -Planococcaceae;
E Firmicutes;c Baciio BacilalesfPlanococcaceae;o er
a Firmcutes;c Balli;o Badllales;dfierOther
EBacteroldetesic FIav~Tacteriia;o Flavobacteriales;f Flavobactedaceae;gCapnocytophaga
*Bacteroldetes;c Bacteroidla;o B~acteroidalesL p- %-18B5;g_
*Bacteroldetes;c Bacteroida;Bacteroidales a votellaceae];gjPrevotea]
* Bactero dete;cBacteroidia;oBacteroidales 24-;g
* Bacteroletes;cBacterodla;o BactemdaleslfPrevotfliceae;gPrevotella
0 Bacteroldetes;c__Bacterodia;o Bacteroidles;frPorphyromonadaceae;gTannerella
*Bacteroldetes;c Bacteridiao Bacterodalesf Porphyromonadaceae;gPorphyromonas
2 Bacteroldetes;cBacteroidia;soBacteroidalesfPorphyromonadaceae;gParabacteroides
*Bacteroidetes;c Bacteroidlamo Bacteroidales;frPorphyromonadaceae;gPaludibacter
E Bacteroldetes;cBacteroldla;oBacteroidalsf-Bacteroidaceae;g_Bacteroides
*BacteroIdetes;cBacteroidia;o Bacteroidaes;frBS11;g_
* Bacteroidetes;c Bacteroidlao Bacteroidales;f g
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m Actinobacteria;c_Acnobacteria;o~~~Acfinomycetales;_Acnomycetaceae;gArcanobacterium
Figure 2-16: Genus-level taxonomy bar chart for skin-implant swab sam-
ples rarefied to 1000 sequences. Note that genera representing <1% of
sample reads are represented as Other Bacteria..
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At the phylum level, community composition was very consistent between
macaques. The main phyla contributing to reads included Bacteroidetes
(37% average of reads), Firmicutes (29% average of reads), Proteobacteria
(17%) of reads and Fusobacteria (15%) of reads (Figure 2-17).
At the genus level, OTUs contributing a high prevalence of sample reads
included Porphyromonas spp. (14% average of reads), Streptococcus spp.
(16% average of reads), Fusobacterium spp. (11% average of reads), and
Prevotella spp. (13% average of reads) (Figure 2-18).
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Figure 2-17: Phylum-level taxonomy bar chart for oral swab samples rarefied to 1000 sequences.
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Spirochaetes;c_Spirochaetes;oSpirochaetalesfSprochaetaceae;gTreponema
Proteobacteria;c__Gammaproteobacteria;o__Pseudomonadales_Moraxellaceae;g_Moraxella
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Proteobacteria;c__Betaproteobacteria;oNeisseriales;fNeisseriaceae;gNeisseria
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" Bacteroidetes;c_Bacteroidia;o__Bacteroidales;_Porphyromonadaceae;gTannerella
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" Bacteroidetes;c_Bacteroidia;o_Bacteroidales;fPorphyromonadaceae;gPaludibacter
* Actinobacteria;cActinobacteria;o_Actinomycetales;fActinomycetaceae;gActinomyces
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Figure 2-18: Genus-level taxonomy bar chart for oral swab samples rarefied
to 1000 sequences. Note that genera representing <1% of sample reads are
represented as Other Bacteria.
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Feces
At the phylum level, community composition was very consistent between
macaques (Figure 2-19). Bacteroidetes phyla accounted for 56% of sample
reads on average (range 39-80%) and Firmicutes phyla accounted for 33%
of sample reads on average (range 16-44%).
At the genus level, community composition was consistent between most
macaques, although most OTUs could only be identified down to the order
or family level (Figure 2-20). Predominant OTUs contributing to the popu-
lation included the Prevotella genus (19% average of reads), Bacteroidales
order (20% average of reads), and the Ruminococcaecaea family (15% aver-
age of reads. Helicobacter spp. were identified in only 7/18 samples, all at
a prevalence of <0.05%.
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Figure 2-19: Phylum-level taxonomy bar chart for fecal samples rarefied to 1000 sequences.
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Figure 2-20: Genus-level taxonomy bar chart for fecal samples rarefied to
1000 sequences. Note that genera representing <1% of sample reads are
represented as Other Bacteria.
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2.7 May-June 2018 Aerobic and Anaerobic
CRC cultures
Aerobic and anaerobic cultures and Kirby-Bauer sensitivities on aerobic
species were performed from cultures of 23 CRCs from 15 macaques by the
Division of Comparative Medicine diagnostic lab in May-June 2018. Sim-
ilarly to 2011 results, the majority of cultures were polymicrobial (Table
2.14. Only 1 CRC cultured was negative for aerobic and anaerobic growth
(macaque #39 CRC 2, and this CRC had a extremely low sample read count
of 35 for the microbiota study). 13 out of the 15 macaques cultured had also
been sampled as part of the microbiota study, although macaque #28 had
been explanted and re-implanted in between the pilot microbiota sampling
and collection of cultures. Data is presented in Tables 2.15, 2.16 and 2.17.
Similar to data collected in 2011, The most common bacterial species iden-
tified was S. aureus with 23 isolates identified from 14/15 macaques. Sim-
ilarly to results from 2011 (Table 2.7), S. aureus isolates remained largely
susceptible to the tested antimicrobials, with the exception of enrofloxacin.
One difference between 2011 and 2018 S. aureus isolates was the presence
of gentamicin resistance in 3 isolates. We noted an increase in the preva-
lence of both S. pyogenes and E. coli cultured from CRCs, including 6 E.
coli isolates with a beta-hemolytic phenotype. The E. coli isolates cultured
in 2018 displayed increased resistance to amoxicillin/clavulanic acid and
ceftriaxone as compared to the two E. coli isolates cultured in 2011. Pro-
teus spp. displayed similar resistance patterns to 2011; however, the three
2018 P. mirabilis were sensitive to cefazolin whereas 2011 isolates displayed
resistance or intermediate resistance (Figure 2.6).
Number of Isolates # (Percentage) of CRCs (N=23)
0 1(4%)
2 5(22%)
3 5(22%)
4 7(30%)
5 2(9%)
6 2(9%)
9 1(4%)
Table 2.14: Number and percentage of isolates per CRC cultured in 2018
(N=23 CRCs), includes both aerobes and anaerobes
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Animal Shod? Site Date Isolate AMP AMC B CRO CZ CR CHLOR ENO E GM LZ MERO N OX STR TE SXT VAID ID
28 B9 CRC2 5/8/18 Enterococcus faecais 20 20 14 0 7 12 15 y 19 9 20 13 0 0 0 0 0 15
38 A9 CRC1 519/18 Enterococcus faecalis 20 20 14 0 7 12 16 i5 19 9 20 13 0 0 0 0 0 15
39 B12 CRCI 5/15/18 Enterococcus faecElis 20 20 14 0 7 12 16 15 18 9 20 13 0 0 0 0 0 15
39 B12 CRC2 5115/18 Enterococcus faecalis 24 24 18 0 8 9 3 20 0 0 25 15 0 0 0 0 0 17
34 E3 CRC1 5/16/18 Enterococcus faecum 0 0 19 0 0 0 20 $ 17 14 26 0 17 0 8 20 0 22
9 B6 CRC2 5/10/18 Staphylococcus aureus 35 40 19 25 41 37 19 M_ 23 20 25 38 20 22 15 23 26 16
9 B6 CRC2 5110/18 Staphylococcus aureus 38 38 18 24 37 38 19 19 22 19 25 36 19 22 14 23 27 16
16 C5 CRC1 6112/18 Staphylococcus aureus 35 37 21 21 34 36 21 26 24 22 26 33 20 22 15 24 29 18
16 C5 CRC2 6/12/18 Staphylococcus aureus 40 37 21 21 34 36 21 26 24 22 26 33 20 22 15 24 29 18
28 B9 CRC1A 5/8/18 Staphylococcus aureus 36 37 17 24 34 38 19 0 0 21 25 37 19 18 14 22 28 15
28 B9 CRC 2A 518/18 Staphylococcus aureus 38 38 19 25 35 38 20 0 24 20 25 33 21 19 14 24 27 16
29 A5 CRC1 5/9/18 Staphylococcus aureus 40 38 18 22 34 40 21 12 23 9 25 30 20 23 15 24 28 16
32 A8 CRC 1 5118/18 Staphytococcus aureus 40 40 17 20 37 35 18 25 22 20 26 35 20 17 13 23 27 16
33 E2 CRC1 5115/18 Staphylococcus aureus 38 38 19 24 37 39 20 11 23 20 25 35 21 21 15 24 28 16
35 BID CRC1 5/15/18 Staphylococcus aureus 38 40 20 25 35 39 21 10 25 21 25 36 20 24 15 8 28 16
35 B10 CRC2 5/15/18 Staphylococcus aureus 35 39 17 22 30 32 17 25 22 19 23 37 19 20 14 23 25 16
36 E4 CRC1 5123/18 Staphylococcus aureus 44 40 18 24 38 40 19 E&b 23 20 26 38 19 19 14 24 18 16
37 B11 CRCI 5/3/18 Staphylococcus aureus 36 34 22 22 32 34 19 24 23 20 25 30 20 20 14 22 26 15
37 611 CRC 1 5/3/18 Staphylococcus aureus 38 36 18 21 34 40 20 24 23 19 24 31 20 20 14 23 27 15
37 B11 CRC2 5/3/18 Staphylococcus aureus 34 35 22 24 32 34 22 27 25 22 25 32 22 22 14 25 28 16
37 B11 CRC2 5/3/18 Staphylococcus surmus 36 40 20 22 34 38 20 27 24 22 24 34 21 22 16 26 24 16
38 A9 CRC1 5/9/18 Staphylococcus aureus 40 40 18 23 40 40 19 11 24 - 25 33 21 22 14 24 38 16
39 B12 CRC1 5115/18 Staphylococcus aureus 38 39 18 24 35 38 20 11 24 20 25 36 21 21 14 10 27 16
39 B12 CRC2 5115/18 Staphylococcus aureus 40 40 19 24 38 37 20 11 23 21 25 36 19 21 15 9 28 17 0
42 D8 CRC1 5/9/18 Staphylococcus aureus 43 44 18 22 40 42 18 25 25 19 23 33 21 24 15 22 25 15 00
42 D8 CRCI 519/18 Staphylococcus aureus 36 38 16 24 35 37 18 18 24 19 24 34 20 21 14 24 27 15
46 E6 CRC 1 5/17/18 Staphylococcus aureus 40 30 20 24 35 35 20 25 0 27 37 21 23 13 25 27 16
51 B18 CRC1 5111/18 Staphylococcus aureus 38 38 16 20 32 32 19 24 24 21 24 32 20 19 14 24 28 17
32 AS CRCI 5/18/18 Staphylococcus chromogenes 23 24 18 30 33 32 22 31 28 30 29 38 27 21 18 23 21 18
33 E2 CRC1 5/15/18 Streptococcus pyogenes 31 38 27 31 30 30 24 21 28 19 28 32 20 27 16 25 V 21
35 B10 CRC1 5115118 Streptococcus pyogenes 40 42 32 40 40 42 27 28 29 19 30 44 17 33 10 27 13 22
35 B10 CRC2 5115/18 Streptococcus pyogenes 39 40 29 37 38 40 27 28 28 18 29 41 17 29 10 26 0 21
36 E4 CRC1 5123/18 Streptococcus pyogenes 44 44 23 40 40 44 27 33 31 23 29 40 16 35 16 28 22 24
38 A9 CRC1 5/9/18 Streptococcus pyogenes 27 24 23 22 24 27 25 18 26 19 27 25 20 27 12 23 0 20
46 E6 CRC 1 5117/18 Streptococcus pyogenes 40 40 28 36 30 30 26 22 31 18 30 35 19 27 10 30 0 23
51 B18 CRC1 5111/18 Streptococcus pyogenes 31 38 27 31 30 30 24 21 28 19 28 32 20 27 16 25 0 21
Table 2.15: Gram-positive aerobic bacterial isolates and Kirby-Bauer sensitivities from 2018 CRC cultures. Color
coding indicates resistant (red), sensitive (green) or intermediate (yellow) antimicrobial phenotype. Macaque #28
has CRCs designated as 1A and 2A because this animal was explanted and reimplanted between the orig-
inal microbiota study and when cultures were obtained. Antimicrobial key: AMP- Ampicillin, AMC- Amoxi-
cillin/Clavulanic Acid, B- Bacitracin, CRO- Ceftriaxone, CZ- Cefazolin, CR- Cephalothin, CHLOR - Chloram-
phenicol, ENO- Enrofloxacin, E- Erythromycin, GM- Gentamicin, LZ - Linezolid, MERO- Meropenem, OX-
Oxacillin, STR- Streptomycin, TE- Tetracycline, SXT- Trimethoprim-Sulfamethoxazole, VA- Vancomycin
Animal Study Site Date isolate AMP AMC CRO CZ CR CHLOR ENO GM LZ MERO N STR TE SXT VAID ID
29 AS CRC 1 5/9/18 Escherichia coli 0 14 0 0 0 24 0 0 0 26 18 15 22 0 0
38 A9 CRC 1 5/9/18 Escherichia coli 0 14 0 0 0 23 0 0 0 25 17 14 19 0 0
35 B12 CRC 2 5/15/18 Escherichia coli -beta 0 8 0 0 0 23 0 19 0 27 17 14 21 14 0
39 B12 CRC 2 5/15/18 Escherichia coli -beta 0 11 0 0 0 23 0 20 0 28 17 14 0 24 0
42 D8 CRC 1 5/9/18 Escherichia coli -beta 0 0 0 0 0 24 0 18 0 24 17 14 21 23 0
16 C5 CRC 2 6/12/18 Escherichia coli -beta 0 11 0 0 0 24 0 22 0 30 20 16 0 26 0
16 C5 CRC 2 6/12t18 Escheichia coli -beta 0 11 0 0 0 23 0 22 0 29 20 16 0 26 0
28 B9 CRC 2A 5/8/18 Escherichia coli -beta 0 0 0 0 0 24 0 18 0 24 17 13 18 23 0
35 B10 CRC 1 5/15/18 Escherichia coli -beta 0 0 0 0 0 24 0 21 0 27 18 16 0 26 0
28 B9 CRC 1A 5/8/18 Proteus mirabilis 0 20 31 19 20 0 0 0 0 27 11 0 7 0 0
28 B9 CRC 2A 5/8/18 Proteus mirabifis 0 20 29 18 17 0 0 0 0 22 11 0 0 0 0
37 B11 CRC 2 5/3/18 Proteus mirabilis 0 22 30 20 24 0 0 0 0 25 0 0 0 0 0
29 A5 CRC 1 5/9/18 Proteus penneri 0 7 0 6 0 8 0 9 0 24 13 7 8 0 0
38 A9 CRC 1 5/9/18 Proteus vulgaris 0 7 0 0 0 7 0 9 0 24 13 0 8 0 0
9 B6 CRC 2 5/10/18 Pseudomonas aeruginosa 0 0 15 0 0 0 17 18 0 26 15 0 8 0 0
9 B6 CRC 1 5/10/18 Pseudomonas aeruginosa 0 0 16 0 0 0 19 17 0 30 15 8 9 0 0 00
35 B10 CRC 1 5/15/18 Pseudomonas aeruginosa 0 0 18 0 0 0 19 19 0 33 16 8 9 0 0
35 B10 CRC 2 5/15/18 Pseudomonas aeruginosa 0 0 0 17 0 0 18 18 0 33 16 9 8 0 0
34 E3 CRC 1 5/16/18 Enterobacter cloacae 0 0 0 .0 0 23 26 21 0 26 19 0 0 0 0
Table 2.16: Gram-negative aerobic bacterial isolates and Kirby-Bauer sensitivities from 2018 CRC cultures. Color
coding indicates resistant (red), sensitive (green) or intermediate (yellow) antimicrobial phenotype. Macaque #28
has CRCs designated as IA and 2A because this animal was explanted and reimplanted between the orig-
inal microbiota study and when cultures were obtained. Antimicrobial key: AMP- Ampicillin, AMC- Amoxi-
cillin/Clavulanic Acid, B- Bacitracin, CRO- Ceftriaxone, CZ- Cefazolin, CR- Cephalothin, CHLOR - Chloram-
phenicol, ENO- Enrofloxacin, E- Erythromycin, GM- Gentamicin, LZ - Linezolid, MERO- Meropenem, OX-
Oxacillin, STR- Streptomycin, TE- Tetracycline, SXT- Trimethoprim-Sulfamethoxazole, VA- Vancomycin
Bacterial Isolate Number (%) of Isolates Aerotolerance
Staphylococcus aureus 23 (27.3)
Escherichia coli 9 (10.7)
Corynebacterium ulcerans 8 (9.5)
Group A P-Streptococcus pyogenes 7 (8.3)
Proteus spp. 5(5.9)
Enterococcus faecalis 4 (4.8) Aerobic
Pseudomonas aeruginosa 4 (4.8)
Enterococcus faecium 1 (1.2)
Enterobacter cloacae 1 (1.2)
Staphlyococcus chromogenes 1 (1.2)
Streptococcus milleri group 1 (1.2)
Prevotella spp. 6(7.1)
Fusobacterium spp. 4(4.8)
Bacteroides spp. 3 (3.6)
Anaerococcus prevotil 2(2.3)
Group F p-Streptococcus constellatus 1 (1.2) Anaerobic
Collinsella aerofaciens 1 (1.2)
Micromonas micros 1(1.2)
Peptinophilis assachrolyticus 1 (1.2)
Propionibacterium propionicum 1 (1.2)
Total 84(100)
Table 2.17: Summary of aerobic and anaerobic bacterial species cultured
from CRCs in 2018. Data from 22 CRCs from 15 macaques
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2.8 Discussion
The Human Microbiome Project and numerous other studies have utilized
16S sequencing techniques to characterize the microbiota of various body
sites in both healthy and diseased states [24, 39]. Published use of these
techniques on macaques have predominantly been focused around studies
examining microbiota changes in the context of various infective states,
including simian immunodeficiency virus (SIV) infection, Shigella infection
and Helicobacterpylori infection [40, 41, 42, 43].
One previous report characterized the gut microbiota from healthy mac-
aques and compared stool samples, luminal samples and mucosal sam-
ples at various intestinal sites [43]. Our fecal microbiota results are con-
sistent with these previous findings; with the Bacteroidetes phylum (and
specifically the Prevotellaceaefamily), and Firmicutes phylum demonstrat-
ing higher prevalence than the Proteobacteria phylum and Spirochaetaceae
families [43]. One difference between our results and those previously pub-
lished is that the prevalence of Helicobacteriaceae was much lower in our
study (on average 0.005% of sample reads) [43]. While Yasuda et al. iden-
tified that the Helicobacteriaceae were more prevalent in mucosal samples
vs. stool samples, they found that stool samples were highly predictive of
Helicobacter abundance elsewhere in other gut sites [431. We have pre-
viously cultured, identified and characterized intestinal helicobacters from
macaques; our low prevalence of idiopathic colitis may be related to the low
prevalence of Helicobacter in the macaques sampled as part of this study
[44, 45, 46, 47].
Two previous publications have analyzed the microbiota of the oral cav-
ity and dental plaque in rhesus macaques; one report characterized dys-
biosis in SIV-infected macaques and one study compared the microbiota
between mild and moderate-severe cases of naturally-occuring periodon-
titis [48, 49]. Macaques at MIT do not receive regular dental scaling and
polishing procedures, and most have varying levels of periodontitis with
severity typically correlating with increasing age. The periodontitis study
identified taxa with differential abundance in diseased vs. healthy sites
[49]. For our study, oral swabs were passed around the cheek pouches,
dorsal tongue, and the gingiva superior to the teeth, to minimize sampling
of dental plaque. Overall, our oral microbiota results featured a combi-
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nation of OTUs identified to be more abundant in the diseased category
(including Prevotella spp., Streptococcus spp. and Treponema spp.) and
the healthy category (Capnocytophaga spp., Gemella spp., Fusobacterium
spp., Actinomyces spp. and Leptotrichia spp.). Porphyromonas gingivalis is
known to be a key human periodontal pathogen; however, there were no
identified differences in relative proportions between diseased and healthy
states in macaques [49]. The SIV-oral microbiota study compared samples
from the dorsal tongue to dental plaque in healthy macaques [48]. Iden-
tified dental plaque taxa were similar to those listed above, however this
study only identified Porphyromonas spp. from the dorsal tongue, and not
from dental plaque samples. These results are in agreement with our iden-
tification of Porphyromonas spp. from non-dental plaque samples.
One previous report compared the skin microbiota between zoo-housed
primates (chimpanzee, gorilla, baboons), two rhesus macaques living in
Cayo Santiago, Puerto Rico and human volunteers [50]. Samples from this
study were collected by swabbing the axillary region (for all species). At the
phylum level, the authors identified predominant contributions from Fir-
micutes (45%), Bacteroidetes (35%), Actinobacteria and Fusobacteria (8-
10% each) in the two macaques sampled. Our skin swab phylum-level re-
sults are fairly similar, although our population had decreased Actinobac-
teria (4% on average) and increased Fusobacteria (17% on average). At
the genus-level, more differences were noted between our results and pre-
viously published findings; specifically, our macaque population had in-
creased contributions from Streptococcus spp., Staphylococcus spp. and
Fusobacterium spp. and decreased contributions from Prevotella spp. and
the Ruminococcaceae family. These differences are likely related to sam-
pling site (skin-implant margin vs. axillary region), our larger sample size
(14 macaques after rarefaction vs. 2 macaques in the published study) and
husbandry (indoor vs. outdoor-housing). We also noted Corynebacterium
spp. identified at >0.1% in all analyzed skin swabs with the exception of
macaque #32. C. ulcerans has previously been reported as a common iso-
late from macaque CRCs [51]. The presence of the phosopholipase D toxin
virulence factor in C. ulcerans can promote infiltration and dissemination
into tissues and further promote skin inflammation [51, 521.
Previous reports utilizing 16S microbiota techniques to analyze puru-
lent exudate are limited to a single recent publication evaluating intra-
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abdominal abscesses [53]. Abdominal abscesses differ from CRCs because
patients are typically clinically ill, and they are not necessarily associated
with implanted materials. Abdominal abscesses typically arise secondary
to Crohn's disease, appendicitis, hepatobiliary disease or penetrating ab-
dominal trauma [54, 55, 56, 57]. Despite etiological differences, abdom-
inal abscess culture results are comparable to CRCs, in that many are
polymicrobial (2-6 species), with similarities in species commonly identified
(Bacteroides fragilis, Prevotella, Porphyromonas spp., and Peptostreptococ-
cus spp., enterococci, streptococci, and Staphylococcus aureus [53]. In this
report, the authors successfully sequenced and analyzed 26/43 abscess
samples. Although samples were divided into polymicrobial and monomi-
crobial categories based on Gram stain and culture results, there was no
significant difference in the mean number of OTUs identified between them
(15.2 and 17 OTUs for polymicrobial and monomicrobial samples, respec-
tively). While the dominant OTUs identified were consistent with the cul-
ture results for "monomicrobial" samples, this was not true for the majority
of polymicrobial samples. The dominant OTUs identified from microbiota
analysis in polymicrobial samples included Lactobacillus spp., Prevotella
spp., Fusobacterium spp., and Bacteroides spp. with "cultureable" Staphy-
lococcus spp., Streptococcus spp., Enterococcus spp. representing a small
minority of sample reads, or not being detected at all [531. This comparison
has similarities to our results comparing culture-dependent and culture-
independent methods from CRC samples; anaerobes predominate in OTU
analysis, whereas cultured organisms such as S. aureus, E. faecalis, Pro-
teus spp. and Streptococcus spp. contribute to a smaller percentage of
sample reads.
While culture-independent methods can identify many more OTUs than
species easily cultured, these techniques are best utilized in a complimen-
tary fashion. Traditional culture methods allow more definitive identifica-
tion to the species level, as well the ability to perform additional antimicro-
bial susceptibility testing; both of these factors are important when treating
a clinically ill macaque. However, like previous publications, [53] cultures
performed in parallel with culture-independent techniques were only able
to identify a small fraction of OTUs and are not necessarily representative
of the predominant flora colonizing CRCs. We did observe some changes in
species prevalence between cultures obtained in 2018 as compared to 2011.
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While S. aureus remained the most prevalent species, we saw increases in S.
pyogenes, E. coli, C. ulcerans and P. aeruginosa and decreases in E.faecalis
and S. dysgalactiae from samples. Kirby-Bauer antimicrobial sensitivities
between 2011 and 2018 species remained relatively stable overall.
Culture-independent techniques can be a useful tool to monitor bac-
terial populations sequentially and potentially assess how updates to im-
plant materials, or sanitization practices can affect bacterial communities
over time. Additionally, our parallel analysis of the microbiota diversity at
different sampling sites within individual macaques has provided a unique
insight on the source of bacterial communities commonly colonizing CRCs.
We had initially hypothesized that fecal contamination was the likely source
of bacterial colonization of CRCs. Analysis of PCoA plots and taxonomy
bar charts suggested that the majority of CRC bacterial communities were
different than fecal communities. This was confirmed by comparison of
unweighted UniFrac beta diversity, where 22/26 macaques had significant
differences between their CRC and fecal bacterial communities. We iden-
tified that CRC bacterial communities were most similar to skin-implant
margin and oral communities, and confirmed that these communities were
not significantly different on unweighted UniFrac beta diversity in 17/23
and 19/26 macaques, respectively. The majority of our macaques are pair-
housed and we hypothesize that grooming behavior between macaques can
contribute to the spread of oral flora to the skin margin. Because macaques
periodically move between housing rooms within the MIT vivarium, we were
unable to evaluate whether housing room location affects the microbiota,
but acknowledge that this could be another potential factor. Our results
also suggest that strict peri-implant skin sanitization and introduction of
regular dental cleanings could be potential targets for limiting bacterial col-
onization of CRCs.
2.9 Conclusions
In this chapter we have discussed how traditional culture methods and
culture-independent methods can be used to characterize bacterial species
colonizing cephalic recording chambers of implanted macaques. We have
identified Staphylococcus aureus, E. coli, C. ulcerans, Proteus spp., E. fae-
calis and Streptococcus spp. as highly prevalent aerobic species using tradi-
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tional culture methods, but microbiota analysis suggests that the predom-
inant species colonizing CRCs are strict anaerobes. Our results confirm
that CRCs are extremely diverse in the composition of bacterial commu-
nities between macaques, and even between CRCs implanted within the
same macaque. Paired analysis of different body sites indicates that there
are more similarities between CRC, skin margin and oral communities than
with fecal communities. Future studies should evaluate how different skin
margin sanitization protocols and introduction of regular dental prophy-
laxis might impact CRC bacterial communities over time.
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Chapter 3
Colonization dynamics of
Enterococcusfaecalis in CRCs
from 2011-2017
Portions of this chapter have been previously published [1] or are currently
in press [58].
3.1 Introduction
In Chapter 2, we introduced characterization of bacterial species coloniz-
ing CRCs from a community perspective, as determined by both culture-
dependent and culture-independent methods. This chapter and the re-
mainder of this dissertation will now focus on how one species, Entero-
coccus faecalis, persists and evolves within CRCs, both within individual
macaques, and within the macaque colony at MIT over a seven-year period.
E. faecalis was the second most prevalent bacterial species isolated from
CRC cultures collected from 25 macaques in 2011. Initial Kirby-Bauer an-
timicrobial sensitivity testing identified that >50% isolates were resistant
to multiple antimicrobial classes, including bacitracin, macrolides (ery-
thromycin), aminoglycosides (gentamicin, neomycin), penicillins/cephalo-
sporins (oxacillin, cephalothin, ceftriaxone, cefazolin), fluoroquinolones (en-
rofloxacin), trimethoprim-sulfamethoxazole, tetracycline and polymyxin B
(Table 3.1). Because of this marked resistance, we extensively character-
ized isolates to improve understanding of their potential pathogenicity.
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Animal ID Study ID Antimcrobial Culture Results AMP AMC B CR E GM OX SXT ENO TE T CRO D N CZ PBJ VA
1 Al GM Enterococcus faecalis #1 17 25 13 11 0 0 0 0 0 0 0 0 12 9 0 15
4 B1 None Enterococcus faecalis #2 16 13 0 13 0 12 0 0 14 0 0 13 0 13 0 9
5 B2 T-PB Enterococcus faecalis #3 24 27 0 14 0 19 0 0 18 7 7 15 14 0 12 0
5 B2 T-PB Enterococcus faecalis #4 25 35 0 16 0 16 0 0 0 0 0 22 0 16 0 20
5 B2 T-PB Enterococcus faecalis #5 16 22 11 13 0 14 0 0 0 0 0 18 0 13 0 15
6 B3 T-PB Enterococcus faecalis #11 0 19 0 11 0 12 0 0 14 0 0 10 0 12 0 13
8 B5 None Enterococcus faecalis #12 18 19 0 12 0 10 0 19 13 0 0 0 0 12 0 13
9 B6 T-PB Enterococcus faecalis #13 16 22 11 11 14 12 0 0 0 0 0 0 1 0 12 0 15
11 B8 None Enterococcus faecalis #14 19 19 11 9 0 12 0 0 0 0 0 0 10 11 0 13
11 88 None Enterococcus faecalis #15 21 24 11 11 10 13 0 0 0 0 0 0 10 12 0 13
15 C4 N, PB, B Enterococcus faecalis #6 23 25 0 13 0 18 0 0 18 0 0 11 16 0 11 0 12
16 C5 N, PB, B, GM Enterococcus faecalis #7 21 22 0 12 0 18 0 0 17 0 0 10 14 0 11 0 12
16 C5 N, PB, B, GM Enterococcus faecalis #8 20 21 0 13 0 18 0 0 17 0 0 10 14 0 11 0 1
18 C7 GM Enterococcus faecalis #9 19 24 11 11 10 0 0 0 0 0 0 0 8 11 0 15
19 C8 GM Enterococcus faecalis #10 25 27 15 10 0 0 0 0 0 0 0 0 11 14 12 0 15
Table 3.1: Aerobic culture and Kirby-Bauer antimicrobial sensitivity results for 15 E. faecalis isolates. Numbers
represent the zone of inhibition measured around each antimicrobial disk. Color coding indicates resistant
(red), sensitive (green) or intermediate (yellow) antimicrobial phenotype. Antimicrobial key: AMP- Ampicillin,
AMC- Amoxicillin/Clavulanic Acid, B- Bacitracin, CR- Cephalothin, E- Erythromycin, GM- Gentamicin, OX-
Oxacillin, SXT- Trimethoprim-Sulfamethoxazole, ENO- Enrofloxacin, TE- Tetracycline, T- Oxytetracycline, CRO-
Ceftriaxone, D- Doxycycline, N- Neomycin, CZ- Cefazolin, PB- Polymixin B, VA- Vancomycin
OPEN=
3.2 Relevance of Enterococcusfaecalis as a
human pathogen
Enterococcus faecalis is an important cause of healthcare-associated in-
fections, and is the third most common cause of central line-associated
bloodstream infections, the fifth most common cause of catheter-associated
urinary tract infections, and the sixth most common cause of healthcare-
associated infections, overall 1591. The enterococci possess mechanisms
of both acquired and intrinsic resistance to multiple antimicrobial agents,
making nosocomial infections especially difficult to treat successfully. Ad-
ditionally, the ability to form biofilm contributes to enterococcal catheter-
associated blood and urinary tract infections [60, 611. CRCs offer an inter-
face for biofilm formation in cranially-implanted macaques, and we hypoth-
esized that E. faecalis isolated from recording chambers would have similar
sequence types, virulence factors, and biofilm genes as human isolates.
3.3 Characterization of 15 E. faecalis CRC
isolates from 2011 sampling
3.3.1 Animals, CRC maintenance and bacterial culture
Sampling of implanted macaques, CRC sanitization procedures and bac-
terial culture techniques were previously described in Section 2.2.1. Of
the 25 macaques sampled, E. faecalis was isolated from 11 animals; two
macaques had two separate isolates and one macaque had 3 separate iso-
lates (Table 3.2)
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Animal Sex Age Lab Study # of Duration of CRC Antimicrobials Packing materials E. faecalis
ID (years) ID ID CRCs implantation (years) used in CRC used in CRC Isolate(s)
1 F 15 A Al 1 1-3 G None #1
4 M 11 B B1 2 1-3 None Sterile non-woven #2
sponge balls
5 M 10 B B2 3 3-5 (2), 1-3 (1) T-PB None #3, #4, #5
6 M 13 B B3 2 3-5 T-PB Sterile non-woven #11
I sponge balls
8 M 13 B B5 3 1-3 T-PB Sterile non-woven #12
sponge balls
9 M 13 B B6 3 <1 T-PB Sterile non-woven #13
sponge balls
11 M 10 B B8 2 1-3 None Silicone elastomer #14, #15
15 M 8 C C4 1 1-3 BNP Sterile petroleum jelly, #6
occasionally with
16 F 10 C C5 2 1-3 BNPorG None #7,#8
18 M 10 C C7 2 1-3 G None #9
19 M 10 C C8 2 <1 G None #10
Table 3.2: Population characteristics of 11 macaques with E. faecalis isolated from CRCs in August, 2011.
Macaque #18 was a cynomolgus macaque; all other macaques were rhesus macaques. Antimicrobial use within
CRCs and CRC packing material are listed for each animal as designated. Antimicrobial key: G, gentamicin
sulfate 0.3%; E, enrofloxacin 2.27% diluted 1:20, T-PB, oxytetracycline 5mg/g-polymyxin B 10,OOOU/g; BNP,
bacitracin zinc 400U/g-neomycin sulfate 5mg/g-polymyxin B 10,OOOU/g
-- __ n-, -
3.3.2 Minimum inhibitory concentration testing
Minimum inhibitory concentrations for key antibiotics were determined by
broth microdilution in CAMHB (Cation-Adjusted Mueller Hinton Broth) as
recommended by the Clinical Laboratories and Standards Institute (CLSI)
[62]. For daptomycin MIC determination, the CAMHB was supplemented
with calcium to a final concentration of 50 pg/ml. Amoxi-cillin-clavulanic
acid and trimethoprim-sulfamethoxazole combinations were tested for MIC
using Etest strips according to the manufacturer's instructions (Etest, bioM6rieux,
Durham, NC). The MIC was read at the lowest concentration where the el-
lipse of inhibited growth intersected the testing strip. All antibiotics used
for broth microdilution were purchased from Sigma-Aldrich Chemical Com-
pany (St Louis, MO). Control strains included vancomycin-susceptible ATCC
E. faecalis 29212 and vancomycin-resistant ATCC E. faecalis 51299.
3.3.3 DNA extraction, PCR and multi-locus sequence
typing (MLST)
DNA was extracted from overnight broth cultures of E.faecalis using a com-
mercially available kit (Qiagen DNeasy Blood and Tissue Kit, USA). Man-
ufacturer instructions were modified by the addition of 50/A of lysozyme
(50 mg/ml) and 10lA mutanolysin (2500 U/ml, Sigma-Aldrich) during a 30
minute incubation at 370 C before the addition of proteinase K and buffer.
Polymerase chain reaction (PCR) amplification of the D-alanine:D-alanine
ligase gene (ddl), 16S rRNA gene, and MLST genes were performed using
the listed primers (Appendix B), with amplification conditions based on
previously published protocols [63, 641. PCR products were separated by
electrophoresis through a 1% agarose gel at 100- 120V for 30-40 minutes,
prior to ethidium bromide staining and visualization with UV light. Prior to
sequencing, PCR products were purified using a commercial kit according
to manufacturer instructions (Qiagen, USA), or purified prior to sequenc-
ing by a commercial laboratory (QuintaraBio, Cambridge, MA). Purified
PCR products underwent Sanger sequencing at the DNA Core Facility at
the Massachusetts General Hospital Center for Computational and Inte-
grative Biology, or at a commercial laboratory (QuintaraBio, Cambridge,
MA). Sequence types were identified using the E. faecalis MLST website
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(http: //pubmlst. org/ef aecalis) at the University of Oxford [651.
3.3.4 Whole genome sequencing, antimicrobial
resistance genes and virulence factor
identification
E. faecalis isolates #1, #12, and #13, from macaques #1, #8, and #9, re-
spectively, were each sequenced on a single SMRT cell on a Pacific Bio-
sciences RS2 at the University of Massachusetts Deep Sequencing Core
Facility. DNA libraries were prepared for sequencing with the SMRTbell
Template Prep Kit 1.0 and the DNA/Polymerase Binding Kit P6 v2, accord-
ing to manufacturer instructions (Pacific Biosciences, Menlo Park, CA). A
total of 87,196, 93,299 and 85,195 reads were obtained for genomes from
isolates 1, 12 and 13, respectively; resulting in 3 polished contigs for iso-
lates 1 and 12, and 2 polished contigs for isolate 13. N50 read lengths
were 24,838, 24,224 and 23,305 bases, and average reference coverage
was 327.48, 338.83 and 293.2 for isolates 1, 12, and 13, respectively. Fil-
tered subreads were assembled de novo using the Hierarchical Genome
Assembly Process (HGAP 3.0) workflow, with the Celera assembler and as-
sembly polishing by Quiver [66]. Quality trimming was performed dur-
ing the preassembly stage of HGAP. This whole genome sequencing project
has been deposited at DDBJ/ENA/GenBank under the accession num-
bers MCFUOOOOOOOO, MCFVOOOOOOOO and MCFWOOOOOOOO for E. fae-
calis isolates #1, #12 and #13, respectively. The genome assemblies de-
scribed in this paper are versions MCFUO1000000, MCFVO1000000, and
MCFWO 1000000. Assembled genomes were annotated using the Pathosys-
tems Resource Integration Center (PATRIC) annotation service, and the
proteomes were compared with vancomycin-susceptible ATCC E. faecalis
29212 [67]. Assembled genomes were analyzed using the PubMLST, Res-
Finder, VirulenceFinder and PATRIC databases to confirm sequence type
and identify genes of interest [65, 67, 68, 69]. The ATCC 29212 genome
used for comparison was retrieved from GenBank under the accession
number CPOO816 [70]. Identification thresholds were set at 98% iden-
tity over a minimum length of 60% for ResFinder, and 95% identity over
a length of 60% for VirulenceFinder. Because fluoroquinolone resistance
often results from point mutations in DNA supercoiling enzymes, DNA gy-
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rase (gyrA) and topoisomerase IV subunits A and B (parC and parE) FASTA
protein sequences were compared between macaque isolates and E.faecalis
reference strain ATCC 29212 using the multiple sequence alignment tool
on PATRIC to identify amino acid polymorphisms.
3.3.5 Static biofilm assay
Biofilm formation was assayed by measuring crystal violet binding, ac-
cording to previously published protocols with slight modification [71, 72].
Macaque E. faecalis isolates, and positive control ATCC E. faecalis 29212,
were plated on tryptic soy agar containing 5% sheep blood, and incubated
at 37'C in 5% CO 2 for 24 h. Sterile 1Ipl disposable loops were used to inoc-
ulate isolates into 5 ml of tryptic soy broth supplemented with 1% glucose
(w/v). Following overnight incubation at 37'C, the optical density at 600
nm was recorded using a microtiter plate spectrophotometer (Epoch, Biotek
Instruments, Inc., Winooski, VT). For each isolate, 2p.l of overnight culture
was diluted into 198pl of tryptic soy broth supplemented with 1% glucose,
in triplicate, in 96 well polystyrene plates. For comparison, 4 negative con-
trols containing glucose-supplemented tryptic soy broth without bacterial
inoculum were included. Microtiter plates were incubated at 370 C, shak-
ing at 100 rpm and biofilm formation was evaluated at 24 h. Following
aspiration of medium and planktonic cells, wells were washed three times
with 200/il of phosphate-buffered saline, inverted, and dried for 45 min.
The remaining biofilm was fixed with 200/l of methanol for 20 min, and
plates were inverted and air-dried for an additional 45 min. Biofilm was
stained with 150pil of 1% crystal violet for 20 min. Excess stain was re-
moved via aspiration, followed by rinsing under running tap water. After
again air-drying, biofilm-bound crystal violet was solubilized via the addi-
tion of 150[d ethanol for 25 min. The absorbance of the extracted dye was
measured at 570 nm using a microtiter plate spectrophotometer, and ad-
justed for the absorbance of the negative control. Biofilm optical density
was normalized to the initial bacterial cell mass by dividing the absorbance
of the extracted dye by the OD,00 of the initial inoculum. Each biofilm test
was run in triplicate, and biological replicates were repeated in triplicate
on a separate day, independently, to confirm results. Beeswarm plots for
each isolate did not qualitatively show systematic bias due to batch ef-
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fects between experiments, thus data was pooled for analysis (Figure 3-1).
Beeswarm plots were generated using the Python programming language
(Python 3.5.2, matplotlib 1.5.1, seaborn 0.8.0), and Bayesian analysis was
done using PyMC3 (ver 3.0 rc2) (Figure 3-1). Data was analyzed using
a Kruskal-Wallis test with Dunn's multiple correction in GraphPad Prism
(GraphPad Software, Inc., La Jolla, CA) with P < 0.05 considered signifi-
cant.
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Figure 3-1: Beeswarm Plot of Crystal Violet Biofilm Experimental Data
3.3.6 Biofilm assessment under flow
In collaboration with Dr. Csar de la Fuente-Nifnez in the Lu laboratory
at MIT, a flow cell system was assembled and sterilized as previously de-
scribed [73, 74], and biofilm formation was assessed using BM2 medium
[62 mM potassium phosphate buffer (pH 7), 7 mM (NH4 ) 2 SO4 , 2 mM MgSO 4 ,
10 pM FeSO 4 , 0.4% (wt/vol) glucose]. The chambers were inoculated with
overnight cultures of E. faecalis isolates #1, #5, #12 and #13, and bacte-
ria were allowed to attach to the surface of the flow cell chambers for 7 h
40 min. Bacteria were then grown for 43 h under a flow of 2.4 ml/min,
after which viable bacteria were stained with SYTO-9 and subsequently
visualized using a confocal laser scanning microscope (Zeiss LSM 700).
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Three-dimensional reconstructions were generated using the Imaris soft-
ware package (Bitplane AG).
3.4 Results from 2011 E. faecalis isolate
characterization
3.4.1 Minimum inhibitory concentration testing
Minimum inhibitory concentration testing for the 15 E. faecalis isolates
confirmed high-level resistance to aminoglycosides, as well as resistance
to bacitracin, chloramphenicol, fluoroquinolones, erythromycin, tetracy-
cline, and trimethoprim-sulfamethoxazole (Table 3.3). Aminoglycoside re-
sistance was especially common, with 14/15 isolates displaying high-level
resistance to streptomycin, 7/15 isolates resistant to neomycin, and 4/15
isolates with high-level resistance to gentamicin. No resistance to van-
comycin, linezolid or daptomycin was identified among isolates. Five iso-
lates (#1, #2 #4, #9 and #11) displayed an elevated meropenem MIC (8
pg/ml) compared to ATCC 29212 (4 pg/ml). No CSLI susceptibility break-
point for meropenem has been established for E.faecalis ; however, 8 pg/ml
is within the previously reported MIC9o [75, 76]. Isolates #6, #7, #11, and
ATCC 29212, possessed MICs to linezolid (4 pg/ml) above the CLSI break-
point of <2 pg/ml. Previous literature suggests these isolates fall within the
MIC9O range for the enterococci, and should be classified as intermediate
resistant [77, 78].
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E. faecalls isolate ID' CLS11Antimicrobial 
___ATCC SuClpib('Iml) 1 4 9 10 13 14 15 2 3 6 7 8 11 12 5 29212 SusceptibleBreakpoints
Ampicillin 2 2 2 2 2 2 2 4 2 4 2 2 4 2 1 2 !8
Bacitracin 8 16 16 16 16 16 16 >128 >128 >128 >128 >128 >128 >128 8 16 NA
Ceftriaxonea >128 >128 >128 >128 >128 >128 >128 128 64 >128 >128 >128 >128 >128 128 >128 IR
Chloramphenicol 64 64 >128 64 64 64 64 32 32 32 64 32 32 32 64 4 8
Ciprofloxacin >16 >16 >16 >16 >16 >16 >16 0.5 1 1 1 1 1 1 16 0.5 S1
Daptomycin 2 1 2 1 1 1 1 1 0.5 1 1 1 2 1 0.5 1 S4
Enrofloxacin >16 >16 >16 >16 >16 >16 >16 0.5 1 0.5 1 0.5 1 1 16 0 NA
Erythromycin >64 >64 >64 >64 0.25 >64 >64 64 64 >64 64 >64 >64 >64 >64 1 0.5
Gentamicin" >2048 >2048 >2048 >2048 16 32 16 32 16 32 32 32 64 32 16 16 Low-Leve IR;
____________ HLAR: >500
Linezolid 2 2 2 2 2 2 2 2 2 4 4 2 4 2 2 4 S2
Meropenem 8 8 8 4 4 4 4 8 2 4 4 4 8 4 1 4 NA
Neomycin" 128 64 256 256 128 256 128 >2048 >2048 >2048 >2048 >2048 >2048 >2048 64 64 L R;
Lew-Levei IR-Streptomycin" >2048 2048 2048 2048 >2048 >2048 >2048 >2048 >2048 >2048 >2048 >2048 >2048 >2048 64 64 HLAR: >1000
Tetracycline 128 >128 >128 >128 128 >128 >128 64 64 64 64 64 64 64 >128 32 54
Vancomycin 1 2 2 2 2 2 2 2 1 2 2 2 2 2 0.5 2 S4
Trimethoprim- >32 >32 >32 0.125 0.064 0.25 0.25 0.064 0.094 0.125 0.064 0.064 0.125 0.094 0.012 0.047 IR
sulfamothoxazolea ___ ______ ______ ______
Amoxicillin- 1.5 1.5 1 1 1 1 1 1.5 1.5 1.5 1.5 1 1.5 1.5 0.5 1 NAclavulanic aci I___ -___ I___ ___ __________ ___
Sequence Type 4 55 330 30
CRC
antimcrobial G T-PB G G T-PB None None None T-PB BNP BNP; G BNP; G T-PB T-PB T-PB
a Intrinsic resistance is known for these antimicrobials
b High-level aminoglycoside resistance (HLAR) is Indicated by boxes
c MIC determined via Etest
Isolate resistance, aside from known intrinsic resistance (IR) and HLAR Is Indicated by red shading with bold text; isolate MIC values exceeding ATCC 29212 are indicated in blue shading with bold
text.
0 G = gentamicin sulfate 0.3%; T-PB = oxytetracycline 5mg/g-polymyxin B 10,OOOU/g; BNP = bacitracin zinc 400U/g-neomycin sulfate 5mg/g-polymyxin B 10,OOOU/g
'Clinical and Laboratory Standards Institute Antimicrobial Susceptibility Testing Standards; NA = not available
Table 3.3: Minimum Inhibitory Concentration (MIC) via Broth Microdilution and Etest Results for Macaque
Chamber E. faecalis Isolates as Compared to ATCC E. faecalis 29212. Sequence types and historical recording
chamber antimicrobial exposure are indicated for each macaque isolate.
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3.4.2 Sequencing and annotation
Multi-locus sequencing typing (MLST) identified three sequence types pres-
ent among the 15 isolates (Table 3.3). Most were either ST4 (N=7) or ST55
(N=7), and a single isolate (isolate #5) was identified as ST330. Proteome
predictions identified 260, 221 and 208 unique proteins encoded by iso-
lates #1 (ST4), #12 (ST55) and #13 (ST4), respectively, not included in
those encoded by vancomycin-sensitive E. faecalis ATCC 29212 (ST30). The
complete dataset may be found at https: //doi. org/10. 1371/j ournal .pone.
0169293. s004.
The vast majority (359/691) of these genes were annotated as hypotheti-
cal and most likely reside on mobile elements. Mobile element related genes
identified included transposases, type III restriction-modification system
proteins, phage proteins, transcriptional regulator proteins, and others,
which were more abundant in the ST4 isolates than ST55. An additional
distinguishing feature between the ST4 isolates and ST55 isolate is the
presence in the latter of the CRISPR (clustered regularly interspaced short
palindromic repeats)-cas (CRISPR-associated genes) system. While both
ST4 isolates lacked CRISPR-cas genes, a type II-A CRISPR-cas system was
identified in ST55 isolate 12, based on the presence of casi, cas2, csnl and
csn2 [79].
3.4.3 Antimicrobial resistance genes
A variety of acquired antimicrobial resistance genes were identified in the
genomes of isolates #1, #12 and #13 using ResFinder and PATRIC (Table
3.4). Four genes encoding resistance to aminoglycosides were identified, in-
cluding str in ST4, aph(3')-III and ant(6')-Ia in ST55, and the bifunctional
aminoglycoside-modifying enzyme aac(6')-aph(2") in ST4 isolate #1. Other
genes noted among the three isolates included macrolide resistance genes
lsa(A) and erm(B), tetracycline resistance genes, tet(M), tet(S), and tet(L),
and the chloramphenicol resistance gene cat. Increased trimethoprim-
sulfamethoxazole resistance was identified in ST4 isolate #1 encoded by
dfrG. The bacitracin resistance genes bcrA (ATP binding domain of ATP
transporter), bcrB (membrane-bound permease of ABC transporter) and
bcrR (regulatory protein of the bcrABD operon) were identified in ST55 iso-
late #12 using the specialty gene finder in PATRIC [67]. Multiple sequence
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alignment of the genes encoding topoisomerase IV subunit A (parC) and
DNA gyrase subunit A (gyrA) revealed single amino acid polymorphisms
in parC codon 80 (Ser to Ile) in gyrA codon 83 (Ser to Ile) in both ST4
fluoroquinolone-resistant isolates as compared to the less fluoroquinolone-
resistant ST55 isolate #12 and ATCC 29212. No single amino acid poly-
morphisms were detected in topoisomerase IV subunit B (parE).
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Antimicrobial (pgiml)
Bacitracin
Chloramphenicol
Ciprofloxacin
Enrofloxacin
Erythromycin
Gentamicina
Neomycina
Streptomycin
Tetracycline
Trimethoprim-
sulfamethoxazole'
Isolate Id C Relevant Resistance Genes Identified"
1 13
8
64
>16
>16
>64
128
16
64
>16
>16
0.25
16
128
12
>128
32
>64
32
>2048
>2048 >2048 >2048
128 128
>32 0.064
64
0.094
ATCC
29212
16
4
0.5
0.25
1
16
64
64
32
0.047
bcrA, bcrB, bcrR (isolate 12)
cat (all isolates)
parC (S801) and gyrA (S831) mutations (isolates 1 and 13)
parC (S801) and gyrA (S831) mutations (isolates 1 and 13)
ermB (isolates 1 and 12), Isa(A) (all isolates and 29212)
aac(6')-aph(2") (isolate 1)
aph(3)-I (isolate 12)
str (isolates 1 and 13), aph(3)-I and ant(6)-la (isolate 12)
tetM (all isolates and 29212), tetL (isolates 1 and 13), tetS (isolate 12)
dfrG (isolate 1)
IN
Sequence Type 4 4 55 30
8 High-level aminoglycoside resistance (HLAR) is indicated by boxes
b MIC determined by Etest
cIsolate resistance, aside from known intrinsic resistance and HLAR, is indicated by red shading with bold text; isolate MIC values
exceeding ATCC 29212 are indicated in blue shading with bold text.
d Assembled genomes were uploaded to ResFinder with a 98% threshold for gene identification and a minimum length of 60%. The
PATRIC specialty gene finder tool was used to identify bcrABR genes. Multiple sequence alignment was performed in PATRIC to identify
amino acid polymorphisms conferring fluoroquinolone resistance.
Table 3.4: Selected Antimicrobial Resistance MIC Results, and Resistance Genes Identified from Whole Genome
Sequence Data
Isolate Id " Relevant Resistance Genes Identified d
3.4.4 Virulence factor and biofilm formation-associated
genes
Genes encoding virulence factors from isolates #1 (ST4), #12 (ST55) and
#13 (ST4) were identified using VirulenceFinder and the specialty feature
tool in PATRIC (Table 3.5). Genes associated with the cytolysin toxin (cylA,
cyLB, cylL and cyLM) were identified in both ST4 isolates. Many genes as-
sociated with biofilm formation were identified, including aggregation sub-
stance (agg), enterococcal surface protein (espfs), endocarditis and biofilm-
associated pili genes (ebpA, ebpB, ebpC), collagen adhesion precursor (ace),
gelatinase toxin (geLE) and sortase (srtA). The ST4 isolates possessed more
biofilm-associated factors compared to ST55 isolate #12, which lacked ag-
gregation substance and gelatinase. Because of this finding, we further hy-
pothesized that ST4 isolates would produce more biofilm than ST55 isolates
and performed biofilm assays to evaluate this hypothesis. Other virulence
factors identified included sex pheromone-associated genes (cad, cCF1 0,
camE, cOB1), the cell wall adhesion expressed in serum gene (efaAfs), the
enterococcal Rgg-like regulator gene associated with macrophage persis-
tence (ElrA), hyaluronidases (hylA, hyLB), and the thiol peroxidase gene to
protect against oxidative stress (tpx) (Table 3.5) [80, 81, 82, 83, 84, 85, 86,
871.
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ST4 ST55 ST30
Virulence Factor Functionc Gene Isolate I Isolate 13 Isolate 12 ATCC 29 2 12d
Collagen adhesin precursor ace + + + +
Aggregation substance agg + + - +
ebpA + + + +
Endocarditis and biofilm-associated pili genes ebpB + + + +
ebpC + + + +
Cell wall adhesin expressed in serum efaAfs + + + +
Enterococcal surface protein esp + + + -
Gelatinase toxin (metalloendoprotease) gelE + + - +
Sortase A SrtA + + + +
Cytolysin (hemolysin-bacteriocin) cyIL + + - +
Post-translational cytolysin modification cy/M + + - +
Transport of cytolysin cyB + + - +
Activation of cytolysin cyA + + - +
Sex pheromone cad + + + +
Sex pheromone cAM373 precursor camE + + + +
Sex pheromone cCFIO + + + +
Sex pheromone cOBI + + + +
Enterococcal Rgg-like regulator EMA + + + +
Hyaluronidase hylA + + + +hy1B - - + -
Thiol peroxidase (oxidative stress resistance) tpx + + + +
a Assembled genomes were uploaded to ResFinder with a 95% threshold for gene identification and a minimum
length of 60%. https://cge.cbs.dtu.dk/servicesNirulenceFinder/
b The PATRIC Specialty Gene Finder tool was used to confirm virulence factors followinq annotation.
c Genes associated with biofilm production are designated with blue shading and bolded text and genes
associated with cytolysin toxin production are designated with red shading and bolded text.
d Genome was obtained from GenBank accession CP008816.
3.5: Acquired Virulence Factor Genes Identified Using VirulenceFindera and PATRIC'. Blue shading indi-
genes associated with biofilm-formation; red shading indicates the cytolysin-hemolysin operon
0)
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3.4.5 Biofilm production
0
E
0Z
10-
8-
6-
4.
.
2-
0-I
**
*
51
0
.0
ATCC 29212 ST 4
Figure 3-2: 24 hour Biofilm Production for 15 E.faecalis Isolates Assessed
by Crystal Violet Staining. ST4 and ST330 isolates produce significantly
more biofilm than ST55 isolates. Mean normalized OD5 7 0 for pooled data
were 2.016 : 0.016 for ST 4 isolates, 1.500 0.2942 for ST55 isolates,
8.191 0.1489 for the ST330 isolate and 1.894 + 0.1833 for the ATCC
29212 control strain.
Significant differences in biofilm production, as measured by crystal violet
binding, were noted among the E.faecalis isolates (Figure 3-2), P < 0.0001,
Kruskal-Wallis with Dunn's Multiple Comparison). The ST330 isolate was a
robust biofilm former, producing more biofilm than the ST4, ST55 isolates,
or control ATCC E. faecalis 29212 (Figure 3-2). Flow cell assays also re-
vealed that ST55 isolate #12 exhibited a biofilm-deficient phenotype when
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ST 55
.
ST 330
compared to ST4 isolates #1, and #13, and ST330 isolate #5 (Figure 3-3).
Interestingly, ST 4 isolate #13 showed a hyper-biofilm phenotype compared
to all other isolates tested (Figure 3-3).
Enterococcus faecalis Enterococcus faecalis Enterococcus faecalis Enterococcus faecalis
ST 4 Isolate #1 ST 330 Isolate #5 ST 55 Isolate #12 ST 4 Isolate #13
Figure 3-3: Biofilm Growth of E. faecalis in Flow Cell Chambers. Attached
cells grown in flow cell chambers for 43 h were stained green with SYTO-9,
and visualized at 63X magnification. Images are representative for each
isolate.
3.5 Discussion
As previously mentioned, human enterococcal infections are often associ-
ated with implanted materials, including central venous catheters, urinary
catheters, biliary stents, and endodontic implants [88, 89, 90, 911. In this
study, our E.faecalis isolates were isolated from chronic CRCs, and are also
likely associated with biofilm. Most isolates belonged to two multi-drug re-
sistant sequence types and we identified a variety of resistance genes and
virulence genes from representative sequenced whole genomes.
3.5.1 Antimicrobial resistance
Minimum inhibitory concentration testing via broth dilution was elected
to both confirm initial Kirby-Bauer disk diffusion results and quantify the
magnitude of resistance. There were some discrepancies between disk dif-
fusion and MIC results; specifically, disk diffusion suggested some isolates
displayed resistance to ampicillin, amoxicillin-clavulanic acid and vanco-
mycin. MIC testing found all isolates to be below the resistant breakpoint
for ampicillin (8 pg/ml) and vancomycin (4 pg/ml). While no CLSI resis-
tance breakpoint is noted for amoxicillin-clavulanic acid, all isolates and
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the ATCC control strain 29212 had an MIC between 0.5-1.5 pg/ml. Dis-
crepancies between disk diffusion classification and MIC susceptibilities
may be attributed to failure to record disk diffusion results at exactly 24
hours, or error in agar inhibitory zone measurement.
Antimicrobial resistance profiles obtained by MIC and Etest related well
to antimicrobial resistance genes identified from representative whole gen-
ome sequence data (Table 3.4). Gentamicin MIC profiles also matched well,
but not perfectly, with a history of gentamicin exposure. Specifically, E.fae-
calis isolates #1, #7, #8, #9 and #10 (5/15 isolates; 33%) were isolated from
macaques #1, #16, #18 and #19 with a history of gentamicin sulfate admin-
istration into their recording chambers. While ST4 isolates #1, #9 and #10
display high-level gentamicin resistance (HLGR), ST55 isolates #7 and #8
from macaque #16 lacked HLGR. The aac(6')-aph(2") gene has previously
been established to confer HLGR, which is supported by the differences
in MIC between HLGR ST4 isolate #1 (>2048 pg/ml) and non-HLGR isolate
#13 (16 pg/ml) [921. The presence of the aac(6')-aph(2") gene was confirmed
to be in close proximity to genes encoding plasmid recombination enzymes
in ST4 isolate #1. The acquisition of such mobile-element-derived genes
may be inhibited by an intact CRISPR-cas system, which was identified in
ST55 isolate #12 [93]. Additionally, both ST4 and ST55 isolates display
high-level streptomycin resistance, and ST55 isolates also demonstrate in-
creased resistance to neomycin. The presence of high-level aminoglycoside
resistance is significant because it abolishes synergistic treatment with the
combination of an aminoglycoside and cell-wall inhibitor [92, 94].
The plasmid-derived bcrABD operon with an upstream regulator bcrR
has previously been identified to confer bacitracin resistance in E. faecalis
[95]. We identified bcrA, bcrB and bcrR in ST55 isolate #12 with 89%, 89%
and 94% homology, respectively, to previously reported bacitracin resis-
tance genes [95]. Previous mutagenesis experiments have established that
the bcrD gene encoding undecaprenol kinase is not required for high-level
bacitracin resistance [95]. While macaque #8 (ST55 isolate #12 ) did not
have a history of bacitracin exposure, triple-antibiotic ointment containing
bacitracin was used within chambers for macaques #15 and #16 (isolates
#6, #7 and #8). Use of triple-antibiotic ointment is the hypothesized source
of selective antibiotic pressure in our macaque colony.
Multiple genes conferring resistance to tetracyclines were identified, in-
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cluding both ribosomal protection genes and genes encoding efflux pumps
[96]. Macaques #5, #6, #8 and #9, from which E. faecalis isolates #3, #4,
#5, #11, #12 and #13 were identified, had a history of exposure to com-
bination oxytetracycline-polymyxin B ointment inside recording chambers
(Figure 3.3). Isolates #4, #5 and #13 displayed a higher MIC (>128 pg/ml)
than isolates #3, #11 and #12, suggesting that the tetL gene may be re-
sponsible for conferring increased tetracycline resistance as compared to
tetS and tetM. Two single amino acid polymorphisms previously identified
to confer fluoroquinolone resistance were observed in genes encoding DNA
gyrase subunit A (gyrA) and topoisomerase IV subunit A (parC) in both ST 4
isolates sequenced [97, 98]. Enrofloxacin is the most commonly used fluo-
roquinolone in our colony and has been administered systemically both pe-
rioperatively, and therapeutically for clinical cases of wounds or suspected
meningitis. Macaque #3 had chamber exposure to dilute enrofloxacin but
E. faecalis was not isolated from the chamber of this individual.
3.5.2 Biofilm formation and virulence factors
The ability of the enterococci to form biofilms contributes to the pathogen-
icity of implant-associated infections, as mature biofilms allow E. faecalis
to withstand antimicrobial agents at 10-1000-fold greater concentrations
than those required to control planktonic bacteria (cells living free-floating
in liquid culture) 199]. We identified virulence factor genes associated with
biofilm formation including aggregation substance (agg), enterococcal sur-
face protein (esp), adhesion of collagen from E. faecalis (ace), gelatinase
(gelE), endocarditis and biofilm-associated pili genes (Ebp) and sortase A
(SrtA) [86, 100, 101, 102, 103]. ST4 isolates produced significantly more
biofilm than ST55 isolates. Interestingly, one ST330 isolate formed a ro-
bust static biofilm, and additional genetic analysis will be needed to relate
this phenotype to genotype (Figure 3-2). Whole genome sequencing of rep-
resentative strains showed that ST55 isolate #12 lacked both agg and gelE,
which were present in ST4 isolates. Nevertheless, we cannot attribute in-
creased biofilm production by ST4 to the presence of agg and gelE, as the
agg- and gelE-positive ATCC 29212 E.faecalis strain showed no significant
differences in biofilm-forming ability compared to either ST4 or ST55 iso-
lates. It is probable that increased biofilm production by ST4 and ST330
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isolates, compared to ST55 isolates, is polygenic in nature, as multiple
genes including esp, agg, gelE, and srtA have been individually shown to
contribute to biofilm formation [104, 105, 106, 107].
As well as genes associated with biofilm formation, we identified the
presence of genes encoding the cytolysin toxin in both ST4 isolates se-
quenced. The cytolysin toxin has been shown to increase the lethality of
infection in multiple species, including mice, rabbits and humans, and can
act synergistically with aggregation substance to increase lethality of infec-
tion in a rabbit endocarditis model [108, 109]. Due to the rarity of con-
firmed Enterococcus-associated implant complications we cannot defini-
tively assess how ST4 isolates bearing the cytolysin toxin contribute to
pathogenicity in macaques with chronic implants.
3.5.3 Translation to the human hospital environment
Our macaque colony models an environment with many similarities to hu-
mans possessing indwelling devices in a long-term care facility. Macaques
are housed in a high-density environment, with approximately 12 animals
per housing room. Human intensive care units (ICUs) vary in size, but re-
cent reports have suggested a median ICU bed density in the range of 12-30
beds [110, 111]. Similar to a mixed-population ICU, macaques are housed
in a mixed population, and surgically naive individuals and individuals
with cephalic implants of varying duration can be pair-housed or housed in
close proximity within the same room. Besides topical antimicrobial expo-
sure inside recording chambers, macaques in our vivarium are exposed to
systemic antimicrobial therapy during the perioperative period and when
clinically indicated, such as prophylactic treatment for wounds resulting
from an altercation with a conspecific. This chronic intermittent antimi-
crobial exposure provides a selective pressure for antimicrobial-resistant
isolates to emerge, as well as provide a niche for intestinal overgrowth and
permit breakdown of colonization resistance [112]. MIC testing suggests
that our E.faecalis isolates remained susceptible to ampicillin, amoxicillin-
clavulanic acid, vancomycin, daptomycin and meropenem. Vancomycin,
daptomycin and meropenem are not used in our facility, and will continue
to be excluded, as these are last-resort antimicrobials to be used for treating
human infections. Finally, chronic cephalic implants serve as a nidus for
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biofilm formation and persistent infection. A variety of bacterial species,
including Staphylococcus, Enterococcus, and Corynebacterium spp. have
been previously cultured from the skin margins of macaque cephalic im-
plants [51, 113]. As discussed in Section 2.6.4, bacterial colonization most
likely arises from the translocation of skin flora or oral flora. Examination
of taxonomy bar charts from Chapter 2 identified that Enterococcus was
present in low abundance at all sampling sites, but contributed to a higher
percent of sample reads in oral and skin samples vs. feces (Table 3.6).
Site Mean Std. Dev Minimum Maximum
CRC 0.0787045 0.2915644 0 1.2773723
Skin 0.0916014 0.1762231 0 0.57471264
Oral 0.01001632 0.0243759 0 0.10303377
Feces 5.4992E-05 0.0190803 0 0.00079777
Table 3.6: Percentage contribution of Enterococcus spp. to sample reads
of microbiota samples from Chapter 2. Samples were rarefied to 1000 se-
quences.
Because of the parallels between the macaque colony under study and
a human hospital environment, it is not surprising to see similarities in
identified pathogens. Specifically, the main two E.faecalis sequence types,
ST4 and ST55, detected in the macaque population have been previously
identified as agents of human infection [114, 115, 116, 117]. These finding
support the use of using implanted macaques to model the epidemiology
of E. faecalis over time.
3.6 Long-term colonization dynamics of E.
faecalis in CRCs over time
Analysis of 2011 antimicrobial resistance data highlighted the importance
of refining CRC sanitization procedures and improving antimicrobial stew-
ardship. As previously mentioned in Section 2.2.4, major updates were
introduced to routine CRC sanitization protocols in September, 2014. For
our next study, our goals were to identify the impact of these changes on
the dominant E. faecalis lineages colonizing implanted macaques, and to
examine how E. faecalis persists in CRCs of implanted research macaques
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over time spans as long as seven years. Specifically, for macaques with
persistent CRC colonization, we wanted to determine if there were changes
in sequence types, antimicrobial resistance profiles, biofilm production, or
other genetic changes conferring increased growth or survival after updated
implementation of CRC sanitization protocols. This next section will exam-
ine how E.faecalis sequence types changed over time in the macaque colony
and evaluate hypotheses for our findings.
3.6.1 Animals
Ten rhesus macaques (Macaca mulatta; 8 males, 2 females) with cephalic
implants were sampled. Macaque cohort and implant parameters are listed
in Table (3.7). All macaques were housed in an AAALAC-International ac-
credited facility under standards outlined by the 8th edition of the Guide
[191. Briefly, husbandry parameters included a 12:12 light-dark cycle,
a diet of commercial primate biscuits (Purina 5038) supplemented with
fruits, vegetables, nuts and cereal. Macaques were pair-housed, with ex-
ceptions for animals showing incompatibility with conspecifics. Macaque
CRC and implant margin samples were obtained from chair-restrained mac-
aques during routine implant sanitization procedures. Briefly, the chamber
was opened and a sterile polyester-tipped applicator swab (Puritan Medi-
cal Products, Guilford, ME) was used to gently sample the chamber and
exudate present. Implant margin swabs were obtained by application of
the swab around the base of the CRC acrylic and/or the restraint pedestal.
The MIT Committee on Animal Care (CAC) approved all study procedures.
Macaques remained on study for the purpose of their CAC-approved cog-
nitive neuroscience research protocol. No macaques were euthanized for
the purposes of this study, but three macaques were euthanized for medi-
cal reasons with intravenous sodium pentobarbital (86 mg/kg, Fatal Plus,
Vortech Pharmaceuticals, Dearborn, MI). Macaque #6 was euthanized for
seizures, macaque #25 for meningitis and retro-orbital abscessation (cul-
turing S. aureus, E.faecalis, Fusobacterium nucleatum, and Prevotella spp.),
and macaque #46 as a result of surgical complications. Macaques #1,
#8, #26, and #50 were euthanized at their research endpoint. We also
compared genomic data between macaques #9 and the 2011 isolate from
macaque #1. To our knowledge, CRC sanitization procedures after Septem-
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ber, 2014 followed updated guidelines and no antimicrobials were used in-
side CRCs post-2014 for macaques included in this study. Animals and
isolates are listed in Figure 3-4
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Animal Study Isolate Year of Year of Year Number CRC Antimicroblals, Packing Euthanasia
ID ID Source SeX Birth Arrival Implanted of CRCs Implant materialsa Materials, Sanitization Solutions Priorto 2 0 14b Date
1 Al CRC F 1996 2000 06/2006 1 Delrin, PMMA, ceramic G, no packing material, P1, saline 01/2015
screws
6 B3 CRC M 1998 2006 4/2008 3 Ultem, PMMA, titanium T-PB, non-woven sponge balls, HP, P1, 03/2015
screws CHX, saline
8 B5 CRC M 1998 2006 11/2008 2 Ultem, PMMA, titanium T-PB, non-woven sponge balls, HP, P1, 08/2016
screws CHX, saline
9 B6 CRC M 1998 2007 4/2011 3 Ultem, PMMA, titanium T-PB, non-woven sponge balls, HP, P1, NAscrews CHX, saline
25 D6 abscess M 2005 2006 06/2013 1 CILUX, PMMA, No antimicrobials, petroleum jelly, CHX, 11/2013
ceramic screws saline
26 A4 CRC F 2009 2016 10/2016 1 Ultem, PMMA, ceramic NA 06/2017
screws 0
27 El CRC M 2008 2011 6/2016 1 PEEK, PMMA, titanium NA NA
straps and screws
47 B16 CRC M 2007 2010 3/2016 1 Ultem, PMMA, titanium NA 3/2016
screws
48 E7 restra M 2007 2012 9/2014 NA Titanium NA NA
reestan
49 E8 pestal F 2009 2013 12/2015 NA Titanium NA NA
50 B1 perestan
50 B17 s M 1997 2006 06/2007 NA Titanium NA 06/2016
PMMA = polymethylmethacrylate bone cement
bG = gentamicin sulfate 0.3%; T-PB = oxytetracycline 5mg/g-polymyxin B 10,OOOU/g; HP = hydrogen peroxide, PI = povodone iodine, CHX = chlorhexidine solution
Table 3.7: Demographics of macaques for long-term E. faecalis colonization study
Macaque Isolate Source
1 CRC
6 CRC
8 CRC
9 CRC
25 Retro-orbital abscess
26 CRC
27 CRC
47 CRC
48 Implant margin
49 Implant margin
50 Implant margin
Month
Year
A ST 55 OST 4 E ST 48 *ST 16 +ST Unknown 0 A 0 Denotes isolates
submitted for WGS
0
0 a
1g
8 11 3 4 5- 7 8 3 1 3 5 7 8 3 4
201113 2014 12015 2016 2017
aDenotes isolates cultured at time of euthanasia; gray shading denotes post-euthanasia I
Figure 3-4: Sequence types of E. faecalis isolates collected from research macaques between 2011 and 2017.
ST is designated by colored symbol with each row representing an individual macaque. Gray shading indicates
timepoints after euthanasia date.
3.6.2 Bacterial isolation
Swabs were plated on tryptic soy agar (TSA) with 5% sheep blood and in-
cubated overnight at 370 C in 5% CO 2 . When necessary, subcultures onto
phenylethyl alcohol blood agar and/or bile esculin azide agar were used to
facilitate isolation of colonies from Gram-negative species. Colonies that
grew on bile esculin azide and/or with a visual appearance consistent with
Enterococcus (light gray, alpha-hemolytic, catalase-negative) were selected
for further isolation.
3.6.3 DNA extraction, PCR and MLST
Crude DNA extraction for 16S sequencing was performed by collecting
colonies with a 11p disposable loop into 200p1 of a solution containing 5%
chelex- 100 resin and 0.02% proteinase K. Samples were heated at 560 C for
1 hour, briefly vortexed, and then heated at 950 C for 10 minutes. Samples
were then centrifuged at 10,000 x g for 3 minutes and stored at -200 C un-
til use. Genomic DNA was extracted from overnight broth cultures using
a commercially available kit with enzymatic lysis, as previously described
in section 3.3.3. DNA was eluted in 10mM Tris-HCl, 0.5mM EDTA and pH
9.5 buffer.
Polymerase chain reaction (PCR) amplification of 16S rRNA gene, MLST
housekeeping genes, tetS, tetM, aph-IIIa, and aac-6'-aph-2" were performed
using primers listed in Appendix B [63, 64, 118, 119, 120]. PCR primers for
mutL and str were designed using Primer-BLAST (https://www.ncbi.nlm.
nih.gov/tools/primer-blast/). Thermocycler parameters used: mutL: 95
'C for 4 min, 35 cycles of 95 0C for 1 min, 58 'C for 45 seconds, 72 0C for
1 minute and final elongation at 72 0C for 8 minutes; tetS, str, and aph-
IIIa: 95 'C for 5 min, 30 cycles of 95 'C for 1 min, 57 0C for 1 min, 72 'C
for 1 minute and final elongation at 72 'C for 8 minutes; tetM: 95 0C for
5 min, 30 cycles of 95 'C for 1 min, 52 'C for 1 min, 72 'C for 1 minute
and final elongation at 72 'C for 8 minutes. PCR bands were separated
by electrophoresis on a 1% gel at 100-120V for 30-40 minutes and visual-
ized with UV light following ethidium bromide staining. PCR products (5
pl) were purified by adding 2 pl of a mixture containing 0.4 U/pl exonucle-
ase I and 0.4 U/pl shrimp alkaline phosphatase and incubated for 20 min
at 37'C followed by 20 min at 80-850 C. PCR products were submitted for
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sequencing at a commercial laboratory (Quintara Biosciences, Cambridge,
MA). Enterococcal sequence types were identified by using the E. faecalis
MLST website (http: //pubmlst. org/ef aecalis) [651.
3.6.4 Whole genome sequencing, assembly and
annotation
E. faecalis genomic DNA from macaques #6, #9, #25 and #27 were se-
quenced on a single SMRT cell per isolate using a Pacific Biosciences RS2
sequencer at the University of Massachusetts Deep Sequencing Core Fa-
cility (Worcester, MA). E. faecalis genomic DNA from macaque #8 was se-
quenced using an Illumina MiSeq at the MIT Biomicro Center. PacBio DNA
libraries were prepared for sequencing with the SMRThell Template Prep
Kit 1.0 and the DNA/Polymerase Binding Kit P6 v2, according to manu-
facturer instructions (Pacific Biosciences, Menlo Park, CA). E. faecalis ge-
nomic DNA from macaque #8 was concentrated using Agencourt AMPure
XP beads at a 1.8x ratio, and eluted in 10 mM Tris-HCl, pH 8.5 buffer to re-
move EDTA from the DNA sample. The bacterial DNA library was prepared
using the Qiaseq FX DNA library kit (Qiagen) with 1pg of DNA per man-
ufacturer's instructions. Fragmentation of DNA was performed at 320 C
for 4 min. AMPure XP beads were used to perform library purification as
indicated in the Qiaseq FX DNA library kit manual. Barcoded and adapter-
ligated DNA libraries were pooled with other DNA libraries. Quality control
prior to sample loading included both sizing Illumina libraries with the Ad-
vanced Analytical Fragment Analyzer and quantifying libraries with qPCR
performed using KAPA SYBR FAST qPCR Master Mix (KM4114) on a Roche
LightCycler 480 II. 2x300 base paired end reads were generated on an Illu-
mina MiSeq using a MiSeq Reagent Kit v3 (Illumina). PacBio Genomes were
assembled using the Hierarchical Genome Assembly Process (version 3.0)
workflow hosted on the SMRT Portal 2.3. Reads, coverage and annotation
are found in Table 3.8. Illumina genome assembly was performed using
the spades tool on the Pathosystems Resource Integration Center (PATRIC)
website, version 3.5.2 [67]. Annotation on assembled genomes was per-
formed using the RAST tool kit on the PATRIC website, version 3.5.2 [67].
Genes encoding antimicrobial resistance and virulence factors were identi-
fied using ResFinder, VirulenceFinder and the PATRIC database specialty
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genes features [67, 68, 691. Identification threshold parameters were set
at 98% identity over a minimum length of 60% for ResFinder, and 95%
identity over a minimum length of 60% for VirulenceFinder.
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Macaque #1 #6 #9 #8 1 #25 #27
ST 4 55 4 55 48
WGS Technology Pacblo PacBIo PacBIo PacBlo Illumina Pacblo
Isolate Date Aug 2011 Aug 2011 May 2014 Mar 2015 Aug 2011 May 2016 Aug 2011 Aug 2016 Nov 2013 Mar 2017
Genome size 3044487 3011796 3024067 3037432 2983064 2986755 3015699 2806131 2919427 2920131
Total Reads 87196 83861 92116 81501 88233 65930 86533 1807478 95407 86807
Contigs 3 2 2 3 2 5 3 19 2 2
N50 24838 17828 13530 16398 15312 7003 24224 364769 15106 16627
Average Reference
Coverage 327.48 257.05 211.55 226.35 239.31 74.75 338.83 142.19 269.22 260.61
Number of Genes
Annotated 2962 2941 2946 2995 2881 2907 2939 2670 2786 2775
NCBI Accession MCFUOOOOOOOO QFYOOOOOOOOO QFYNOOOOOODO QFYMOOOOOOOO MCFWOOOOOOOO QFYLOOOOOOOO MCFVOOOOOOOO QFYJOOOOOOOO QFYKOOOOOOOO QFYIOOOOOOOONumber I_____ I_____ I___ _ IIIIII
Table 3.8: Whole genome sequencing metadata
CO
3.6.5 Antimicrobial susceptibility testing
Minimum inhibitory concentrations (MICs) for selected antimicrobial agents
were determined by the broth microdilution method in Cation-adjusted
Mueller Hinton Broth as recommended by the CLSI breakpoints (M07-A9,
M 100-2D) [121, 122]. All antibiotics used for broth microdilution were pur-
chased from Sigma-Aldrich Chemical Company (St Louis, MO). E. faecalis
strain ATCC 29212 and 51299 were used as standard reference strains.
MICs were performed at least three times on separate experimental days.
For the purposes of this study, intrinsic aminoglycoside resistance was de-
fined for MICs <500 Pg/ml for gentamicin, <1000 pg/ml for streptomycin
and <1000 pg/ml for neomycin. For povidone-iodine, a 10% solution (Tri-
adine, Triad Group Inc, Hartland, WI) was diluted with cation-adjusted
Mueller Hinton broth to test concentrations of 2.5% to 0.0098%. MICs were
recorded 24 hours following incubation. To determine the minimum bacte-
ricidal concentration for povidone-iodine, 5pl from selected wells spanning
the MIC were spotted onto 5% sheep blood TSA. Following overnight in-
cubation at 37'C in 5% CO2, spots were examined for positive or negative
growth.
3.6.6 Variant analysis
The variant analysis service on the PATRIC website was used for vari-
ant identification using the BWA-mem aligner and FreeBayes SNP caller.
For macaque #6, filtered subreads from E. faecalis strains isolated in May
2014 and March 2015 were individually compared to the 2011 isolate. For
macaque #9, filtered subreads from strains isolated in April 2014 and
May 2016 were individually compared to the 2011 isolate. To examine
inter-macaque variation, filtered subreads from the 2011 ST55 isolate from
macaque #8 were compared to the 2011 ST55 isolate from macaque #6, the
2011 ST4 isolate from macaque #9 were compared to the 2011 ST4 iso-
late from macaque #1, and the 2017 ST48 isolate from macaque #27 was
compared to the 2013 ST48 isolate from macaque #25. During genome
analysis, it was determined that the genome of the April 2014 ST4 isolate
from macaque #9 was likely mixed, thus it was excluded from subsequent
genome sequence-based analyses. Variant filtering was performed to ex-
clude variants with <50% frequency, covered by fewer than 10 reads, or
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those found in genes with three or more variants called, due to the possi-
bility of mapping errors or recombination events. Putative de novo variants
are archived at https://f igshare. com/s/a7dc6538f8cOff2ae216.
3.6.7 Biofilm analysis
Biofilm production was assayed using the crystal violet method as previ-
ously described in Section 3.3.5, with minor modifications [721. Briefly,
5pl of overnight E. faecalis culture were inoculated into 1 9 5 pl of tryptic
soy broth supplemented with 1% glucose, in replicates of 6-12 in a 96-
well plate. Following 22-24 hours of static incubation at 370 C, the OD6 0 0
was measured to determine overnight colony growth using a microtiter
plate spectrophotometer (Epoch, Biotek Instruments, Inc., Winooski, VT).
Biofilm staining was performed as previously described in Section 3.3.5.
Biofilm production was normalized to bacterial growth by dividing OD5 7 0
by the OD6 00 , and the normalized OD5 7 0 values were used for statistical
analysis.
3.6.8 Daptomycin kill cuve
Time-kill curves with daptomycin were performed according to previously
published protocols [123]. Briefly, IOml aliquots of cation-adjusted Mueller
Hinton Broth with 50 pg/ml CaCl2 were inoculated with 5 colonies of mac-
aque #6 ST55 isolates from 2011, 2014 and 2015, Macaque #9 ST 4 iso-
lates from 2011, 2014 and 2016 and the ATCC control strain 29212. After
isolates reached a McFarland standard of 0.5, 0. 1ml were added to flasks
containing 10ml fresh Mueller Hinton broth with 0, 1, 2, 4, and 8 pg/ml
daptomycin. Samples for OD6 0 and spot dilutions were collected at 0, 2,
4, 6, 8 and 24 hours after inoculation. Following overnight incubation at
370 C, colonies were enumerated and kill curves plotted.
3.6.9 Protein alignments
Mutant diacylglycerol kinase amino acid sequences were submitted to Phyre2
[124] to generate predicted structures and aligned to DgkB from S. aureus
in PyMol version 2.0.7 [1251.
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3.6.10 Mutagenicity assay
Mutagenicity was determined with slight modifications to previous proto-
cols [126]. 50-125pul of overnight E. faecalis culture in brain heart infusion
broth was plated onto BHI agar impregnated with 50 pg/ml of rifampicin
in replicates of 3-5 plates. To determine the concentration of the overnight
inoculum, serial dilutions of the overnight culture inoculum were spotted
onto TSA with 5% sheep blood (Remel). Colonies were enumerated follow-
ing overnight incubation at 37'C in 5% CO 2 and the concentration of the
plated inoculum was determined. The mutation frequency was calculated
as follows:
1 = # of rifampicin-resistant colonies/inoculum plated
3.6.11 Phage induction
Overnight cultures of ST48 isolates from macaques #8, #25, the 2017 iso-
late from macaque #27, and #47 and were adjusted to an OD6 0 0 of approx-
imately 0.15 in duplicate, in 3ml of fresh brain heart infusion broth (BHI)
and incubated at 37'C shaking at 150 rpm for 90 minutes. Norfloxacin
(3ptg/ml) was added to one set of tubes and cultures were incubated for an-
other 2.5 hours at 37'C with continued shaking. The second set of tubes
was centrifuged to pellet cells and resuspended in 2ml 10mM- 1mM Tris-
EDTA buffer; then re-spun and resuspended in 2ml TE buffer with 1mM
CaCl 2 . The resuspended cultures were transferred to a 6-well plate and
exposed to 254-nm UV light (8W bulb) for 45 seconds. 1ml of UV-exposed
cultures was added to 4ml of fresh BHI with 100 mM CaCl 2 and incubated
37'C shaking at 150 rpm for two hours. After incubation, tubes were cen-
trifuged and the supernatant was passed through a 0. 2 p PES filter. 50pl
of supernatant was mixed with 501l of overnight donor cultures (2011 iso-
lates from macaques 1 and 2) and incubated for 5 minutes at 250 C. 5ml of
0.25% molten BHI agar with 100mM MgCl 2 and 100mM CaCl2 was added
and 1ml was added onto 1.5% bottom BHI agar with 100mM MgCl 2 and
100mM CaCl 2 in duplicate in 6-well plates. After top agar solidification,
plates were incubated at 370 C overnight and examined for plaques the fol-
lowing day.
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3.6.12 Dessication resistance
Cultures of ST55 (2011 isolate from macaque #6), ST4 (2011 and 2016 iso-
lates from macaque #9) and ST48 (2016 isolate from macaque #9, 2013
isolate from macaque #25 and 2017 isolate from macaque #27) were culti-
vated in 5 ml BHI, shaking at 370 C overnight. The overnight inoculum was
serially diluted in PBS and dilutions spotted onto blood agar, as previously
described, for enumeration of colonies the following day. Additionally, 2 Pl
aliquots were spotted on the bottom of an empty petri dish and allowed to
dry under the blower of a class II biosafety cabinet for 4 days. After incuba-
tion, each spot was resuspended in 100 /l of PBS and serial dilutions were
spotted onto blood agar prior to overnight incubation at 370 C. Colonies
were enumerated the following day and percent recovery was calculated as
follows:
2ptl x CFU/ml recovered% recovery =100% x
21l x CFU/ml overnight inoculum
3.6.13 Growth curves
200pl of overnight cultures of 2011 and 2016 ST4 isolates from macaque
#9, and ST48 isolates from macaques #6 (2017 isolate), #9, and #25 were
inoculated into 10ml of fresh BHI broth and incubated at 37'C shaking at
150 rpm. At times 0, 0.5, 1, 1.5, 2, 3, 4, 5 and 6 hours post-inoculation,
an aliquot of culture was removed to measure the OD6 0 0 . 10l of serial
dilutions of aliquots removed at times 0.5, 1, 1.5, 2, 4 and 5 hours post-
inoculation, were spotted onto TSA with 5% sheep blood, incubated over-
night at 37'C in 5% CO2 . Colonies were enumerated the following day and
graphs of colony count and OD6 0 0 over time were made for each isolate.
3.6.14 ST4-ST48 co-culture experiment
Overnight cultures of ST4 (2011 and 2016 from macaque #9) and ST48
isolates (2016 from macaque #9 and 2017 isolate from macaque #27) were
diluted to an OD 00 of approximately 0.2 in fresh BHI broth. Diluted cul-
tures were mixed together as follows: 10 ml ST 4 2011 + 10 ml ST 48 2016,
10 ml ST 4 2011 + 10 ml ST 48 2017, 10 ml ST 4 2016 + 10 ml ST 48
2016 and 10 ml ST 4 2016 + 10 ml ST 48 2017. 4 ml of mixtures and 2 ml
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of individual isolates were added in duplicate to 12 well flat-bottom tissue
culture plates and incubated at 37'C overnight, shaking at 150rpm. Cells
were passaged daily for 5 days as follows: 40 MI was transferred to 4ml fresh
BHI in an adjacent well and 1.5 ml collected for pelleting by centrifugation.
DNA was extracted from pellets collected on days 1 and 5 using the DNeasy
blood and tissue kit as previously described in Section 3.3.3. Quantitative
PCR was performed to evaluate changes from days 1 to 5 in ST 4 and ST 48
isolates via rhamulokinase (rhamK) and fsr quorum-sensing system (fsrB),
respectively, using primers listed in Appendix B. qPCR experiments were
run using the Fast SYBR Green master mix (ThermoFisher) on an Applied
Biosystems 7500 Fast Real-Time PCR system using the following thermo-
cycler settings: 95 'C for 20 seconds, 40 cycles of 95 0C for 1 second (melt),
60 "C for 30 seconds (anneal/extend). Threshold cycles (C) differences be-
tween co-cultured isolates were graphed and compared to mono-cultures
at days 1 and 5.
3.6.15 Statistics
Biofilm measurement data was analyzed using Bayesian estimation, imple-
mented in the Python programming language, using PyMC3. All code and
data for making the violin plots are archived online on GitHub (https: //
github.com/ericmjl/mia-stats/releases/tag/mia-mbio) and Zenodo (https:
//zenodo.org/account/settings/github/repository/ericmjl/mia-stats; DOI
10.5281/zenodo. 1248852). Mutagenicity data, and dessication resistance
data were analyzed using GraphPad Prism (GraphPad Software, Inc., La
Jolla, CA) with P <0.05 considered significant.
3.7 Results of long-term E. faecalis
colonization study
3.7.1 E.faecalis isolates and sequence types
To identify the genetic lineages of E.faecalis colonizing research macaques,
we compared the MLST of 20 strains isolated from 10 macaques over a
seven-year period, to 4 strains isolated in 2011 (Figure 3-4). From the 10
more recently sampled macaques, we identified four dominant E. faecalis
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sequence types: ST4, ST16, ST48, and ST55. Macaques #6 and #9 re-
mained colonized by ST55 and ST4 strains, respectively, over the 4-5 year
course of sampling. The May 2016 sample from macaque #9 was colonized
by both ST4 and ST48 strains. Macaque #8, initially colonized with a ST55
strain in 2011, yielded only an ST16 strain in May and July 2014. Samples
collected at the time of euthanasia of macaque #8 in August 2016 yielded
both ST16 and ST48 strains.E.faecaUs strains belonging to ST48 were first
identified in our macaque colony in a sample collected from macaque #25
in November 2013. Subsequent samples from macaques #26, #27, #47,
#48, and #49, show that ST48 became the predominant lineage identified
in 2016 and 2017. We also identified one unknown sequence type from
macaque #50. This isolate is a single locus pstS variant of ST594, contain-
ing the pstS 21 allele rather than pstS 12 found in ST594. Isolates from
macaques #48, #49, and #50 were collected from swabs of the skin margin
surrounding the CRC implant.
3.7.2 Antimicrobial susceptibility
To determine changes in antimicrobial resistance over time for ST55 and
ST4 strains, and to evaluate the resistance profiles of the more recent ST 16
and ST48 strains, we determined MICs for a diverse panel of antimicro-
bials (Tables 3.9, 3.10). ST55 isolates were susceptible to ampicillin and
enrofloxacin, intrinsically resistant to gentamicin, and resistant to baci-
tracin, erythromycin, and tetracycline, and high-levels of streptomycin and
neomycin. There were no remarkable changes in MICs in ST55 isolates from
macaque #6 over a four-year period. ST4 isolates showed susceptibility to
ampicillin, bacitracin, and erythromycin, intrinsic gentamicin resistance,
and resistance to enrofloxacin and tetracycline, and high-level resistance
to streptomycin. The only change in MICs noted for ST4 isolates over the
five year sampling period was an increase in neomycin resistance, from 128
pg/ml in the 2011 isolate to 256 pjg/ml in the April 2014 isolate, and a fur-
ther increase to 2048 pg/ml in the 2016 isolate. ST16 isolates displayed
susceptibility to ampicillin and bacitracin, resistance to enrofloxacin and
erythromycin, and high-level aminoglycoside resistance, including high-
level gentamicin resistance. ST48 isolates expressed fewer resistances,
showing susceptibility to ampicillin, bacitracin, enrofloxacin, erythromycin
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and tetracycline, and only intrinsic aminoglycoside resistance (Table 3.10).
We also examined the effectiveness of povidone-iodine and evaluated both
minimum inhibitory concentrations and minimum bactericidal concentra-
tions. The MIC for povidone-iodine for all ST4, ST48 and ST55 isolates was
0.3125%, and the minimum bactericidal concentration was 0.625%.
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Macaque ID I
6 9
Isolate Date Aug 2011 jMa 204 IM-arch 2015 Aug 2011 jApril 2014 1 May 2016.
Sequence Type 55 M4
Antimicrobial (pg/ml)
CLSI Resistance
Breakpoint
(pg/mi)
Ampicillin
Bacitracin
Enrofloxacin
Erythromycin
Gentamicin
Neomycin
Streptomycin
Tetracycline
1-2
>128
1
>64
16-64
>2048
>2048
64
1
>128
1
>64
32
>2048
>2048
64
1
>128
1
>64
32
>2048
>2048
64
1-2
8-16
64
0.25
8-16
128
>2048
128-256
1
4
64
0.25
16
256
>2048
256
1
8
64
0.5
16-32
2048
>2048
256
516
NA
NA
>8
Low level IR;
HLAR >500
Low level IR;
HLAR NA
Low level IR;
HLAR >1000
>16
Povodone-lodine | 0.3125% 0.3125% 0.3125% 0.3125% 0.3125% 0.3125% NA
Table 3.9: Minimum inhibitory concentration testing in ST55 and ST4 E.faecalis strains over time isolated from
macaques #6 and #9
I
Maca ue ID
25 4 7 I 27 8 48 9 7 I 2
Nov. March May July Aug. Aug. Aug. March April May July Aug.
Isolate Date 2013 2016 2016 2016 2016 2016 2016 2017 2017 2014 2014 2016
Sequence Type F 48 16
(pg/m)
CLSI
Resistance
Breakpoint
(pg/ml)
nt I r I A UIGI
Ampicillin 1 2 1 1 2 1 2 1 1 0.5 1 1 516
Bacitracin 16 16 8 16 16 16 8 16 16 4 8 8 NA
Enrofloxacin 1 1 1 1 2 1 2 0.5 1 32 32 64-128 NA
Erythromycin 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.125 0.125 >64 >64 >64 8Low level IR-
Gentamicin 8 16 16 16 128 32 8 16 16 >2048 >2048 >2048 HLAR >500
Low level IR;
Neomycin 256 128 64 128 512 128 64 128 64 >2048 >2048 >2048 HLAR NA
Low level IR;
Streptomycin 128 128 64 64 128 64 64 128 64 >2048 >2048 >2048 HLAR >1000
Tetracycline 2 2 2 2 2 2 1 1 0.5 256 128 256 16
Povodone-lodine 0.3125% 0.3125% 0.3125% 0.3125% 0.3125% 0.3125% 0.3125% 0.3125% 0.3125% 0.3125% 0.3125% 0.3125% NA
Table 3.10: Minimum inhibitory concentration testing in ST48 and ST16 E.faecalis strains
A. 41. b l
N
8
3.7.3 Antimicrobial resistance genes
Genome sequences were examined to identify antimicrobial resistance genes
present in ST4, ST55, and ST48 strains, and to determine if there were
changes in antimicrobial resistance genotypes over time in sequential iso-
lates from the same macaque. Known antibiotic resistance genes were iden-
tified employing ResFinder and the specialty gene tool on the Pathosystems
Resource Integration Center (PATRIC) [68, 671. Antimicrobial resistance
genes identified in the genome sequences are displayed in Table 3.11. All
sequenced ST55, ST4 and ST48 isolates possessed the lsa(A) gene encod-
ing an ABC-efflux pump; however, only ST55 isolates displayed phenotypic
resistance to erythromycin [127]. Erythromycin resistance in ST55 isolates
therefore is most likely attributable to the uniquely occurring plasmid-
encoded ermB identified in ST55, but not in ST4 or ST48 isolates. The
tetracycline resistance of ST55 and ST4 isolates could be attributed to
chromosomal tetM and tetS genes found in the ST55 strains, and plasmid-
encoded tetL and tetM genes detected in the ST4 strains. Selected PCR
on the May 2014 ST16 isolate confirmed the presence of tetM and tetS
as the likely origin for tetracycline resistance in this strain. Both ST4
and ST55 isolates possessed the chloramphenicol acetyltransferase gene
cat on a plasmid; while we did not assess chloramphenicol MICs on new
isolates, we previously confirmed chloramphenicol resistance in the 2011
ST4 and ST55 isolates (Figure 3.3). Plasmid-encoded aminoglycoside resis-
tance genes identified included ant(6)-Ia and aph(3')-III in ST55 isolates, str
in ST4 isolates, and ant(6)-Ia in ST48 isolates. Marked neomycin resistance
in ST55 isolates was most likely due to the aph(3')-III gene, while high-level
streptomycin resistance likely resulted from str and ant(6)-Ia genes [128].
PCR was used to confirm the presence of str, aph-HIa, and aac-6'-aph-2" in
the May 2014 ST16 isolate from macaque #8, with high-level gentamicin
resistance most likely conferred by the aac-6'-aph-2" gene [128]. Fluoro-
quinolone resistance, (i.e. enrofloxacin), typically arises from mutations
in DNA supercoiling enzymes. We confirmed the stable persistence of pre-
viously identified mutations in topoisomerase IV (parC) and DNA gyrase
subunit A (gyrA) 3.4. Additionally, deletion of 16bp upstream of a MATE
family efflux pump was identified in the 2016 ST4 strain, which might ex-
plain the increased neomycin resistance observed in this lineage over time.
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MacaquellD 6 9 8 25 27
ST ST55 ST4 ST168 ST48 ST48
Antimicrobial Gene Aug 2011 May 2014 Mar 2015 Aug 2011 May 2016 May 2014 Aug 2016 Nov 2013 Mar 2017
Resistance __ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _
Macrolides/ Isa(A) + + + + + NA + + +
Lincosamides erm(B) + + + - - NA - - -
tet(L) - - - + + NA - - -
Tetracycline tet(M) + + + + + + - - -
tet(S) + + - - + - - -
Bacitracin bcrABR + + + - - NA bcrA only bcrA only bcrA only
Chloramphenicol cat + + + + + NA - - -
str - - - + + + - - -
. ant(6)-la + + + - - NA + + +
Aminoglycoside aph(3)-II + + + - - + - - -
aac-6'-aph-2" - - - - - + - - -
Fluoroquinolone parC - - - S821 S821 NA - -
-
gyrA - - - S841 S841 NA - - -
aDetermined by PCR
NA = not assessed
Table 3.11: Antimicrobial resistance genes identified by whole genome sequencing and PCR from selected E.
faecalis strains
3.7.4 Virulence factor genes and biofilm production
We examined previously identified (Table 3.5) virulence factors in the strains
that were sequenced (Table 3.12). Profiles were largely similar across strains,
with variability noted in the presence of aggregation substance agg, gelati-
nase gelE, serine protease sprE, the quorum-sensing locusfsr, the cytolysin
operon, and the hyaluronidase hyLB. All sequenced ST55 and ST4 strains
contained the E.faecalis pathogenicity island, which harbored the cytolysin
operon in the ST4 strains [129]. The pathogenicity island was not present in
the ST48 strains that were sequenced. Phenotypically, all ST4 strains dis-
played beta hemolysis on sheep blood agar plates. This is presumably due
to the cytolysin operon, but cannot be stated with certainty since hemolysis
of ovine erythrocytes by the cytolysin is difficult to detect [1301. A plasmid-
encoded bacteriocin was identified in the ST4 strains, possibly contributing
to the hemolytic activity observed in this strain. Finally, no changes in vir-
ulence factor genes over time within isolates from the same macaque were
observed.
Next, we examined if the ability of E. faecalis to persistently colonize
the CRCs was associated with the ability to form biofilms, by measuring
the biofilm-forming capacity of 15 strains (Figure 3-5). Posterior credible
intervals from Bayesian estimation modeling identified a subtle increase
over time in biofilm formation among ST55 strains from the same animal,
and a more substantial increase in the 2016 ST4 isolate compared to prior
isolates from the same macaque. ST48 isolates showed variable biofilm
forming capabilities; however, nearly all isolates formed more biofilm than
the ST55 and ST4 strains from 2011 and 2014 (Figure 3-5). This find-
ing suggests that increased biofilm formation may have contributed to the
strain succession leading to ST48 predominance following the change in
maintenance sanitization protocol.
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MacaguelD 6 9 25 8 27
ST ST 55 ST4 ST 48
Virulence Factor Function Gene Aug 2011 May 2014 Mar 2015 Aug 2011 rMay 2016 Nov 2013 Aug 2016 Mar 2017
Collagen adhesin precursor ace + + + + + + + +
Aggregation substance agg - - - + + ++ + ++
Endocarditis & bioflim- ebpA + + + + + + + +
associated pili genes + + + + +ascaepiigns ebpC + + + + + + + +
Cell wall adhesin expressed efaAfs
in serum + + + + + + + +
Enterococcal surface
protein esp + + + + + + + +
Gelatinase toxin gelE - - - + + + + +
Serine protease SprE - - - + + + + +
Sortase A SrtA + + + + + + + +
Quorum-sensing locus fsrABDC - - - - -+
Cytolysin (hemolysin- CYL- 
- -
bacteriocin)
Post-translational cytolysin cy/M - - - + + - - -
modification
Transport of cytolysin cyiB - - - +- - -
Activation of cytolysin cylA - - - + + - - -
Sex pheromone cad + + + + + + + +
Sex pheremone cAM373 camE
precursor I + + + + + + + +
Sex pheromone cCFIO + + + + + + + +
Sex pheromone cOBI + + + + + + + +
Enterococcal Rgg-like EIrA
regulator + + + + + + + +
. hylA + + + + + + + +
Hyaluronidase hylB + + + - - + + +
Thiol peroxidase tpx + + + + + + + +
Table 3.12: Virulence factor genes identified by whole genome sequencing from selected E. faecalis strains
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Figure 3-5: Posterior credible intervals of biofilm production from 15 E. faecalis strains. Biofilm was measured
using a crystal violet assay [721. Each macaque is represented in a different color with ST labeled as indicated.
Experiments were performed a minimum of three times on different days using 6-12 replicates per strain. Violin
plots show the Bayesian estimated posterior of mean OD5 7 o readings; interquartile range is indicated by the
thicker black bars inside each violin, and median is indicated by the white circle.
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3.7.5 Gene and mobile element differences between
strains
To identify if E. faecalis strains of the same ST were isogenic, we compared
annotated gene lists from PATRIC. Comparison of ST55 annotated gene
lists from macaque #6 between the 2011 and 2014 strains identified only
one difference for a gene not annotated as hypothetical proteins (a termi-
nase small subunit in the 2014 strain), thus these two strains could be
considered isogenic. The 2015 ST55 strain from macaque #6 had multiple
differences in annotated genes as compared to 2011/2014 isolates and was
not considered isogenic. For ST4 strains, multiple differences in annotated
genes were identified between 2011 and 2016 strains from macaque #9;
thus these isolates were not isogenic. Comparison of the ST48 annotated
gene lists between the 2013 isolate from macaque #25 and the 2017 isolate
from macaque #27 did not reveal differences in genes annotated, therefore
these two isolates could be considered isogenic. Comparison of the ST48
annotated gene lists between the 2016 isolate from macaque #8 and the
2013/2017 isolates from macaques #25 and #27 revealed multiple differ-
ences in annotated genes, thus these strains are not considered isogenic.
To understand how E. faecalis strains differed from one another in their
mobile genetic element content both within and between macaques, we
analyzed the plasmid and prophage content of all sequenced strains. All
sequenced ST55 strains harbored a plasmid similar to pB of E. faecalis
strain CLB21560 (99% identity over 74% coverage; GenBank accession
CPO 19514. 1). All sequenced ST4 strains harbored a plasmid that was sim-
ilar to pEF123 of E.faecalis strain EF123 (99% identity over 85% coverage;
GenBank accession KX579977. 1). ST48 strains isolated in 2013 and 2017
both contain a presumed plasmid most closely related (97% identity over
59% coverage) to pBEE99 of E.faecalis strain E99 [131]; however, no known
rep genes were identified. Sequential isolates from the same macaque dis-
played only minor changes in their plasmid gene contents over time, and
the same plasmids from ST55, ST4, and ST48 strains were all found in
more than one animal, suggesting that they were stably maintained.
In contrast to relatively stable plasmid maintenance in strains from the
same ST, prophage content was found to be more dynamic between strains
(Figure 3-6). The two ST55 strains isolated from different macaques in
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2011 contain an identical prophage region; however, this region appeared
to be duplicated in the 2014 strain and further shuffled in the 2015 strain
from macaque #6 (Figure 3-6A). Separately, a prophage region detected in
the ST4 strain isolated from macaque #1 in 2011 was absent from the se-
quenced ST4 strains of macaque #9 (Figure 3-6B). The ST48 strains con-
tained multiple small, phage-like elements, one of which is found in all E.
faecalis strains [132]. We evaluated the possibility that one of these ele-
ments might have contributed to the sequence type shift within the colony.
This was attempted by trying to induce release of lysogenic bacteriophages
from ST48 isolates and examining for their activity against ST55 and ST4
isolates. Unfortunately, neither exposure to UV light nor addition of nor-
floxacin succeeded at inducing a phage that would plaque on the 2011
isolates of ST55 and ST4 from macaques #6 and #9, respectively.
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A
Macaque #8 2011 ST55
Macaque #6 2011 ST55
Macaque #6 2014 ST55 * 44
Macaque #6 2015 ST55 44011144004441 0114
4"wlAA.AA
TIN M"I F 44F
B
MacaqueM#1 2011 ST4
Macaque #9 2011 ST4
Macaque #9 2016 ST4
Figure 3-6: Differences in prophage content between ST55 (A) and ST4 (B) strains. Phages were compared to
one another using BLAST, and plots were generated using EasyFig [1331. Grey shading indicates regions with
>95% nucleotide identity)
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3.7.6 Variant analysis
We next identified variants between strains of the same ST. Specifically, we
evaluated for variants in genes in common between ST, or variants in genes
that might affect growth, antimicrobial resistance, or survival. Classifica-
tion and numbers of variants are listed in Table 3.13, and putative identi-
fled variants are archived at https: //f igshare. com/s/a7dc6538f 8c0f f 2ae216.
Overall, ST4 isolates had a higher average number of variants detected
(both within and between macaques; 44) than ST55 and ST48 isolates (23
and 28, respectively). In all cases, approximately half of all variants de-
tected were nonsynonymous changes, with the remaining variants divided
between synonymous mutations, intergenic variants, and insertion/deletion
variants. Both ST4 and ST55 isolates had nonsynonymous variants iden-
tified within a transcription regulator containing a diacylglycerol (DAG) ki-
nase domain (Figure 3-8), the phosphate transport ATP-binding protein
pstB, and DNA mismatch repair genes (mutL for 2016 ST4 isolate (Fig-
ure 3-9) and mutS for the 2011 ST55 isolate (Figure 3-10). Mutant ST4
and ST55 DAG kinase sequences were submitted to Phyre2 to generate a
structural model of each protein [124]. The top match was the DAG ki-
nase DgkB from S. aureus [1341. Comparison of the ST4 mutant to the
wild type S. aureus DgkB protein revealed that the A168S mutation was
on a loop sequence and was not predicted to be located in proximity to
the adenosine-diphosphate (ADP)-binding site (Figure 3-7A). Comparison
of the ST55 mutant to the wild type S. aureus DgkB protein revealed that
the T401 mutation was predicted to be approximately 4 angstroms from
ADP (Figure 3-7B).
141
B s
Figure 3-7: Mutant E. faecalis DAG kinase predicted protein structures
(cyan) were aligned to the S. aureus DgkB predicted protein structure
(green). ADP is shown as a stick figure in the binding pocket. A. ST4
mutant with A168S (magenta) is distant to the binding pocket. B. ST55
mutant with T401 (magenta) located approximately 4 angstroms from ADP.
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- -- 'mmmlhL-- -
Reference Variants Comparison Genome
Genome
Macaque 6 Macaque 8
Isolate Year 2014 2015 2011
Total 21 19 28
Macaque 6 Non-synonymous 12 10 13
2011 Synonymous 4 4 6Intergenic 5 5 5
Insertions/Deletions 0 0 4
Macaque 9 Macaque 1
Isolate Year 2016 2011
Total 44 43
Macaque 9 Non-synonymous 31 26
2011 Synonymous 8 10Intergenic 5 4
Insertions/Deletions 0 3
Macaque 27
Isolate Year 2017
Total 28
Macaque 25 Non-synonymous 16
2013 Synonymous 7Intergenic 3
Insertions/Deletions 2
Table 3.13: Numbers and types of variants identified within and between E. faecalis strains
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Figure 3-8: Multiple sequence alignment for nucleotide and amino acid
DAG kinase sequences showing Cl 19T/T40I in ST55 2014 and 2015 iso-
lates and G502T/A168S in the 2016 ST4 isolate.
I 199( 2000. 2002 2004 200e 200(k 20'
M6 ST551L-.-
M9 ST4L_
2014
2015
2011
2016
2011
2016
r--O 2014
AA C AA C AC
AAC AA C AC
AA C AA C AC
C O T O
C 0 T G
C 0 T G
A A T A A - - - - - -
A A C A A 4C A CEC 0 T G
-
-.-
-
-
-
G T 
680 . 662 . 64 . 666 . 6SB . 670 . 672
N H Y LNJB QBQ A V L L
M6ST55 2015 N H Y L N Q QA V L LM6 ST55 G 2011 N H Y L*E Q Q A V L L
. r 2016 - - L L
M9 ST4 E 2011 N H Y L NBQ -
2016 N H Y L B QQ AEV L LN
Figure 3-9: Multiple sequence alignment for nucleotide and amino acid
mutL sequences showing C1999T/Q666* in the 2016 ST4 isolate.
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Figure 3-10: Multiple sequence alignments for nucleotide and amino acid
mutS sequences showing a deletion leading to a framshift and nonsense
mutation resulting in QWL to RS* in the 2011 ST 55 isolate.
3.7.7 Evaluation of daptomycin time-kill curves
To evaluate possible effects of the identified mutations in the DAG kinase
gene we performed daptomycin time-kill curves using daptomycin at Ix, 2x,
4x and 8x the MIC (1, 2, 4 and 8 p.tg/ml) (as previously determined using the
methods listed in section 3.3.2. We hypothesized that E. faecalis strains
with functional mutations in DAG kinase would have impaired bacterial
membrane integrity and thus, altered time-kill curves upon exposure to
daptomycin. No changes in sensitivity to daptomycin at 1, 2 or 4 ig/ml
were noted; isolates with DagK mutations did display delayed killing with
exposure to 8 ug/ml as compared to wild-type and ATCC 29212 strains
(Figure 3-11).
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Figure 3-11: Time-kill curves for ST55 and ST4 macaque E. faecalis isolates and ATCC 29212. Isolates with
DagK mutations are indicated with an asterisk.
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3.7.8 Identification of transient hypermutator
phenotype
To evaluate the effects of the identified mutL and mutS we measured muta-
genicity in ST55 and ST4 strains with a standard rifampicin mutagenicity
assay [126]. We hypothesized that strains with mutations in DNA mis-
match repair genes might have higher spontaneous mutation rates, and
confirmed a hypermutator phenotype in the 2011 ST55 isolate and the
2016 ST4 isolate (Figure 3-12). The median mutation frequencies for the
2011 ST55 isolate and 2016 ST 4 isolate were approximately 30-fold and
40-fold higher, respectively, than isolates with wild-type versions of mutL
and mutS from the same macaque. Representative mutagenicity data are
shown in Figure 3-12.
A Macaque 6 ST55 Isolates B Macaque 9 ST4 Isolates
10-5 1 10-5
I-
C 10-8 10-6 = -
U. 10-7  . 10-7
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10- 10-8
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Isolate Year Isolate Year
Figure 3-12: Rifampicin mutagenicity assay for ST55 and ST4 isolates over
time. A. ST 55 isolates from 2011-2015 from macaque #6. B. ST4 isolates
from 2011-2016 from macaque #9. Data from a representative experiment
shown; bar represents sample mean. **** P<0.0001, 1-way ANOVA with
Holm-Sidak's multiple comparisons test.
3.7.9 Dessication resistance
To evaluate whether ST48 success in the colony was related to increased
environmental survival we performed dessication experiments to compare
selected ST55, ST4 and ST48 isolates. The ST4 2016 isolate showed the
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best percent recovery as compared to all other isolates tested; representa-
tive data is shown in Figure 3-13.
2.5
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~1.5
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0.0 0
Figure 3-13: Percent recovery from dessication for selected ST4, ST55 and
ST48 isolates. **** P<0.0001. One-way ANOVA with Thkey's multiple com-
parison test.
3.7.10 Growth kinetics and ST4-ST48 co-culture
To further evaluate competition between ST48 and ST4 isolates we evalu-
ated growth kinetics of selected isolates. We hypothesized that ST48 suc-
cess in CRCs might be related to faster growth kinetics vs. ST4 isolates. We
measured growth kinetics of selected ST48 and ST4 isolates over a 6-hour
period and found that ST48 isolates began the exponential growth phase
more rapidly than the 2011 and 2016 ST4 isolates as measured by changes
in OD600 (Figure 3-14). On both OD600 and CFU/ml curves the 2016 ST4
isolate showed delayed growth kinetics (with a right-shifted curve) as com-
pared to all other tested isolates. When comparing CFU/ml counts for the
3 isolates from macaque #9 (2011 ST4, 2016 ST4 and 2016 ST48) we noted
that the 2011 ST4 and 2016 ST48 isolates had similar concentrations at 5
hours.
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To examine competition over a longer timescale, we designed a co-culture
experiment to measure relative differences in ST4 and ST48 over a 5-day
period based on differential gene expression between ST using quantita-
tive PCR. This experiment revealed that growth differences exist, but these
differences varied within ST (Figure 3-15). First we compared co-cultured
ST48 from macaque #9 with ST 4 isolates from 2011 and 2016. On day 5,
we found a decreased amount of ST48 with a static amount of 2011 ST4,
but a static amount of ST48 with a decreased amount of 2016 ST4. These
findings were not replicated when co-culturing ST4 isolates from macaque
#9 with an ST 48 isolate collected from macaque #27. Both the 2011 ST4
and the ST48 isolate maintained static levels at day 5 vs. day 1. When com-
paring the 2016 ST4 from macaque #9 with the ST48 isolate from macaque
#27 we found that the initial amount of ST4 was lower on day 1, but in-
creased by day 5, while ST48 remained stable.
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Figure 3-15: Relative amounts of ST4 and ST48 at days 1 and 5 following inoculation of mono and co-cultures.
Relative amounts were determined based on Ct threshold, with lower Ct values indicating larger numbers of
bacteria.
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3.8 Discussion
Sequential sampling of ten macaques over a seven-year time span allowed
a unique opportunity to observe how E. faecalis persists within a polymi-
crobial community associated with a chronic implant. This has high rel-
evance to human infections, where E. faecalis often persists on implanted
medical devices such as intravascular catheters, ureteral stents, and in-
traocular lens materials [88, 135, 136]. Genome sequencing and pheno-
typic characterization uncovered two surprising findings. First, minimiz-
ing antimicrobial pressure appears to have driven the displacement of more
drug-resistant strains by a less resistant, stronger biofilm-forming lineage.
Second, transient hypermutator strains arose in two different ST in two
different animals that were persistently colonized by the same strain.
3.8.1 Colonization patterns
Analysis of CRC cultures collected in 2011 identified 15 E. faecalis isolates
from 11 macaques, with ST4 and ST55 as the predominant sequence types
(n=7 each) (Figure 3.3). Both ST4 and ST55 have been identified among
human clinical isolates [65]. Interestingly, the majority of recorded ST4
isolates were identified in samples from Asia, while ST55 strains are more
commonly isolated from patients in Europe and the United States [137].
The native habitat of rhesus macaques includes a wide territory, ranging
from Afghanistan to China and India [138]. While the majority of our re-
search colony originates from primate centers located in the United States,
these colonies originated from primates imported from Asia. Due to the
length of time animals are present in our vivarium, it is difficult to deter-
mine whether strains colonizing macaque CRCs originated as commensal
strains arriving with the macaques, or if strains were acquired after arriv-
ing at our vivarium. The relatively low diversity of strains detected and the
presence of the same strain in multiple animals suggests that at least some
animals became colonized at our facility.
Analysis of E. faecalis isolates collected since initial sampling in 2011
revealed different colonization patterns in individual animals. Macaque #6
remained colonized by the ST55 lineage from 2011 to 2015, while macaque
#9 remained colonized by ST4 from 2011 to 2016, then gained ST48 prior
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to August 2016 sampling. Both animals appear to have been colonized by
the same strain over a 4-5 year time span, since fewer than 50 variants
were observed between strains from the same animal (Figure 3.13. Strains
of the same ST isolated from different animals also were very closely related
to one another, suggesting that animals either transmitted strains to one
another or acquired them from a common source. Macaque #8 was colo-
nized by a ST55 strain in 2011, but subsequent sampling identified only
ST16 isolates in 2014, with the addition of a ST48 strain in 2016. While
a ST48 strain was first isolated in 2013 from macaque #25, our data indi-
cate an increased prevalence of ST48 in samples collected in the 2016-2017
timeframe, coincident with the decrease of ST4 and ST55 strains in more
recently implanted macaques. In the MLST database, only a single isolate
of ST48 has been reported, and was identified from a fecal surveillance
sample in a hospitalized patient in Spain [65].
3.8.2 Antimicrobial resistance patterns
Antimicrobial resistance within STs remained stable overall, in both geno-
type and phenotype, with the exception of increased neomycin resistance
in ST4 over time. While we did not identify differences in antimicrobial re-
sistance gene content within ST4, we detected a 16 bp deletion upstream of
a MATE family efflux pump in the 2016 isolate that had a higher neomycin
MIC. This efflux pump shows similarity to the NorM pump, which has been
shown to efflux aminoglycosides [139]. We hypothesize that the observed
deletion causes increased expression of the efflux pump, and thereby in-
creases neomycin resistance. In co-colonization situations, we did not ob-
serve increases in MIC for the ST48 strain isolated from macaque #9 (co-
colonized with ST4) or identify additional resistance genes in the genome
of the ST48 strain isolated from macaque #8 (co-colonized with ST16).
In September 2014, CRC sanitization procedures were updated to pro-
hibit antimicrobial use within CRCs. Removal of this selective pressure for
antibiotic-resistant strains corresponded with the appearance of compar-
atively antibiotic susceptible ST48 isolates. Despite the standardized use
of 1-2% povidone-iodine as part of routine cleaning procedures, E.faecafs
has clearly persisted within CRCs and around the skin-implant margin of
CRCs. This persistence likely arises from the inability of the disinfectant to
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penetrate biofilms within the time duration of application, as the MIC and
MBC for ST4, ST48 and ST55 strains are less than the current povidone-
iodine concentration used (0.3125% and 0.625%, respectively). Addition-
ally, the polymethylmethacrylate acrylic used for anchoring CRCs to the
skin margin represents a likely reservoir for strains. This area is difficult to
effectively sanitize with topical disinfectants, and polymethylmethacrylate
has previously been demonstrated to permit E. faecalis biofilm formation
[135].
Virulence factor genotypes remained stable over time within sequence
types; however, crystal violet assays suggested an increase in biofilm pro-
duction noted over time in ST4 and ST55 isolates. The 2016 ST4 iso-
late, in particular was found to produce significantly more biofilm than
the 2011 or 2014 strains from the same animal. While no differences in
virulence factor genes were observed in this strain, the increased biofilm
formation in the 2016 strain could be due to one or more of the variants
identified in the strain, or to a recombination event detected within the
enterococcal surface protein (esp), a gene that has been previously shown
to play a role in biofilm formation in E. faecalis [711. Additionally, we de-
termined that seven of nine tested ST48 strains were robust biofilm for-
mers. Genome sequencing confirmed the presence of multiple biofilm-
associated genes in select ST48 isolates, including the quorum-sensing
operon fsrABDC which was not present in ST4 and ST55 isolates. The
fsrABDC operon controls expression of the secreted proteases gelatinase
(gelE) and serine protease (sprE) [103, 140, 141]. Gelatinase contributes
to virulence and biofilm production via cleavage of host cell proteins to aid
in surface attachment and dissemination based on bacterial density [1031.
An additional difference in virulence factor gene content between strains
is that ST4 isolates possessed the hemolysin-bacteriocin operon encoding
the cytolysin within their pathogenicity island, which was not identified in
ST48 or ST55 isolates [130]. While the presence of the cytolysin toxin has
previously been established as a marker for increased virulence, morbidity,
and mortality in both human enterococcal infections and animal models
[142, 143, 109, 144, 145], no additional signs of disease were observed in
the animal colonized with this ST4 strain.
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3.8.3 Variant analysis
Analysis of single nucleotide variants (SNVs) within STs over time revealed
three gene families with variants in common between ST4 and ST55 iso-
lates: a transcriptional regulator containing a diacylglycerol (DAG) kinase
domain, the phosphate transport ATP binding protein pstB, and DNA mis-
match repair genes mutL and mutS. We first evaluated affected isolates for
phenotypic effects of the identified DAG kinase mutations. DAG kinases are
highly conserved enzymes among eukaryotes and prokaryotes and function
in phospholipid membrane turnover processes. Specifically, DAG kinases
catalyze the conversion of DAG to phosphatidic acid and prevent the lethal
accumulation of DAG within the bacterial membrane [1341. Daptomycin
is a cyclic lipopetide antibiotic proposed to exert its bactericidal activity
via insertion and disruption of the bacterial cell membrane [146]. We hy-
pothesized that disruption of DAG kinase functionality by the identified
mutations would result in decreased DAG turnover, and increased DAG
accumulation in the membrane, with a subsequent increase in membrane
fragility, and thus increased susceptibility to killing by daptomycin. Anal-
ysis of time-kill curves revealed that isolates with DAG kinase mutations
did not have increased susceptibility to daptomycin. In fact, we noted that
mutated isolates were slightly more resistant to killing by daptomycin at
8pg/ml at 4, 6, and 8 hours as compared to their wild-type counterparts
(Figure 3-11). Despite the appearance of decreased susceptibility, at 24
hours, all isolates exposed to 8pig/ml were dead. Given that there were no
changes in kill-curves observed for lower daptomycin concentrations, we
hypothesize that the identified DAG kinase mutations are likely insignif-
icant in affecting functionality. Protein structural alignment of the ST4
mutated DAG kinase protein with the wild-type S. aureus DgkB revealed
that the A 168S mutation was quite distant from the ADP-nucleotide bind-
ing pocket and unlikely to cause significant functional disruption (Figure
3-7 A). Protein structural alignment of the ST55 mutated DAG kinase with
the wild-type S. aureus DgkB predicted the T401 mutation to be approxi-
mately 4 angstroms from ADP, which is farther away then typical hydrogen
bond distances of 2.7-3.3 angstroms [1471 (Figure 3-7 B.)
Because hypermutator phenotypes have been observed before in infec-
tion contexts [148], we were interested in determining whether the iden-
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tified mutL and mutS mutations affected strain mutagenicity. The 2016
ST4 isolate from macaque #9 was identified to have a C 1999T transition in
mutL, resulting in a Q667* nonsense mutation in the protein (Figure 3-9).
The ST55 2011 isolate from macaque #6 was found to have a 10 bp deletion
causing a frameshift in the mutS protein, resulting in mutations at protein
positions 437-439 (QWL to RS*) and premature truncation of the protein
(Figure 3-10). To evaluate the effects of these identified mutations, we per-
formed rifampicin mutagenicity assays, and confirmed that the 2011 ST55
and 2016 ST4 isolates displayed a hypermutator phenotype (Figure 3-12).
Previous work has evaluated the effects of mutated mutS and mutL genes
in emerging antimicrobial resistance in Enterococcus faecium with mixed
conclusions [148, 149]. While one study did not identify a hypermuta-
tor phenotype in E. faecium with mutL and mutS mutations in two strains
that developed linezolid resistance during therapy, another case presenta-
tion described recJ and mutL mutations in a daptomycin-nonsusceptible
E. faecium blood culture isolate from an endocarditis patient [148, 149].
We would expect that isolates with a hypermutator phenotype would be
more likely to accumulate nucleotide polymorphisms. When comparing the
number of variants between isolates from the same macaque, we did iden-
tify more variants when comparing the 2016 ST4 to 2011 ST4 isolate from
macaque #9 (44 variants total), than between ST55 isolates from macaque
#6 (21 and 19 SNVs for 2014 and 2015 isolates, respectively) (Figure 3.13).
We also noticed that 90% of the variants detected in the 2016 ST4 isolate
were single nucleotide polymorphisms, compared to 75-80% of variants in
other comparisons. While the ST55 hypermutator phenotype did not per-
sist, future antimicrobial therapy for macaque #9 could be complicated by
the presence of the ST4 hypermutator isolate. To our knowledge, this is the
first description of an E. faecalis isolate with a mutL mutation that arose in
vivo. While limited studies have examined hypermutator E.faecalis strains,
hypermutator phenotypes in chronic Pseudomonas aeruginosa infections
contribute to the development of antimicrobial resistance in cystic fibrosis
patients [150, 151].
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3.8.4 Strain succession in E.faecalis within CRCs of
implanted macaques
We performed several experiments to evaluate hypotheses for the success
of ST48 and loss of ST4 and ST55 strains in macaques implanted with
CRCs since 2014. First we evaluated the potential for strain succession
caused by emergence of a lysogenic bacteriophage. Despite the presence
of multiple phage elements in ST48 genomes, we were unsuccessful at in-
ducing lytic bacteriophage from ST48 that would form plaques on ST4 and
ST55 isolates. Next, we evaluated the ability of different strains to survive
dessication. This hypothesis was also rejected as ST48 isolates did not
demonstrate increased survival vs. other strains, and the ST4 2016 isolate
demonstrated significantly more resistance to dessication (Figure 3-13). Fi-
nally, we evaluated growth kinetics of ST48 and ST4 isolates and their rel-
ative amounts at 1 and 5 days following co-inoculation in a tissue culture
plate. ST48 isolates did require a shorter time to reach exponential growth
in acute growth experiments than ST4 isolates; however, success over a 5-
day period varied depending on the isolate. Specifically, conflicting results
were observed when evaluating ST4 and ST48 isolates from macaque #9,
the 2016 ST4 isolate was outcompeted by ST48 at day 5, but the relative
amount of the ST48 isolate had decreased vs. the 2011 ST4 isolate at day
5. Thus, we cannot draw definitive conclusions about the success of ST48
based on growth kinetics alone. The effects of potential synergy or antag-
onism between E. faecalis strains and other members of the polymicrobial
CRC community are another possible factor in strain succession and are
challenging to evaluate experimentally.
3.9 Conclusions
This chapter has provided insights into how different E. faecalis lineages
have both persisted and been displaced by other ST within polymicrobially-
contaminated CRCs in research macaques over a seven-year period. Over-
all, our data suggest that improved antimicrobial stewardship has allowed
less-resistant, more robust bioflim-forming ST48 E. faecalis strains to pre-
dominate in newly implanted macaques, over the previously identified more-
resistant E. faecalis strains characterized from 2011 CRC cultures. In two
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macaques monitored sequentially since 2011, ST48 strains were able to col-
onize in a polymicrobial milieu of CRCs that were previously colonized with
strains belonging to other, more drug-resistant STs. We have also demon-
strated that E. faecalis strains can persistently colonize CRCs, with little
change in antimicrobial resistance, and that the ability to form biofilms
likely contributes to this persistence. Because of the importance of biofilm
formation in E. faecalis pathogenicity, the remaining chapter will evaluate
alternative techniques for treating E. faecalis biofilms.
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Chapter 4
Evaluation of alternative
strategies to treat E.faecalis
biofilm
4.1 Introduction
In Chapter 3 we discussed the extensive antimicrobial resistance noted in
ST4 and ST55 E. faecalis strains isolated from macaque CRCs. As previ-
ously discussed in section 3.8, the ability to form biofilm contributes to the
pathogenicity of E.faecalis by allowing strains to coat medical devices, and
withstand 10-1 000x antimicrobial concentrations compared to planktonic
cultures [99, 152, 153]. Biofilms are composed of cells encased in a ma-
trix of secreted polysaccharides, proteins, extracellular nucleic acids and
lipids, sometimes collectively termed "extracellular polymeric substance"
[152]. Because biofilm is hypothesized to be an essential factor for the
persistence of E. faecalis inside and around macaque CRCs, we wished
to evaluate alternative strategies for treating biofilm. Specifically, we were
especially interested in evaluating strategies to target biofilm formed by
multi-drug resistant E. faecalis isolates, as this has particular relevance
for human hospital-acquired isolates.
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4.2 Trends in antimicrobial development and
the current antimicrobial crisis
The 2013 Antibiotic Resistance Threats report by the Centers for Disease
Control and Prevention estimated that there were over 2 million illnesses
and 23,000 deaths caused by antibiotic resistance [154]. Despite the grow-
ing trend of antimicrobial resistance, only two new antimicrobial classes
(linezolid and daptomycin) have been released since the year 2000 (Fig-
ure 4-1). Additionally, the appearance of resistant strains has closely fol-
lowed the release of new antimicrobial agents, which further complicates
the effectiveness of new agents (Figure 4-1). Recently, infections with bacte-
rial strains resistant to all known antimicrobial agents have been reported
[155], necessitating the urgent need for alternative treatment strategies,
such as the use of lytic bacteriophage and antimicrobial peptides.
Antibiotic deployment
Tetracycline
Chloramphenic A 
Vancomycin
Streptomcin te Ampicihin
Sulfonamides Erythromycin Cephalosporins Daptomycin
nicilli Met Linezolld
1930 1935 1940 1946 1950 1955 160 18S 1970 1975 1980 1985 1990 1995 2000 2005
Suffonamd Ch oramphenic I An picillin Vancomycin Linezolld
Penicillin Streptomycin Erythromycin DpoyiI I Daptomycin
Tetracycline Methicilin
Cephalosporins
Antibiotic resistance observed
Figure 4-1: Timeline of antibiotic deployment and the evolution of antibiotic
resistance. The year each antibiotic was deployed is depicted above the
timeline, and the year resistance to each antibiotic was observed is depicted
below the timeline. Reprinted with permission from [156].
4.3 History of lytic bacteriophage therapy
4.3.1 Discovery of bacteriophages
Bacteriophages (phages) are small viruses that naturally infect and kill bac-
teria, but not eukaryotic cells. Phages were first discovered independently
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in 1915 and 1917 by Frederick Twort and Felix d'Herelle, noted as clearings
on bacterial agar plate cultures ("plaques") [157, 158]. It was d'Herelle who
first coined the term "bacteriophage", from the combination of "bacteria"
and the Greek "phaegin" to imply that the phages were eating the bacteria
[159].
4.3.2 Therapeutic use of lytic bacteriophages
Phages were first used therapeutically by d'Herelle in 1919 to successfully
treat four Shigella dysentery patients; however the first published use of
phage therapy in humans was described for treatment of Staphylococcus
skin carbunculosis [160, 159]. Staphylococcal phage was injected at the
at the base of the carbuncle and clinical improvement was noted with 48
hours of treatment [160]. D'Herelle devoted his career to studying phage for
therapeutic use. He reported successful treatment of dysentery patients in
Sudan and India, bubonic plague in Egypt, and advised other physicians
on use of phage to successfully treat septicemic and pneumonic plague in
Senegal, intravenous phage to cure staphylococcal and streptococcal sep-
ticemia, typhoid fever and infantile diarrhea [159]. While at the Pasteur
Institute, d'Herelle met a Georgian scientist named George Eliava and the
two eventually collaborated to transform Eliava's Microbiology Institute in
Tbilisi into a world center for bacteriophage research. Unfortunately, com-
munist politics complicated matters; Eliava was arrested by the secret po-
lice and executed in 1937. D'Herelle was visiting Paris and never returned
to Tbilisi, however the George Eliava Institue of Bacteriophages, Microbi-
ology and Virology exists to this day as a major center for phage research
[161].
4.3.3 Bacteriophage production
While in Paris, d'Herelle produced different commercially-available phage
cocktails which were marketed by the French company that later became
L'Oreal. In the United States, large pharmaceutical companies, including
Eli Lilly, Swan-Myers of Abbot Laboratories, E. R. Squibb and Sons (now
Bristol-Myers Squibb), and Park, Davis and Company (now part of Pfizer) all
produced bacteriophage preparations in the 1930s [162]. Unfortunately,
the Western world lost interest with bacteriophages for several reasons.
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Three reports published by the American Medical Association questioned
the efficacy of phage based on lack of standardized phage preparations and
poorly controlled studies additionally confounded by personal biases from
the authors [1631. While the first electron micrographs of phages were
obtained in 1939 in Germany, the first published images of phage in the
US were not widely disseminated until 1942 [164, 162, 163, 1651. Some
researchers questioned whether phages were even viruses, attributing their
effects to a "lytic principle".
The beginning of the modern antibiotic era began with the discovery
of penicillin in 1928 by Sir Alexander Fleming [166]. US pharmaceuti-
cal manufacturers soon abandoned phage production in favor of penicillin,
which gained immediate popularity with widespread success for treating
World War II soldiers, and later the general public [167, 1681. Phage ther-
apy also became controversial from a political standpoint as it was used by
enemies of the West: German and Japanese WWII armies as well as the
former Soviet Union. Finally, many older publications evaluating the use
of phage therapy were never translated into English, and studies were of-
ten not properly controlled, leading to further Western skepticism. While
active bacteriophage use and research has continued in Georgia, Poland,
and other Eastern European countries to this day, it is only recently with
the emergence of serious multi-drug resistant pathogens, that interest in
phage therapy has been revitalized in the United States.
4.3.4 Current use of lytic bacteriophage therapy
In 2006, the US Food and Drug Administration first approved bacterio-
phages for use in food safety; specifically, a preparation of 6 individual
phages with activity against Listeria monocytogenes for application to ready-
to-eat meat and poultry products [169]. More recently completed clinical
trials for phage therapy of human infections include the multi-center, ran-
domized, single-blind European Phagoburn study (evaluating treatment for
burn wounds infected with E. coli and Pseudomonas aeruginosa, and a
phase I clinical trial evaluating the topical safety of phage targeting S. au-
reus at Walter Reed Army Institute of Research [170, 1711. In the United
States, use of phage to treat humans is currently restricted to patients
that have exhausted other antimicrobial options. Recently, phages were
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successfully used to treat an aortic graft chronically infected with resistant
P. aeruginosa in a 76-year old patient living in Connecticut [172].
4.3.5 Advantages and challenges of lytic bacteriophage
therapy
Bacteriophages have several potential advantages over traditional antimi-
crobial therapy. Because bacteriophages have a different mechanism of
action than traditional antibiotics (namely, lysis of bacterial cells by phage
lysin proteins), they can be effective against multi-drug resistant bacte-
rial strains. The phage life cycle encompasses two primary strategies for
survival and replication (Figure 4-2) [173]. The lytic phage cycle involves
injection of phage DNA into the bacterial cell, hijacking of the bacterial
host processes to replicate new phage DNA and synthesize capsid proteins,
assembly of phages, and release of new phages by lysis of the bacterial
cell (Figure 4-2A). The second replication strategy is lysogeny, where phage
DNA is integrated into the bacterial chromosome (Figure 4-2B). Lysogenic
phages can remain dormant within the bacterial chromosome for many
generations of bacterial replication, or revert to a lytic phenotype, either
spontaneously, or under cellular stress (i.e. radiation, exposure to antimi-
crobials or carcinogens). One challenge for use of bacteriophages thera-
peutically is making sure to select only phages utilizing the lytic replica-
tion cycle. Besides the unpredictable lysis kinetics for a lysogenic phage,
the process of lysogeny can facilitate horizontal gene transfer in bacteria
(transduction) and spread antimicrobial resistance genes as a result of mis-
packaging bacterial DNA within the phage capsid [1741. This limitation
can be overcome by sequencing phages to identify genes associated with
lysogeny (i.e. integrase) [175, 1761.
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Figure 4-2: (A) Lytic phages: (1), attachment; (2), injection of phage DNA into the bacterial host; (3), replica-
tion of phage DNA, and production of new capsids; (4), phage assembly; (5), release of mature phages (lysis).
(B) Lysogenic phages: (1 and 2) attachment and injection of phage DNA; (3a), lysogenic phages can initiate a
lytic cycle (b) or integrate their DNA into the host bacterium's chromosome (lysogeny). Lysogenized cells can
replicate normally for many generations (1b) or undergo lysogenic induction (2b) spontaneously or because of
inducing agents such as radiation or carcinogens, during which time the integrated phage DNA is excised from
the bacterial chromosome and may pick up fragments of bacterial DNA. Reprinted with permission [173]
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Phages are highly specific in infecting their intended bacterial species,
and can even be specific in targeting certain strains within a species. This
narrow spectrum of activity allows the potential to precisely target only
pathogens of interest, sparing widespread disruption of the microbiota.
Disruption of the gut microbiota with broad-spectrum antimicrobials can
lead to overgrowth of secondary pathogens, such as Clostridium difficile, a
major cause of morbidity and mortality [177]. Additionally, multiple bac-
teriophages targeting the same bacterial species can be combined together
without increased risk for systemic side effects, whereas administration of
more than one or two antimicrobials simultaneously can lead to organotox-
icity. Combination of multiple bacteriophages targeting the same bacterial
species can also decrease the likelihood of the bacteria becoming resistant
to the phage.
Bacteriophages are self-replicating, which offers the potential advan-
tage for a decreased dosing frequency. This was demonstrated with early
treatment of Shigella patients by d'Herelle, where patients recovered within
4-20 hours after a 2cc dose of a high-titer phage culture, and patients with
staphylococcal septecemia improved the following day [159]. Decreased
dosing frequencies are advantageous, as previous research has demon-
strated that patient compliance decreases with antibiotics dosed multiple
times per day vs. once daily [178]. Additionally, missed antibiotic doses
or noncompliance with completing the full course can contribute to the
development of antibiotic resistance [1791.
Another advantage of bacteriophages over conventional antimicrobials
is their ability to distribute widely through the body, including passage
through privileged sites such as the blood brain barrier. Early studies
found that intraperitoneal injection of phage into mice could prevent death
following intracerebral inoculation of Shigella dysenteriae [180]. Phages
were isolated from the brains of mice (both infected and uninfected with
S. dystenteriae) within 2 hours following intraperitoneal inoculation, with
infected mice demonstrating much higher titers of phages in their brain tis-
sue than uninfected mice [180]. D'Herelle utilized multiple routes of phage
administration when treating patients, including oral, intravenous, intra-
muscular, and direct injection in buboes for patients with bubonic plague
[159]. Because phages do not infect eukaryotic cells, the only potential
side effects are related to endotoxic shock accompanying rapid bacterial ly-
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sis; this can also potentially occur with the administration of conventional
antimicrobial agents [1811.
Bacteriophage therapy shows advantages over traditional antimicrobials
when considering time and cost of development. From pre-clinical testing
to FDA approval, development of a new pharmaceutical is estimated to take
10-15 years and cost above 1.3 billion dollars [182, 1831. New bacterio-
phages can be isolated rapidly from the environment, and quickly evaluated
for therapeutic potential against pathogens of interest, prior to sequencing
and purification steps.
A final advantage of bacteriophage therapy is their potential efficacy
against bacterial biofilms. Recent publications have evaluated phages in
treating biofilms from multiple species, including E. faecalis, S. aureus,
Klebsiella pneumonia, and Pseudomonas aeruginosa among others [184,
185, 186, 187]. It is hypothesized that bacteriophages show efficacy against
biofilms via multiple mechanisms. Phages secrete depolymerases which are
capable of degrading extracellular polymeric substance (EPS), a major com-
ponent of biofilm [188, 189]. As well as lysing bacterial cells from within,
adsorption of multiple phages to the bacterial membrane can weaken the
bacterial membrane in selected bacterial species [190]. Because of these
previous findings, we hypothesized that we could isolate lytic phages with
activity against E. faecalis and that they would be successful at treating
biofilm.
4.4 Introduction to antimicrobial peptides
Antimicrobial peptides (AMPs) are a class of naturally occurring, evolu-
tionarily conserved small peptides, typically 10-50 amino acids in length
[153, 1911. AMPs have been isolated from a variety of species across the an-
imal kingdom including mammals (humans, cows, pigs, macaques), inver-
tebrates (silk moths, honeybees, scorpions), amphibians (frogs) and plants
[192, 193]. Typically, AMPs are isolated from blood cells, haemolymph
and/or epithelial tissues and function as part of the innate immune system
through both direct killing of bacteria and immune modulation [192, 191].
AMPs commonly feature clusters of cationic and hydrophobic residues (>
30%), an overall positive charge of +2 to +9, and the ability to fold into am-
phipathic structures (Figure 4-3) [192, 1911. The amphipathic structures
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interact with the negatively charged bacterial membrane (lipopolysaccha-
ride in Gram-negative bacteria and wall-associated teichoic acids in Gram-
positive bacteria) 4-4 [191]. Bactericidal mechanisms of AMPs include both
insertion and disruption of the bilayer and translocation across the mem-
brane to affect internal targets 4-4[1911. Acquisition of resistance to AMPs
is not well described, with exceptions for bacterial species with a decreased
density of acidic lipids (Morganella, Serratia) or species able to secrete pro-
teases (Porphyromonas) [192]. AMPs have previously demonstrated efficacy
in treating bacterial biofilms from multiple species, including S. aureus,
P. aeruginosa, Listeria monocytogenes, and E. coli [194, 73, 195], thus we
were interested in evaluating whether they could be used to treat E.faecalis
biofilms.
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Magainin 2
Human a-defensin 3
Protegrin Indolicidin
Figure 4-3: AMP structures. Clustering of cationic and hydrophobic amino
acids into distinct domains in selected AMPs. Red colorations designates
basic (positively-charged) amino acids; green coloration designates hy-
drophobic amino acids; other amino acids not shown. Reprinted with per-
mission from [192].
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Figure 4-4: The membrane target of AMPs of multicellular organisms and
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4.5 Isolation and characterization of lytic
bacteriophages with activity against
multi-drug resistant E. faecalis
4.5.1 Isolation of lytic bacteriophages
Initial isolation methods
200 ml of raw sewage was collected from a municipal sewage throughway at
the intersection of Portland St and Main St in Cambridge, MA into a ster-
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ilized glass bottle. Sewage was vacuum-filtered through a 0.4pim asym-
metrical polyethersulfone (aPES) (ThermoFisher) bottle-top filter followed
by a 0.2pm aPES bottle-top filter to obtain sewage filtrate. 15 aliquots
of 9ml of sewage filtrate was combined with 9ml of double-strength tryp-
tic soy broth (TSB) supplemented with 2mM CaCl 2 in 50ml conical tubes.
Phage enrichment was performed by inoculating filtrate-broth mixtures
with 250pl of overnight 2011 ST4 and ST55 E.faecalis cultures and incu-
bating overnight, shaking at 37'C, 150rpm. The following day, phage en-
richment tubes were centrifuged at 4000 x g for 10 min to pellet cells and
debris. Phage enrichments were assayed for plaque-forming units using
the double-agar overlay technique [196]. Briefly, molten 0.5-0.6% TSA with
10mM CaCl2 was inoculated with 200l of log phase test E. faecalis strains
and poured onto 1.5% TSA bottom agar with 10mM CaCl 2. Plates were
allowed to solidify in the hood, then 5pjl of each enrichment supernatant
was spotted onto the surface of the solidified top agar. Spots were allowed
to dry for 10-20 minutes, then plates were incubated at 37'C overnight.
Plates were examined for plaques the following day. Chloroform was added
to initial enrichment tubes at a 5% vol/vol concentration; enrichment tubes
were stored at 40 C.
Plaque purification and titer methods
Individual plaques were picked with a sterile pipet tip into a 1.5ml micro-
centrifuge tube containing 100pl of TSB with 2mM CaCl2 and incubated at
37'C for 10 minutes. The pipet tip was removed and the microcentrifuged
tube was briefly vortexed. Serial 10-fold dilutions were made in TSB with
2mM CaCl 2. 5pl of the serial dilutions were spotted onto solidified double
agar overlay plates inoculated with E. faecalis , as described above. Plates
were allowed to dry, incubated at 370 C overnight and examined for plaques
the following day. Plaques were enumerated to determine the phage titer
as plaque-forming-units (PFU)/ml. Plaque picking, serial dilution and spot
testing was repeated a minimum of 3-4 times to ensure purity of individual
phages.
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Phage propagation, PEG precipitation and imaging
Overnight broth cultures of E.faecalis strains in brain heart infusion (BHI)
broth were diluted 1:100 in fresh BHI in a 250ml Erlenmeyer flask and
incubated for 1.75 hours at 37'C at 250rpm, until reaching an OD600 of ap-
proximately 0.15. Phages were resuspended from plaques into 400 1 1 of SM
buffer and filtered through a 0.2pim filter. 75pl of filtered phage was added
to the log-phase E.faecalis cultures and incubated at 37'C. Cultures were
monitored for lysis by periodic measurements of OD,00 . Once ODcoo had
stabilized and visible lysis was observed, phage lysates were centrifuged at
5000 x g for 10 minutes and filtered through a 0.21tm bottle top filter. Fol-
lowing centrifugation, log of PEG-8000 and 5.8g of sodium chloride were
added for final concentrations of 10% (w/v) PEG-8000 and IM NaCl and
lysates were split into two 50-ml aliquots in 50ml conical tubes. Tubes
were incubated overnight at 40 C to facilitate precipitation. The following
day, tubes were centrifuged at 10,000 x g for 1 hour and the pellets were
re-suspended in 2ml of SM buffer and sterile-filtered using a 0.211m syringe
filter. 2 00pl of re-suspended phage preparations were applied to a square
mesh transmission electron microscopy (TEM) grid (FCF200-Ni, Electron
Microscopy Sciences, Hatfield, PA) for 90 seconds, blotted, washed with
20il sterile water for 30 seconds and stained with 4/l 2% uranyl acetate
for 30 seconds. Grids were blotted, dried for 1-2 hours and imaged using
an FEI Technai Spirit transmission electron microscope at the W. M. Keck
Microscopy Facility, Whitehead Institute.
4.5.2 Phage lysis kinetics and host range
Overnight cultures of 2011, 2014 and 2015 E. faecalis ST55 isolates from
macaque #6 and ATCC E. faecalis strain 29212 were inoculated into 5ml
of TSB and incubated at 37'C, shaking at 150rpm. After isolates reached
a McFarland standard of 0.5, 0. 1ml were added to flasks containing IOml
fresh Mueller Hinton broth with no phage (control), phage 1 or phage 3
at a multiplicity of infection of approximately 80. Aliquots for OD6 00 were
collected at 0, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 4 and 5 hours after inoculation.
Aliquots for serial spot dilutions were collected at 0, 1, 2 and 3 hours after
inoculation. Following overnight incubation at 370 C, colonies were enu-
merated and kill curves plotted. 5pl of phages 1 and 3 were spotted onto
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double agar overlay plates inoculated with ST4 2016 and ST48 2017 from
macaques #9 and #27, respectively.
4.5.3 Phage precipitation, DNA extraction, sequencing
and analysis
20 ml aliquots of Phage 1 and Phage 3 were each treated with DNase I and
RNase at final concentrations of 20pig/ml and 10pig/ml, respectively, for 75
minutes at 37'C. After incubation, 5ml of 5M NaCl/50% polyethylene gly-
col was added and tubes were stored at 40 C overnight. The following day,
tubes were centrifuged for 60 min at 4,000 x g at 40C. The supernatant
was decanted and the pellet was resuspended in Iml of 10mM Tris/ 1mM
EDTA/100mM NaCl. The resuspended pellets were transferred to 1.5ml
microcentrifuge tubes and centrifuged for 10 minutes at 14,000 x g lml of
supernatant was used for DNA extraction and transferred to a clean 1. 5ml
microcentrifuge tube. 100pl of 0.5M EDTA and 100pl of 10% sodium do-
decyl sulfate was added and tubes were inverted to mix. 250pl of phenol-
chloroform-isoamyl alcohol (25:24:1) was added to each tube, vortexed, and
centrifuged at 10,000 x g for 4 minutes. 700pl of supernatant was care-
fully transferred to a clean tube before the addition of 630pl isopropanol
and 701 L of 5M NaCl. Tubes were gently inverted and centrifuged at 10,000
x g for 10 minutes. After decanting the supernatant, 500pl of 70% ethanol
was added and tubes were centrifuged for 5 minutes at 10,000 x g. The
supernatant was decanted and tubes were left open under the blower of
a class II biofsafety cabinet to air dry the pellet. DNA pellets were resus-
pended in 50pl of DNase-free water and DNA was quantified using a Nan-
oDrop spectrophotometer (ThermoFisher Scientific). Phage DNA libraries
were prepared using the QIAseqFX DNA library kit (Qiagen) with 765 ng
of DNA per manufacturer's instructions. Fragmentation of DNA was per-
formed at 320 C for 5 minutes. AMPure XP beads were used to perform
library purification as indicated in the QIAseq FX DNA library kit manual.
Barcoded and adapter-ligated DNA libraries were pooled with other DNA
libraries. Quality control prior to sample loading included sizing Illumina
libraries with the Advanced Analytic Fragment Analyzer and qPCR using
KAPA SYBR FAST qPCR Master Mix (KM4114) on a Roche LightCycler 48011.
2x300 base paired end reads were generated on an Illumina MiSeq using
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a MiSeq Reagent Kit v3 (Illumina). Phage genomes were assembled using
the SPAdes assembler on PATRIC. Assembled contigs were queried using
BLASTn and BLASTx https : //blast .ncbi .nlm.nih. gov/Blast . cgi [197] to
identify similar phage genomes and to search for integrase genes that might
identify lysogenic potential. Assembled contigs >700 base pairs were an-
notated on RAST [198, 199, 2001.
4.5.4 AMP MICs
Minimum inhibitory concentration testing was performed for five antimi-
crobial peptides against the 15 2011 E. faecalis isolates using the broth
microdilution technique in LB medium with an initial inoculum of approx-
imately 5x 10' cells (obtained by diluting an overnight culture 1/100) in
polystyrene microtiter plates. The five AMPS evaluated were isolated from
a variety of species (human LL-37, porcine PR-39, honeybee apidaecin
Ia, toad buforin II and flounder pleurocidin) in order to evaluate differ-
ent AMP classes and mechanisms of action (alpha-helical/cathelicidins,
proline-rich, DNA-binding agents). The MIC was interpreted as the lowest
concentration of peptide or antibiotic at which complete inhibition of visible
bacterial growth was observed after 24h of incubation at 370 C. Plates were
grown under the same conditions for an additional 24h to confirm growth
inhibition. Each agent was tested with 6 replicates. MIC testing for LL-37
and PR-39 was also performed on the 2015 ST55 isolate from macaque #6,
the 2016 ST4 isolate form macaque #9 and the 2017 ST48 isolate from
macaque #27 using LB broth. Briefly, overnight cultures were inoculated
into 5ml Mueller-Hinton broth and grown at 37'C, shaking at 150rpm until
a McFarland standard turbidity of 0.5 was reached. 1.5pl was then inocu-
lated into a round-bottom polystyrene plate containing test concentrations
of LL-37 and PR-39 of 40 pg/ml down to 1.25pg/ml in duplicate. Plates
were incubated for 24h at 37'C and the MIC was interpreted as the lowest
concentration of peptide at which complete inhibition of visible bacterial
growth was observed.
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4.6 Results
4.6.1 Initial isolation, plaque purification and titers
Plaques were identified on ST55 double-agar overlay plates from sewage
filtrate enriched with 2011 ST55 E. faecalis isolates #2, #3, and #7 and
designated as phages 3, 1, and 2, respectively. No plaques were identified
from spots of ST4 enrichments and repeated isolation attempts were un-
successful. After plaque purification, phage 1 demonstrated a large, clear
plaque morphology, while phages 2 and 3 demonstrated small, clear, plaque
morphologies (Figure 4-5). Approximate phage titers following the purifi-
cation steps were 6x10 7 PFU/ml for phage 1, 3.4x104 PFU/ml for phage 2
and 1x106 for phage 3.
4.6.2 Phage morphology
Transmission electron microscopy identified all three phages to be likely
Siphoviruses based on their non-enveloped head, capsid morphology and
flexible, noncontractile tails [201]. Phage 1 displayed an icosahedral cap-
sid morphology, approximately 65nm in diameter (Figure 4-6A). Phages 2
and 3 displayed prolate capside morphologies, approximately 99x36nm and
109x44nm, respectively (Figure 4-6B and C).
Figure 4-5: Photographs of plaques formed by Phages 1 (A) and 3 (B) on
top agar impregnated with the 2015 ST55 E. faecalis isolate from macaque
#6.
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Figure 4-6: Transmission electron micrographs of three lytic bacteriophages with activity against ST55. A. Phage
1 (icosahedral capsid), B. Phage 2 (prolate capsid), C. Phage 3 (prolate capsid)
4.6.3 Phage lysis kinetics
Due to inconsistent phage lysis following propagation of phage 2, phages
1 and 3 were selected for use in further experiments. Phage lysis kinetic
graphs for phages 1 and 3 are displayed in Figure 4-7. Both phages failed
to infect ATCC E.faecais 29212, but showed efficacy against ST55 isolates
from macaque #6. 2014 and 2015 ST55 isolates showed complete killing
by both phages at 2 hours; the 2011 ST55 isolates showed decreased titers
but were not killed entirely. This result may be attributed to propagation
of the phage using the 2011 ST55 isolate and development of some level of
resistance. No plaques were identified on spot testing against ST48 isolates;
large plaques were identified inconsistently from phage 3 at low dilutions
(1:10, 1:100), against the 2016 ST4 isolate.
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Figure 4-7: Phage 1 and 3 kill curves against ATCC 29212 and ST55 E.faecalis isolates from macaque #6. Top
curves show OD600 values over time and bottom curves show CFU/ml counts over time.
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Following assembly, phage 1 had a total length of 558,919 bp with 5
contigs >700bp, an N50 of 533 bp and a GC content of 40.58%. Phage 3
had a total length of 185,840 bp with 35 contigs >700bp, an N50 of 534
bp and a GC content of 40.30%. Submission of phage 1 to BLASTn identi-
fied the closest sequenced phage genomes as Enterococcus phages PMBT2
(99% identity, accession number MG708276. 1), EfaCPT1 (97% identity, ac-
cession number JX193904. 1) and IME-EF4 (90% identity, accession num-
ber KF733017. 1). Submission of phage 3 to BLASTn identified the closest
sequenced phage genomes as Enterococcus phages IME-EFI (99% iden-
tity, accession number KF192053. 1), vBEfaSIME 198 (99% identity, acces-
sion number KT932699. 1), EF-P29 (98%, accession number KY303907. 1),
and EF-PlO (97% identity, accession number KY472224. 1). Annotation on
RAST identified 69 coding sequences for phage 1 (with 20 non-hypothetical
protein annotations) and 79 coding sequences for phage 3 (with 15 non-
hypothetical protein annotations). Gene annotation lists are archived at
https: //f igshare. com/s/ccf cd9994c95a294049b. No genes for either phage
1 or 3 were annotated as integrase genes by RAST, or identified following
BLASTx query for integrase genes, supporting that both phages are unable
to initiate lysogeny.
4.6.4 MIC results for AMPs
On initial screening of the 15 2011 E. faecahs isolates, we identified that
MICs against apidaecin Ia, buforin II and pleruocidin were mostly >20pg/ml
for all isolates tested (Table 4.1). The majority of ST55 strains displayed
MICs for PR-39 and LL-37 at >20pg/ml and 10-20pg/ml, respectively. ST4
strains displayed MICs for PR-39 and LL-37 at 5pg/ml and 5- 1Opg/ml, re-
spectively. Because LL-37 and PR-39 seemed to be the MICs with the most
promising antimicrobial activity, they were chosen for use in further exper-
iments. Later screening of MICs for LL-37 and PR-39 against 2015 ST55,
2016 ST4 and 2017 ST48 isolates found that ST4, ST55 and ST48 were
resistant to both AMPs (MIC >40pg/ml).
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LL-37 Cecropin PR-39 Apidaecin la Buforin I Pleurocidin
E. faecalis ST Animal ID (pg/mL) (pg/mL) (pg/mL) (pg/mL) (ig/mL)
isolate -human- Pig- -honey-bee- -toad- -winter
-hmn Ipg Ihnybe -tad flounder-
2011 EFI 4 1 10 5 >20 >20 10
2011 EF2 55 4 10-20 >20 >20 >20 >20
2011 EF3 55 5 >20 >20 >20 >20 >20
2011 EF4 4 5 5 5 >20 >20 >20
2011 EF5 330 5 >20 >20 >20 >20 >20
2011 EF6 55 11 Reduced at 5, but MIC >20 Reduced at 5, but MIC >20 >20 >20 >20
2011 EF7 55 16 10 >20 >20 >20 >20
2011 EF8 55 16 10 >20 >20 >20 >20
2011 EF9 4 18 5 5 >20 >20 20
2011 EFIO 4 19 5 5 >20 >20 20
2011 EF1 55 6 20 >20 >20 >20 >20
2011 EF12 55 8 20 5 >20 >20 >20
2011EF13 4 9 5 5 >20 >20 20
2011 EF14 4 11 5 5 >20 >20 20
2011 EF15 4 11 5 5 >20 >20 20
2015 55 6 >40 >40 NA NA NA
2016 4 9 >40 >40 NA NA NA
2017 48 27 >40 >40 NA NA NA
Table 4.1: MICs of selected AMPs against 2011 E. faecalis strains and 2015-2017 ST55, ST4 and ST48 strains.
4.7 Evaluation of different methods to treat E.
faecalis biofilm
4.7.1 General methods for biofilm treatment
experimental setup
E. faecalis isolates were inoculated onto TSA with 5% sheep blood and in-
cubated overnight at 37'C with 5% CO 2. The following day, cultures were
inoculated into 5ml of TSB with 1% glucose and incubated at 37'C, shak-
ing at 150rpm between 5 hours and overnight. To inoculate biofilm plates,
5pl of the TSB broth culture was added to 195jl of fresh TSB with 1% glu-
cose in replicates of 3-12 per isolate, depending on the experiment. Plates
were incubated overnight, statically at 370 C. The following day, the OD6 00
was recorded and wells were emptied by inversion. Wells were washed 2-3x
with 200A PBS prior to addition of tested anti-biofilm treatments. After
addition of anti-biofilm treatments, plates were incubated overnight, stat-
ically at 37'C. The following day, well contents were emptied by inversion,
wells were washed 3x with 200Ql PBS and stained with crystal violet ac-
cording to the protocol described in section 3.3.5. Biofilm production was
normalized to bacterial growth by dividing OD5 7 0 by the OD300 , and the nor-
malized OD570 values were used for statistical analysis. Due to the noisi-
ness of crystal violet assays, single outliers were removed using the Grubbs
outlier test. Non-parametric data was analyzed using Kruskal-Wallis with
Dunn's multiple comparison test, parametric data was analyzed with one-
way ANOVA with Dunnett's multiple comparison or Holm-Sidak's multiple
comparison testing with P<0.05 considered significant. For combination
biofilm treatments, two-way ANOVA testing was performed with post-hoc
Tukey's multiple comparison testing.
Tested antimicrobial agents were purchased from Sigma in powdered
form, weighed, and dissolved in sterile water at concentrations of either
5mg/ml or 1mg/ml. Norfloxacin was dissolved in a solution of 0. 1M HCl
and then diluted with water.
Sodium dodecyl sulfate, sodium bicarbonate and sodium periodate were
weighed out and dissolved in sterile water at a concentration of 0.4% w/v
for each and serially diluted in PBS for testing anti-biofilm efficacy.
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Antimicrobial peptides were synthesized using the Fmoc strategy by Dr.
C6sar de la Fuente-Nifiez. Peptides were purified by reverse-phase HPLC
using analytical C 18 columns (Phenomenex, USA). Molecular mass and pu-
rity of the synthesized peptides were confirmed by MALDI-ToF mass spec-
trometry. Analytical HPLC was also used to confirm the purity of the pep-
tides.
Phages were added at a concentration of approximately 5-50 x107 PFU
per well. Final volumes of treatments were either in 100pl or 200/l of PBS
or SM buffer.
4.7.2 Efficacy of antimicrobials against E. faecalis
biofilm
We first evaluated the efficacy of multiple antimicrobial agents by them-
selves in treating E. faecalis biofilms. Low-concentration antimicrobials
tested included tetracycline (16-32pg/ml), bacitracin (32-128uig/ml), ery-
thromycin (16-64pig/ml), gentamicin (16-64jpg/ml) as well as ampicillin
(64pg/ml), norfloxacin (64ptg/ml) and vancomycin (64ptg/ml). We also tested
high concentrations of tetracycline (80-320pg/ml), bacitracin (160-640pg/ml),
erythromycin (80-320jpg/ml) and gentamicin (80-320pg/ml) against 2011
ST55 and ST4 isolates from macaques #6 and #9 respectively.
At lower antimicrobial concentrations, no significant decrease in biofilm
was noted for tetracycline, bacitracin, erythromycin or gentamicin as com-
pared to PBS for the 2015 ST55 or 2016 ST4 isolates from macaques #6 and
#9, respectively (Figure 4-8). 2016 and 2017 ST48 isolates from macaques
#9 and #27, respectively, showed minor but inconsistent decreases in biofilm
when exposed to bacitracin (Figure 4-8). Because ST55 and ST4 isolates
had strain-dependent resistance to tetracycline, bacitracin, erythromycin
and gentamicin, we also tested much higher concentrations for these an-
timicrobials (Figure 4-9). Treatment with high concentrations of tetracy-
cline actually resulted in increased biofilm, most likely due to decreased
solubility and precipitation at the higher concentrations, thus results were
excluded from statistical comparisons. We observed that bacitracin at
high concentrations (160-320ig/ml) significantly decreased biofilm pro-
duction for both the 2011 ST55 isolate from macaque #6 and the 2011 ST4
isolate form macaque #9. The highest concentration of bacitracin tested
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(640pg/ml) decreased biofilm for the 2011 ST55 isolate from macaque #6,
but no difference was observed for the 2011 ST4 isolate from macaque #9.
We are unsure of the reason for this discrepancy, especially since the ST4
isolate showed a much lower bacitracin MIC (8-16pg/ml) than the ST55
isolate (>128pg/ml). We also evaluated biofilm treated with ampicillin, nor-
floxacin and vancomycin at 64pg/ml. We did not identify any decreases in
biofilm for ST55, ST4 and ST48 isolates (Figure 4-10), and treatment with
norfloxacin actually appeared to increase biofilm production in all three
strains. Sub-inhibitory concentrations of ciprofloxacin have been reported
to up-regulate biofilm production in P. aeruginosa through altering cell-
cell signaling pathways [202]; however we would have expected to only see
this phenotype in the fluoroquinolone-resistant ST4 isolate, and not the
fluoroquinolone-sensitive ST55 and ST48 isolates (MIC 1-2pg/ml).
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Figure 4-8: Evaluation of tetracycline, bacitracin, erythromycin and gentamicin against E. faecalis biofilms
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Figure 4-9: Evaluation of high concentrations of bacitracin, erythromycin and gentamicin against 2011 E. fae-
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Figure 4-10: Evaluation of ampicillin, norfloxacin and vancomycin against E. faecalis biofilms
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4.7.3 Efficacy of sodium dodecyl sulfate, sodium
bicarbonate and sodium metaperiodate mixture
against E. faecalis biofilm
Based on a previous study evaluating a 0.1% weight-volume mixture of
sodium dodecyl sulfate (SDS), sodium bicarbonate and sodium periodate,
we evaluated varying concentrations of this mixture against E. faecalis
bioflims [203]. We observed that concentrations greater than 0.1% reli-
ably decreased biofilm as compared to the PBS control for ST55, ST4 and
ST48 E. faecalis strains (Figure 4-11).
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Figure 4-11: Evaluation of SDS-bicarbonate-periodate against E.faecalis biofilms
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4.7.4 Efficacy of antimicrobial peptides LL-37 and
PR-39 against E. faecalis biofilm
Next we evaluated the ability of LL-37 and PR-39 to decrease biofilm. We
evaluated LL-37 against all three ST and PR-39 against ST4 strains. Our
results did not find antimicrobial peptides to be consistently effective at
decreasing biofilm for any strain (Figure 4-12).
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4.7.5 Efficacy of lytic bacteriophage against E. faecalis
biofilm
We next evaluated the ability of lytic bacteriophages 1 and 3 to decrease E.
faecahs biofilm, at a dose of 5x107 PFU/well for phage 1, 5x108 for phage 3
and in combination. For ST55 (which was susceptible to plaque formation
upon exposure to phages 1 and 3), biofilm was significantly decreased as
compared to the control, for both phages individually, as well as in com-
bination (Figure 4-13. Biofilm from the 2016 ST4 was also significantly
reduced by treatment with phage 3, even though this isolate only intermit-
tently forms plaques with exposure to phage 3. Neither phage 1 or 3 was
effective at decreasing ST48 biofilm.
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Figure 4-13: Evaluation of lytic bacteriophages 1 and 3 against E. faecalis biofilm. Phages were tested at a dose
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4.7.6 Efficacy of combination antimicrobial and phage
treatment against E. faecalis biofilm
We next evaluated whether phage in combination with antimicrobials would
be synergistic against E. faecalis biofilm. We evaluated combinations of
phages at a dose of 5x10 7 PFU/well with bacitracin, erythromycin, gen-
tamicin at concentrations of 64pig/ml (Figures 4-14, 4-15, 4-16). From
two-way ANOVA results, no interaction was observed between phages and
antimicrobials for any strain. Post-hoc testing confirmed that phages 1, 3
and both phages in combination were more effective as compared to the
control for ST55, and phage 3 and both phages in combination were ef-
fective for ST4. For ST48, post-hoc testing identified bacitracin treatment
as providing some efficacy against biofilm, consistent with previous results
(Figure 4-8).
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Iii IL IIIii
No Phage
Phage 1
Phage 3
Both Phage
I
C)
IIIiii
C'
Antimicrobial 64 pg/ml
Source of Variation % of total variation P value P value summary Significant?
Interaction 14.24 0.0541 ns No
Antimicrobial 1.581 0.5499 ns No
Phage 60.62 <0.0001 **** Yes
Dunnett's multiple comparisons test Mean Diff. 95.00% Cl of diff. Significant? Summary Adjusted P Value
No Phage vs. Phage 1 0.0541 -0.0194 to 0.1276 No ns 0.1882
No Phage vs. Phage 3 0.2131 0.1396 to 0.2866 Yes **** _<0.0001
No Phage vs. Both Phage 0.2158 0.1423 to 0.2893 Yes **** _<0.0001
Figure 4-15: Evaluation of combination antimicrobials and lytic phage against the 2015 ST55 E.faecalis isolate.
All antimicrobials were tested at a concentration of 64pig/ml and phages were tested at 5x 107 PFU/well
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ST48 2017 - Macaque #27
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II1 III
m No Phage
Phage 1
m Phage 3
Both Phage
IIIIi II
C,
Antimicrobial 64 pg/ml
Source of Variation % of total variation P value P value summary Significant?
Interaction 10.68 0.7319 ns No
Antimicrobial 18.17 0.0293 * Yes
Phage 14.26 0.0640 ns No
Dunnett's multiple comparisons test Mean Diff. 95.00% Cl of diff. Significant? Summary Adjusted P Value
SM Buffer vs. Bac 64 0.1251 0.022 to 0.2282 Yes * 0.0144
SM Buffer vs. Ery 64 0.08864 -0.01448 to 0.1918 No ns 0.1046
SM Buffer vs. Gent 64 0.1008 -0.002368 to 0.2039 No ns 0.0567
Figure 4-16: Evaluation of combination antimicrobials and lytic phage against the 2016 ST4 E.faecalis isolate.
All antimicrobials were tested at a concentration of 64pg/ml and phages were tested at 5x107 PFU/well
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4.7.7 Efficacy of combination antimicrobial and
antimicrobial peptide treatment against E.
faecalis biofilm
Because previous work has identified synergy between antimicrobials and
antimicrobial peptides [731, we wanted to evaluate if combination therapy
would be effective against E. faecalis biofilms. Specifically, we were inter-
ested in the abilities of AMPs to work with antimicrobials targeting bacterial
cell wall integrity. We evaluated ampicillin, bacitracin and vancomycin at
concentrations of 64pg/ml with LL-37 (all strains) and PR-39 for the ST4
strain at a concentration of 1Opg/ml. We did not identify synergistic inter-
actions or efficacy with any combinations of antimicrobials and peptides
based results of two-way ANOVAs (Figures 4-17, 4-18, 4-19).
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ST55 2015 AMPs + Antimicrobials
T
TT
PBS
LL-37
T
T
0.0-L-
00
Antimicrobial 64 pg/ml
Source of Variation % of total variation P value P value summary Significant?
Interaction 1.338 0.9548 ns No
Antimicrobial 31.76 0.0933 ns No
AMP 0.1275 0.8634 ns No
Figure 4-17: Evaluation of combination antimicrobials and antimicrobial peptides against the 2015 ST55 E.
faecalis isolate. All antimicrobials were tested at a concentration of 64pg/ml and LL-37 was tested at a concen-
tration of 1Opg/ml
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01.0-
E 0.5-
0z
ST4 2016 AMPs + Antimicrobials
2.5-
O 2.0-
1.5-
*~1.0-
0Z 0.5-
0.0-I
T
T
PBS
LL-37
PR-39
1I
cc
0
Antimicrobial 64 pg/mI
Source of Variation % of total variation P value P value summary Significant?
Interaction 13.01 0.6390 ns No
Antimicrobial 11.94 0.2916 ns No
AMP 2.565 0.6588 ns No
Figure 4-18: Evaluation of combination antimicrobials and antimicrobial peptides against the 2016 ST4 E.faecalis isolate. All antimicrobials were tested at a concentration of 64pg/ml and LL-37 and PR-39 were tested
at a concentration of 1Opg/ml
i iii ii
ST55 2015 AMPs + Antimicrobials
PBS
LL-37
Antimicrobial 64 pg/mI
Source of Variation % of total variation P value P value summary Significant?
Interaction 1.338 0.9548 ns No
Antimicrobial 31.76 0.0933 ns No
AMP 0.1275 0.8634 ns No
Figure 4-19: Evaluation of combination antimicrobials and antimicrobial peptides against the 2017 ST48 E.
faecalis isolate. All antimicrobials were tested at a concentration of 64uig/ml and LL-37 was tested at a concen-
tration of 1Opg/ml
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4.7.8 Efficacy of combination phage and AMP treatment
against E. faecalis biofilm
Finally, we wanted to evaluate if phages and AMPs would work synergisti-
cally against E. faecalis biofilms. We evaluated combinations of phages 1,
3 and both phages with LL-37 for the 2015 ST55 isolate, combinations of
phage 3 with LL-37 and PR-39 against the 2016 ST4 isolate and phage 3
with LL-37 for the ST48 isolate. Phages were tested at a concentration of
5x10 7 PFU/well and peptides were tested at a concentration of 10ptg/ml.
No synergy was identified between phages and AMPs with any combination
therapy (Figures 4-20. 4-21, 4-22).
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ST55 2015 - Macaque #6
T
No Phage
Phage 1
Phage 3
Both Phage
1.0-
F 0.8-
0 0.6-
: 0.4-
0Z 0.2-
AMP Treatment - 10 pg/ml
Source of Variation % of total variation P value P value summary Significant?
Interaction 2.629 0.1072 ns No
AMP 1.592 0.0543 ns No
Phage 79.59 <0.0001 _ _**** I Yes
0q
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
No Phage vs. Phage 1 0.5682 0.4519 to 0.6845 Yes **** _<0.0001
No Phage vs. Phage 3 0.1689 0.05261 to 0.2852 Yes ** 0.0029
No Phage vs. Both Phage 0.511 0.3947 to 0.6273 Yes **** _<0.0001
Figure 4-20: Evaluation of combination lytic phage and antimicrobial peptides against the 2015 ST55 E.faecalis
isolate. Phages were tested at a concentration of 101 PFU/well and LL-37 was tested at a concentration of
lpg/ml. Experiments performed with replicates of 6.
T
Tr
0.0-I-
T T
S
ST4 2016 - Macaque #9 No Phage
Phage 3
TF
T
--r
-r
-b
AMP Treatment - 10 pg/ml
Source of Variation % of total variation P value P value summary Significant?
Interaction 1.41 0.2617 ns No
AMP 4.26 0.0242 * Yes
Phage 78.92 <0.0001 **** Yes
Dunnett's multiple comparisons test Mean Diff. 95.00% Cl of diff. Significant? Summary Adjusted P Value
PBS vs. LL-37 0.06903 -0.08429 to 0.2224 No ns 0.4808
PBS vs. PR-39 -0.1189 -0.2722 to 0.03445 No ns 0.1440
Figure 4-21: Evaluation of combination lytic phage and antimicrobial peptides against the 2016 ST4 E. fae-
calis isolate. Phage 3 was tested at a concentration of 10 PFU/well and LL-37 and PR-39 were tested at a
concentration of 10pg/ml. Experiments performed with replicates of 6.
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ST48 2017 - Macaque #27
No Phage
Phage 3
UT
0.0--
AMP Treatment - 10 pg/mI
0C14
Source of Variation % of total variation P value P value summary Significant?
Interaction 3.388 0.1682 ns No
AMP 1.103 0.4237 ns No
Phage 66.17 <0.0001 **** Yes
Dunnett's multiple comparisons test Mean Diff. 95.00% C of diff. Significant? Summary Adjusted P Value
PBS:No Phage vs. PBS:Phage 3 0.4774 0.2503 to 0.7045 Yes *** _0.0001
PBS:No Phage vs. LL-37:No Phage 0.1384 -0.08872 to 0.3654 No ns 0.3052
PBS:No Phage vs. LL-37:Phage 3 0.4396 0.2125 to 0.6667 Yes *** _0.0003
Figure 4-22: Evaluation of combination lytic phage and antimicrobial peptides against the 2017 ST48 E.faecalis
isolate. Phage 3 was tested at a concentration of 107 PFU/well and LL-37 was tested at a concentration of
10pg/ml. Experiments performed with replicates of 6.
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4.8 Discussion
We evaluated the efficacy of traditional antimicrobials, antimicrobial pep-
tides and lytic bacteriophages, alone, and in combination, against biofilm
produced by E. faecalis strains isolated from CRCs of research macaques.
Our results revealed that antimicrobial treatment of biofilm was generally
ineffective, regardless of MIC, as demonstrated by evaluating ST48 biofilms
treated with antimicrobials at concentrations ranging from 2-4x to 256x
the MIC. The only antimicrobial showing efficacy at decreasing biofilm was
bacitracin, which showed efficacy at 1.25x the MIC for ST55, 10x the MIC
for ST4 and 2-4x the MIC for ST48. Previous studies evaluating treatment
for S. aureus biofilms have noted efficacy of bacitracin for both in vitro and
murine skin wound models, with the former evaluating bacitracin as a
component of triple antibiotic ointment [204, 205].
Next, we evaluated two antimicrobial peptides; human LL-37 and porcine
PR-39. Both peptides are members of the cathelicidin family of peptides,
characterized by intracellular storage in an unprocessed form, and acti-
vated after cleavage from an approximately 100-amino acid N-terminal do-
main [2061. LL-37 acquires an alpha-helical structure in its activated state,
while PR-39 is rich in proline and adopts a more extended structure [206].
While both peptides showed MICs of 5-40pg/ml against planktonic cultures
of ST4 isolates, ST48 and ST55 isolates demonstrated MICs of >40pug/ml.
Previous studies have identified lack of correlation between MICs on plank-
tonic cultures with anti-biofilm activity, with small cationic peptides dis-
playing strong biofilm inhibition against Listeria monocytogenes and Pseu-
domonas aeruginosa despite significantly higher MICs [194]. When evalu-
ating anti-biofilm activity, we did find consistent anti-biofilm activity from
either LL-37 or PR-39 at 10pg/ml. Additionally, combining AMPs together
did not offer any benefit vs. using either peptide alone. Limited work has
examined effectiveness of AMPs against E.faecalis and has mostly focused
on planktonic MICs rather than as antibiofilm agents. The AMPs melittin (a
peptide component of bee venom) demonstrated MICs of 2-4[tg/ml against
ATCC E.faecalis 29212 and 1.25-2.5ptM (3.5-7pig/ml) against E.faecium in
previous studies [207, 2081. Melittin is less desirable for use as an AMP
because of its cytotoxic and pro-apoptotic effects on eukaryotic cells [209].
Previously, pleurocidin has also been demonstrated to have MICS of 2.5-
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5pM (6.7-13.5pig/ml) against E.faecium, however our strains demonstrated
MICs of 10 to >20pg/ml. Our findings of PR-39 (aka cecropin P1) being
ineffective on planktonic cultures was supported by previous work demon-
strating MICs of >256pg/ml against ATCC E.faecalis 29212 [207, 210].
Previously, lytic bacteriophages (both naturally isolated and genetically
engineered) have demonstrated remarkable efficacy at diminishing E. fae-
calis biofilms [184, 211]. We were surprised to see that lytic phage 3
demonstrated efficacy against biofilms formed by ST4 despite inconsistent
plaque formation on double-agar overlay assays. We additionally identified
some efficacy of phage 3 against biofilm the 2017 ST48 isolate when eval-
uating phage-AMP combination therapy (Figure 4-22), and had previously
confirmed that phage 3 does not form plaques on ST48. Phage 3 efficacy
against ST48 was not consistent between different experiments (Figure 4-
16), thus this finding needs further evaluation before definitive conclusions
can be drawn. Mechanisms of biofilm disruption by phages include both
penetration and infection of biofilm-forming bacteria as well as secretion of
enzymes (polysaccharidases, polysaccharide lyases and hydrolases) which
are able to degrade the EPS layer [212, 188, 213]. It is the latter mech-
anism that we hypothesize as the source of efficacy of phage 3 against
ST4 (and potentially ST48) biofilms. Phage enzymes have been described
against Gram-negative bacteria, including P. aeruginosa, Enterobacter ag-
glomerans, and Serratia marcescens, as well as Gram-positive Staphylococ-
cus epidermidis [214, 215, 216]. Similarly to our findings, evaluation of
phage efficacy against S. epidermidis strains identified a statistically sig-
nificantly decrease in biofilm production after 24 hours of treatment, in
strains both highly and poorly susceptible to lysis on agar plates [216].
Combinations of the antimicrobial agents ceftazidime, ciprofloxacin, imi-
penem and tobramycin with D-enantiomeric cationic peptides were previ-
ously shown to decrease the minimum biofilm inhibitory concentrations of
antimicrobials from 2-16 fold for several Gram negative bacterial species
including P. aeruginosa, E. coli, Acinetobacter baumannii, Klebsiella pneu-
moniae and Salmonella enterica [74, 73]. The hypothesized mechanism of
synergistic action is related to peptide-mediated dispersal of biofilms allow-
ing antimicrobial penetration [74, 217]. We hypothesized that LL-37 would
promote synergy for ST4 strains in combination with various antimicro-
bials at concentrations significantly higher than the MICS; i.e. ampicillin
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was tested at 64x MIC, bacitracin was tested at 8x the MIC, and vancomycin
was tested at 32-64x MIC. We unfortunately did not observe any synergy, as
assessed by 2-way ANOVA, for any of the strains or antimicrobials tested
(Figure 4-18). Possible reasons for failure to observe synergy is that an-
timicrobials and peptides interacted antagonistically, or the mechanism of
peptide-antibiotic synergy is unrelated to biofilm dispersal in E.faecalis vs.
Gram-negative bacteria.
We did not identify synergy between antimicrobials and lytic phages for
ST55, ST4 or ST48 E. faecalis isolates tested; the observed decreases in
biofilm for ST55 and ST4 were strongly related to phage treatment based on
post-hoc testing and results observed for phage treatment alone. We also
failed to identify synergy between peptides and bacteriophage treatment.
Combination of phages and antimicrobial peptides has not previously been
evaluated; future work should aim to understand the mechanisms of anti-
biofilm properties to improve predictions for whether combinatorial thera-
pies are more efficacious than bacteriophages alone.
Finally, chemical biofilm treatments consisting of sodium dodecyl sul-
fate, sodium bicarbonate and sodium periodate were efficacious in reduc-
ing biofilm for all three E. faecalis ST tested. Because sodium periodate is
a skin irritant, chemical treatment of biofilm should be limited to abiotic
implant surfaces, or for treating external surfaces (such as PMMA). The
toxicity levels of sodium periodate are not well-described; the LD50 in mice
is reported to be 58 mg/kg [218], but the contact time required for skin
irritation has not been evaluated.
4.9 Conclusions
In this chapter we have described isolation and characterization of lytic
bacteriophages with efficacy against multi-drug resistant E. faecalis. We
evaluated the treatment efficacy of bacteriophages, two antimicrobial pep-
tides and a chemical mixture against E.faecalis biofilms using in vitro mod-
els. Our results suggest that lytic bacteriophages are highly efficacious in
decreasing E.faecalis biofilms for susceptible strains, while neither antimi-
crobials nor the antimicrobial peptides LL-37 or PR-39 showed consistent
anti-biofilm properties. Finally, chemical treatment offers another potential
tool for treating biofilms on abiotic implant surfaces. Future studies should
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evaluate safety, efficacy and optimal dosing strategies for these alternative
therapies, using cell culture and animal models of infection. Further char-
acterization of bacterial binding targets for lytic phage may offer insight into
genetic manipulation for expanding E. faecalis susceptible strain range.
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Chapter 5
Summary, Conclusions and
Future Directions
In this dissertation, we have probed the complex bacterial ecosystem colo-
nizing CRCs in macaques under study for cognitive neuroscience research.
Our goals were to better understand which bacterial species were most
prevalent inside CRCs, and to characterize antimicrobial resistance for an
improved ability to treat infectious complications of implants when they
arise.
In Chapter 1 we introduced the use of CRCs in research macaques
and the more common types of acute and chronic complications observed
with surgical implantation. While uncommon, infectious complications
can have devastating outcomes for affected macaques, necessitating under-
standing of the bacterial species potentially contributing to infections. CRC
sanitization protocols were updated in September, 2014 and we wished to
understand how improved CRC sanitization techniques and prohibition of
topical antimicrobials affected bacterial species commonly colonizing CRCs
(and their antimicrobial resistance profiles).
In Chapter 2 we compared traditional culture-dependent techniques for
characterizing bacterial communities with state-of-the-art, culture-indepen-
dent, next-generation sequencing techniques. Use of 16S community anal-
ysis on purulent polymicrobial samples is a novel use of this technique
as compared to the previously described literature. As well as identify-
ing aerobes and anaerobes living within CRCs, we compared communi-
ties between CRCs, the implant-skin margin, the oral cavity and feces to
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determine that CRC communities vary between macaques, and in most
cases, have greater similarities to skin margin and oral communities than
fecal communities. While skin, oral and fecal bacterial communities in
macaques have been previously evaluated individually, this is the first time
communities have been compared together. Our data lays a preliminary
foundation for a "macaque microbiome project" and can serve as a non-
human primate reference point for comparison with future macaque and
human studies.
Future work should evaluate skin and oral samples before and sequen-
tially after CRC implantation to identify shifts in bacterial communities
over time. Because CRC colonization is hypothesized to arise from skin
and oral communities, the use of different skin margin sanitization proto-
cols and the role of a regular dental hygiene program could be evaluated
to see if overall bacterial burden can be decreased. As utilization of cus-
tom, PMMA-free CRC implants increases, more definitive conclusions can
be made regarding the role of PMMA on the composition of CRC bacterial
communities.
We determined that the vast majority of species living within CRCs are
obligate anaerobes and are under-represented by traditional cultures, even
when using anaerobic culture techniques. We also identified that the most
prevalent aerobic species cultured from CRCs is S. aureus, and that iso-
lates have maintained an antimicrobial-sensitive phenotype between 2011
and 2018. We determined that E. faecalis was the second most prevalent
aerobic species isolated from CRCs in 2011 and displayed a multi-drug re-
sistant phenotype, necessitating further understanding of this opportunis-
tic pathogen. We were encouraged by noting decreases in the prevalence
of both E. faecalis and Proteus spp. cultured from CRC samples between
2011 and 2018; because these species showed marked antimicrobial re-
sistance, we hope that improved antimicrobial stewardship will continue to
minimize selection for potential resistant pathogens.
In Chapter 3 we discussed characterization and long-term colonization
dynamics of E. faecalis isolated from macaque CRCs between 2011 and
2017. We performed antimicrobial susceptibility testing to confirm resis-
tant phenotypes, evaluated biofilm production and analyzed whole genome
sequences to identify resistance and virulence factor genes, and to ana-
lyze variants. We determined that ST4 and ST55 lineages isolated from the
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same macaques remained relatively stable over time for resistance and vir-
ulence factor genotypes, but noted subtle increases in biofilm production
phenotype over time. Variant analysis identified mutations in the DNA re-
pair genes mutS and mutL, and we confirmed that isolates with mutations
in these genes displayed a hypermutator phenotype. This phenotype is im-
portant to identify as future antimicrobial treatment, if warranted, can be
complicated by increased development of resistance.
We identified a shift in E. faecalis lineages from ST4 and ST55 strains
displaying marked antimicrobial resistance, to ST48 strains displaying a
strong biofilm phenotype, but minimal antimicrobial resistance. The ma-
jority of this shift occurred following updates to our CRC sanitization pro-
tocol. We hypothesize that the loss of selective pressure from prohibition of
antimicrobial use within CRCs, and more judicious use of antimicrobials
overall, allowed the less resistant ST48 lineage to predominate over more
resistant strains. Future work should continue to monitor E. faecalis ST
and resistance patterns, as implanted macaques can serve as a model for
evolution and E. faecalis strain succession within a hospital environment.
In Chapter 4 we evaluated different techniques for treating E. faecalis
and decreasing E. faecalis biofilm. We isolated lytic bacteriophages from
sewage and demonstrated their efficacy in killing multi-drug resistant ST55
E. faecalis isolates, as well as treating E. faecalis biofilms. Transmission
electron microscopy identified these phages as likely Siphoviruses based
on their morphology, which was also confirmed by comparison of phage
genomes to previously sequenced phages. Future work should aim to iden-
tify the receptors necessary for phage efficacy and fully characterize optimal
lysis kinetics.
Finally, we investigated multiple techniques for treating E.faecalis biofilm.
We demonstrated that traditional antimicrobials, even at concentrations
well above MICs, were ineffective at decreasing E. faecalis biofilm. We con-
firmed that a detergent solution of sodium dodecyl sulfate, sodium bicar-
bonate and sodium periodate at 0.1% w/v each was effective at decreasing
biofilm for all strains tested. Because sodium periodate has potential lo-
cal toxicity effects, use of this solution should be reserved for non-biologic
surfaces (dental acrylic, implant hardware) until safety can be evaluated in
an in vivo model.
We evaluated two cathelicidin antimicrobial peptides; human LL-37 and
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porcine PR-39. While both peptides showed potential anti-bacterial activity
against ST4 E. faecalis isolates based on MICs, neither were able to show
consistent anti-biofilm activity. Future work should evaluate other antimi-
crobial peptides of different classes for efficacy against E. faecalis biofilm,
as these types of therapies appear to show promise for Gram-negative,
biofilm-forming bacterial species.
We demonstrated that lytic bacteriophages are effective at decreasing
biofilm in both ST55 and ST4 strains. As well as the ability to pass through
the biofilm and infect cells, phages can secrete enzymes able to degrade ex-
trapolymeric substance. We tested varying combinations of antimicrobials,
antimicrobial peptides and lytic bacteriophages to evaluate synergistic in-
teractions, but only recognized reliable decreases in biofilm associated with
bacteriophage treatment combinations. Future work should evaluate the
safety, efficacy and optimal dosing regimen of lytic bacteriophages against
biofilm using an in vivo mouse skin wound model.
Overall, this work has provided a better understanding of CRC bacterial
communities; exploring at both the population level as well as an in-depth
examination of how an individual species persists and evolves over time.
Macaques are a popular research model for understanding cognitive neuro-
science, and our work has implications for improving animal health at both
our institution and other institutions. We have demonstrated that CRC
communities are complex bacterial ecosystems and can vary between and
within individual macaques. We have also shown that increased antimi-
crobial stewardship has decreased the prevalence of mutli-drug resistant
E. faecalis in newly implanted macaques, increasing the probability of suc-
cessful antimicrobial treatment for infectious sequelae in the future. Our
results emphasize the importance of biofilm production in facilitating the
persistence of E.faecalis in implanted macaques, and highlight the need for
evaluating novel strategies when treating biofilm-associated infections. We
have identified promising results associated with lytic bacteriophages and
further in vivo studies should be undertaken to evaluate efficacy of phages
for future treatment of both veterinary and human multi-drug resistant E.
faecalis infections.
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Appendix A
2011 Macaque CRC Sanitization
Survey
213
CRC Sanitization Survey Part 1
Date of Sample Date of Last Cleaning Days (Cleaning - Recent Use of AntinIcrobialAnimal ID Sex Age .ab Study iD Episode(s) of Suspected Meningifs? C Recording? Gross Appearance of Discharge CleanIng Fruency antimcrobals? used
I F 15 A Al 0 8/16/11 No response Puwlentthick,copous(12fui) 81111? No response 1? No? NA
2 F 14 A A2 0 8/16/11 No response Serous, minimal (1/6 full) 8112/11? No response 4? No? NA
3 F 12 A A3 0 8/16/11 No response Not available 8/15/11? No response 1? No? NA
4 M 11 B B1 0 8/19/11 Yes Purulent, slg ( wel SID to 1-2 1 No NAI I copious (1/2 full) xWwook
5 M 10 B 82 0 /19/11 No Purulent, foul odor, copious (overflowing 15/11 I xweek to 1 4 Yes T-PBwith packing) x/2 weeks
6 M 13 B B3 0 8/24/11 No *Serous &22/11 2 x/week 2 Yes T-PB
7 M 12 B B4 0 8/23/11 No Purulent, hemorrhngc, crusting, foul odor 89/11 1 x/2 weeks 14 No NA
minimal (1/6 fuN)
8 M 13 B 85 0 8/24/11 No Serus t p ent, cr1ng, m &11? 1 x/week 8 Yes T-PB(front well). minimal
g M 13 B B6 0 8/24/11 No Serous 822/11 2 xweek 2 Yes T-PB
10 M 10 B B7 0 8/24/11 Yes? Purulent, minimal (1/4 full ater gauze 819/11 1 x/week 5 No NA
removal)
11 M 10 B B8 0 8/26/11 No response *Serous, gray tissue along well margins No response No response No response No response No response11I I 0 B 8 /6/1 Nrsos (center well),slight _____ _____
12 M 12 C C1 0 8/17/11 No Serosanguinous to purulent, minimal (1/4 815111 3 x/week 2 Yes Gfull)
13 M 12 C C2 0 8/17/11 No Serous, rninimal (1/4 ful) 8115/11 3 x/week 2 Yes BNP
14 M II C C3 5/2009 8/17/11 No Serous, minimal (1/4 ful) 8115/11 2 x/week 2 No NA
15 M 8 C C4 0 8/17/11 No Serosangumous minimally purulent. 8115/11 2 x/week 2 No NA15 M 8 C 04 0 8/17/11 No ~~~~~~~minimal (1/4 fUl)___ _____________________
16 F 10 C C5 0 8/17/11 No Serous, minimal (1/4 full) 8115/11 1 x/week 2 No NA
17 F 11 C C6 0 8/17/11 No Serous, purulent (center), minimal (1/4 8115/11 3 x/week 2 Yes BNP
18 M 10 C C7 0 8/17/11 No Serous, minimal (1/6 full) 81111 3 x/week 2 Yes G
19 M 10 C C8 11/2011 8/19/11 Yes Serosanguinous, moderate (1/3 ful) 8117/11 3 x/week 2 No NA
20 F 11 D Di 0 8/18/11 No response Not available No response No response No response No response No response
21 M 8 D D2 0 8/23/11 No -Hemorrhagic 8116/11 1 x/week 7 No NA
22 M 7 D D3 12/2011,10/2011,(32011),1/2011, 8/23/11 No Serosangulnous, moderate (1/3 ful) 811811 3 x/week 5 No NA
____ 5/2010, 3/2010?,_1/2010, (12/209) _______________ ______
23 M 7 D D4 0 8/23/11 Yes Serous, slightly hemorrhagic, slight 822/11 1-2 x/week I No NA
24 M 11 D D5 0 8/23/11 No 1 sigh M,f d'817/11 1 x/week 6 No NA copious (1/2 ful)
25 M 6 D 06 5/2010 8/23/11 No response Not available No response No response No response No response No response
co
 
-
4 
0)
 
C
 
A 
-
9
 
c
a*
 
-
41
 
-
4 
-
o 
0
 
-
.
 
0 
1 
1 
0
 
C
 
A
 
F
 
C
 
A
00
0 
0
 
0
 
0) 
0
 
0
 
0
 
0
 
0
 
0
 
0
 
w
 
w
 
O
w
 
w
 
w
 
w
 
w
 
>
>
 
>
5
?
 
S2 
2 
2 
2 
9 
W
 
I
M
 
C,
o 
00
00
0 
0 
0 
0 
0 
0 
a
I 
0
 
00
 
0 
0
 
0 
0 
00
 
0
'a
 
V
lx
il
CA
 
A 
-
C 
C
A
 
C
A
 
~
 
A 
C 
C
A 
C
d 
C
A
 
d
 
C.
A 
C.
) 
C 
CA
 
C
AI
l 
-
e'
 
CA
 
CA
 
C 
CA
 
C 
i
3 
M 
W
 Il 
I a"a
CL
 
CA
 
-
-
fI
1s
I 
r
s 
is
~
 
~
IL
2
I 
I 
I'
21
5
C-) C) C,, C C,,
co
 
cc
 
-
J 
I2
 
C."
 
-
P, 
ca
0
0~
~~
~~
~-
 
n
 
.
.
3(2
 3
b 
i
02
~c
 
(a 
po
 
42
0 
2 
0 
2)
11
11
 I ____
 
I I' I
0 '1 1
i'!!
 
5 
I-
-
I r
r 5 
SI
U
fil
 
5. 
"
 
1 1
J ~
 
1 
j1 
i ii 
I
_
_
_
 
I 
I~ 
dM
'10
 -
;
oil 
ll 
i
II
F
_
_
_
_
 
z 
02
21
6
C) C/) 0 CIO
o
 
0
 
00
 
0
 
0 
0
04 
2 
2 
2
-
3_
__
__
__
_ 
5_
__
__
_ 
Fl
a_
__
__
__
_
~
~
~
~
~
l 
U
 
R
M
 
P j
-
I ~~
li 
g 
_
 U
 I 
w
S
L
~
m
to
~
F! 
I 
jI
z S
L
-
u
 
0 
-
C)
 
C)
 
~
' 
I
21
7
C) C/) 0 C/)
a
ll
SR
I
IT
 
IT
 
w
21
8
0 C-) CO C.0
Appendix B
Primers
219
Table B. 1: PCR primers
Target Gene Sequence (5'-3') Amplicon Size (bp) Reference
16S V4 - F515/R806 GTGCCAGCMGCCGCGGTAA 291 Caporaso, J. et al. 2011GGACTACHVGGGTWTCTAAT
16S V4-V5 - F515/R926 GTGYCAGCMGCCGCGGTAA 411 Caporaso, J. et al. 2011CCGYCAATTYMTTTRAGTTT
E. faecalis ddl gene CAGAAGTGMGAGCACGATG 647 Lieberman, M.T., et al., 2018 In press
______________ AGGTAAAGTCGTACGGACAT
16S universal primer AGAGTTTGATCCTGGCTGAG 1550 Coenye, T., et al., 1999AAGGAGGTGATCCAGCCGCA
pstS - MLST A1TACATCACGTCTAC GC 583 Ruiz-Garbajosa, P., et al., 2006
aroE - MLST TGGAAAACTTTACGGAGACAGC 459 Ruiz-Garbajosa, R, et al., 2006GTCCTGTCCATTGTTCAAAAGC
gdh - MLST GGCGCACTAAAAGATATGGT 530 Ruiz-Garbajosa, P., et al., 2006CCAAGATTGGGCAACTTCGTCCCA
gyd - MLST CAAACTGCTTAGCTCCAATGGC 395 Ruiz-Garbajosa, P., et al., 2006CATTTCGTTGTCATACCAAGC
gki - MLST GATTTTGTGGGAATTGGTATGG 438 Ruiz-Garbajosa, R, et al., 2006ACCATTAAAGCAAAATGATCGC
xpt - MLST AAAATGATGGCCGTGTATTAGG 456 Ruiz-Garbajosa, P., et al., 2006AACGTCACCGTTCCTTCACTTA
yiqL - MLST CAGCTTAAGTCAAGTAAGTGCCG 436 Ruiz-Garbajosa, P., et al., 2006GAATATCCCTTCTGCTTGTGCT
MUMt TCGGTCAAATGCACGGAACT 569 Lieberman, M.T., et al., 2018 In pressTTAATGGGGGTCTTGAATGCGT
aac(6'-aph(2") CCAAGAGCAATAAGGGCATA 222 Khani M., et al.CACTATCATAACCACTACCG
aph(37-111a GGCTAAAATGAGAATATCACCGG 523 Emaneini, M. et alCTTTAAAAAATCATACAGCTCGCG
str ATTGCTCTCGAGGGTTCAAG 423 Lieberman, M.T, et al., 2018, In pressCGTTGAGACACTCCAAAACTCA
tetM GTTAAATAGTGTTCTTGGAG 657 Choi J.M., et al.CTAAGATATGGCTCTAACAA
tetS TGGAACGCCAGAGAGGTATT 660 Emaneini, M. et al.ACATAGACAAGCCGTTGACC
FsrB AATCAGATGGCTGAACAGGTTCA 181 In-house design
___ sr________ ACTAAATGGCTCTGTCGTCTAGA
RhamK CTAGTTTAGTCCATGAGTACTGC 119 In-house designTCCAGATTGATCCAGCAGACA I I
C
Cl
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